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Résumé 
L’asthme est connu comme l’une des maladies chroniques les plus fréquentes 
chez la femme enceinte avec une prévalence de 4 à 8%. La prévalence élevée de l’asthme 
fait en sorte qu’on se préoccupe de l’impact de la grossesse sur l’asthme et de l’impact de 
l’asthme sur les issus de la grossesse. La littérature présente des résultats conflictuels 
concernant l’impact de l’asthme maternel sur les issus périnatales comme les naissances 
prématurées, les bébés de petit poids et les bébés de petit poids pour l’âge gestationnel 
(PPGA). De plus, les données scientifiques sont rares concernant l’impact de la sévérité 
et de la maîtrise de l’asthme durant la grossesse sur les issus périnatales. Donc, nous 
avons mené cinq études pour réaliser les objectifs suivants: 1. Le développement et la 
validation de deux indexes pour mesurer la sévérité et la maîtrise de l’asthme. 2. 
L’évaluation de l’impact du sexe du fœtus sur le risque d’exacerbation de l’asthme 
maternel et l’utilisation de médicaments antiasthmatiques durant la grossesse; 3. 
L’évaluation de l’impact de l’asthme maternel sur les issus périnatales; 4. L’évaluation de 
l’impact de la sévérité de l’asthme maternel durant la grossesse sur les issus périnatales; 
5. L’évaluation de l’impact de la maîtrise de l’asthme maternel durant la grossesse sur les 
issus périnatales.  Pour réaliser ces projets de recherche, nous avons travaillé avec une 
large cohorte de grossesse reconstruite à partir du croisement de trois banques de données 
administratives du Québec recouvrant la période entre 1990 et 2002. Pour les trois 
dernières études, nous avons utilisé un devis de cohorte à deux phases d’échantillonnage 
pour obtenir, à l’aide d’un questionnaire postal, des informations complémentaires qui ne 
se trouvaient pas dans les banques de données, comme la consommation de cigarettes et 
d’alcool pendant la grossesse. 
 Nous n’avons trouvé aucune différence significative entre les mères de fétus 
féminins et de fétus masculins pour les exacerbations de l’asthme pendant la grossesse 
(aRR=1.02; IC 95%: 0.92 to 1.14). Par contre, nous avons trouvé que le risque de bébé 
PPGA (OR: 1.27, IC 95%: 1.14-1.41), de bébé de petit poids (OR: 1.41, IC 95%:1.22-
1.63) et de naissance prématurée (OR: 1.64, IC 95%:1.46-1.83) était significativement 
  
plus élevés chez les femmes asthmatiques que chez les femmes non asthmatiques. De 
plus, nous avons démontré que le risque d’un bébé PPAG était significativement plus 
élevé chez les femmes avec un asthme sévère (OR:1.48, IC 95%: 1.15-1.91) et modéré 
(OR: 1.30,  IC 95%:1.10-1.55)  que chez les femmes qui avaient un asthme léger. Nous 
avons aussi observé que les femmes qui avaient un asthme bien maîtrisé durant la 
grossesse étaient significativement plus à risque d’avoir un bébé PPAG (OR:1.28, IC 
95%: 1.15-1.43), un bébé de petit poids (OR: 1.42,  IC 95%:1.22-1.66), et un bébé 
prématuré (OR: 1.63,  IC 95%:1.46-1.83) que les femmes non asthmatiques. D’après nos 
résultats, toutes les femmes asthmatiques même celles qui ont un asthme bien maîtrisé 
doivent être suivies de près durant la grossesse car elles courent un risque plus élevé 
d’avoir des issus de grossesses défavorables pour leur nouveau-né. 
 
Mots-clés : Asthme, grossesse, bébé de petit poids pour son âge gestationnel, bébé de 
petit poids, bébé prématuré, fétal gender, Exacerbation de l’asthme  
  
Abstract 
Asthma is known as one of the most frequent chronic diseases encountered during 
pregnancy with prevalence estimated between 4 and 8%. The high prevalence of asthma 
during pregnancy results in some concerns about the impact of pregnancy on maternal 
asthma and also the impact of maternal asthma on perinatal outcomes. The literature 
presents conflicting results concerning the impact of maternal asthma during pregnancy 
on perinatal outcomes, such as preterm birth, low-birth-weight (LBW) infant and small-
for-gestational-age (SGA) infant. Also, scientific evidence is scarce regarding the impact 
of asthma severity and control during pregnancy on these perinatal outcomes. We thus 
conducted a research project composed of five studies to achieve the following 
objectives: 1. to develop and validate two database indexes, one to measure the control of 
asthma and the other to measure asthma severity; 2. to evaluate the effect of fetal gender 
on maternal asthma exacerbations and the use of asthma medications during pregnancy; 
3. to evaluate the impact of maternal asthma on adverse perinatal outcomes; 4. to evaluate 
the impact of the severity of asthma during pregnancy on adverse perinatal outcomes; 5. 
to evaluate the impact of adequately controlled maternal asthma during pregnancy on 
adverse perinatal outcomes. A large population-based cohort was reconstructed through 
the linking of three of Quebec’s (Canada) administrative databases covering the period 
between 1990 and 2002. A two-stage sampling cohort design was used to collect 
additional information on the women’s life-style habits by way of a mailed questionnaire 
for the three last studies.  
 We have observed no significant differences between mothers of a female and 
male fetus as to the occurrence of asthma exacerbations (aRR=1.02; 95% CI: 0.92 to 
1.14). We have found that the risk of SGA (OR: 1.27, 95% CI: 1.14-1.41), LBW (OR: 
1.41, 95% CI:1.22-1.63) and preterm delivery (OR: 1.64, 95%CI:1.46-1.83) was 
significantly higher among asthmatic than non-asthmatic women. Moreover, our results 
showed that the risk of SGA was significantly higher among severe (OR:1.48, 95%CI: 
1.15-1.91) and moderate asthmatic women (OR: 1.30,  95%CI:1.10-1.55) than mild 
  
asthmatic women. Also, mothers with adequately controlled asthma during pregnancy 
were found to be at higher risk of adverse perinatal outcomes than non-asthmatic women 
(SGA (OR:1.28, 95%CI: 1.15-1.43), LBW (OR: 1.42,  95%CI:1.22-1.66), and preterm 
deliveries (OR: 1.63,  95%CI:1.46-1.83)). According to our results, all asthmatic women 
even those with adequately controlled asthma should be closely monitored during 
pregnancy because they are at increased risk of adverse perinatal outcomes. 
  
Keywords : Asthma, Pregnancy, Small for gestational age, Low birth weight, Preterm 
birth, Fetal gender, Asthma exacerbation 
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1. Introduction 
Asthma is one of the most prevalent chronic diseases affecting Canadians. 
According to 2000-2001 Statistics Canada survey, 8.4% of the adult population (aged 12 
and more) had physician-diagnosed asthma (over 2.5 million Canadians) (1). Despite 
several advances in the treatment of asthma, there has been an increase in the prevalence 
of asthma among adults in the past 20 years in Canada and in many other industrialized 
countries (2). This increase over the past decades has made asthma the most common 
chronic disease during pregnancy affecting approximately 8% of women (3-7). The high 
prevalence of asthma during pregnancy results in some concerns about the impact of 
pregnancy on maternal asthma and also the impact of maternal asthma on perinatal 
outcomes. 
 
It has been reported that fetus gender could influence the course of maternal 
asthma. A few studies have suggested that a pregnant woman’s asthma may worsen when 
carrying a female fetus (8-11). It has also been reported that asthma during pregnancy 
could increase the risk of pregnancy induced hypertension, caesarean delivery, 
prematurity, low birth weight (LBW) infant and perinatal/neonatal mortality (12-16). In 
addition, it is reported that women with poorly controlled asthma during pregnancy are 
more likely to deliver LBW, small for gestational age (SGA) and preterm infants than 
non asthmatic pregnant women (14, 17-19). Also, it has been concluded by a few authors 
that there was no difference between women with adequately controlled asthma and non-
asthmatic women for the risk of adverse perinatal outcomes (20-22).  
 
Although there are several studies in the literature examining the impact of fetal 
gender on the course of asthma and the impact of maternal asthma on perinatal outcomes, 
  
conflicting results, methodological differences between studies, questionable clinical 
significance of some of the results as well as lack of statistical power in several studies, 
make it difficult to conclude with a reasonable degree of certainty on these associations. 
To overcome these methodological issues and in order to further investigate the 
association between fetal gender and maternal asthma, we conducted a large population-
based cohort study. To study the association between maternal asthma and perinatal 
outcomes including low birth weight (LBW), preterm birth and small for gestational age 
(SGA) baby, we added a second stage of sampling to the cohort in order to obtain 
additional essential confounding variables. 
 
This thesis is presented by articles including one methodological article and four 
articles presenting the results of the epidemiologic studies in which we investigated the 
associations described in the previous paragraph. The methodological paper presents the 
results of a study related to the development and validation of database indexes of asthma 
severity and control. These indexes measure the control and the severity of asthma in 
currently treated asthmatic patients using the information obtained from the 
administrative healthcare databases of the Canadian province of Quebec; Régie de 
l’Assurance Maladie du Quebec (RAMQ) and MED-ECHO over a period of 12 months. 
These two indexes were used to measure asthma severity and control in two of the four 
epidemiologic studies. 
  
This thesis includes six other chapters. The objectives of our studies are presented 
in the second chapter. The third chapter is devoted to the literature review, wherein, a 
summary of existing knowledge in the field of asthma during pregnancy and its 
consequences on the health of the mother and the newborn is presented. The 
pathophysiology of asthma and asthma treatment which were not covered in the articles 
were also discussed in details to give a better understanding of the disease.  In the fourth 
  
chapter, the methodology employed to conduct the studies is explained. In this section, 
more details regarding the two-stage sampling design and the data collection via 
questionnaires which were not presented in the articles will be presented. Chapter five 
includes five articles which form the result section of my thesis. The last two chapters are 
devoted to the general discussion and conclusion, respectively.  
  
 
  
2. Objectives 
This thesis includes five scientific articles which describe the five studies that 
were undertaken. The research objectives pursued within each of the five studies are 
described in this chapter.   
 
Study 1. Development and Validation of Database Indexes of Asthma Severity and 
Control 
To develop and validate two database indexes, one to measure the control of 
asthma and the other to measure the severity of asthma in currently treated asthma 
patients using information related to dispensed asthma medications and medical 
services. 
 
Study 2. Effect of Fetal Gender on Maternal Asthma Exacerbations in Pregnant 
Asthmatic Women 
To evaluate the effect of fetal gender on the risk of uncontrolled maternal asthma 
through the study of exacerbations, use of inhaled short-acting beta2-agonists 
(SABA) and inhaled corticosteroids (ICS) during pregnancy. 
 
Study 3.  Impact of maternal asthma on perinatal outcomes  
To evaluate the potential effect of asthma during pregnancy on adverse perinatal 
outcomes including SGA infant, LBW infant, and preterm birth. 
 
 
  
Study 4. Effect of maternal moderate to severe asthma on perinatal outcomes  
To evaluate the effect of the severity of asthma during pregnancy on the risk of 
having a SGA infant, a LBW infant, and a preterm birth. 
 
Study 5. Are controlled asthmatic pregnant women more at risk of perinatal 
outcomes than non-asthmatic women? 
To investigate whether or not asthmatic women with controlled asthma are at 
increased risk of having a SGA infant, a LBW infant, or a preterm birth over non 
asthmatic women. 
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3. Literature review  
3.1. Asthma 
The Greek physician Hippocrates used the word asthma for the first time to 
describe an illness. In Greek it means ‘labour breathing’ (23). Asthma is a chronic 
inflammatory disease which affects the respiratory tract and is characterized by 
intermittent or persistent episodes of reversible bronchoconstriction due to increased 
responsiveness of airways to various stimuli (2, 23-26). Both genetic and environmental 
factors are believed to contribute to the initiation and progression of the disease (27). 
Clinically, asthma is manifested by wheezing, dyspnea, chest tightness, and cough (25-
27). Although the first manifestation of the disease can occur at any age, half of the 
patients have asthma onset prior to age 10 years, occurring twice often in boys than in 
girls, and by the age 30, the prevalence of asthma has become equal between sexes (28, 
29). In addition, half of the children suffering from asthma have a substantial or complete 
remission of symptoms during adolescence, but in many cases, the patients may suffer 
from recurrence of asthma symptoms in adult life (27, 28, 30). 
 
3.1.1. Prevalence of asthma  
Asthma is one of the most prevalent chronic diseases affecting Canadians. 
According to the 2000-2001 Statistics Canada survey, about 2.2 million Canadians have 
been diagnosed with asthma by a physician (8.4 % of the population aged 12 years or 
more) (31). In Canada, an estimated 12% of children and 6% of adults have active asthma 
(taking medications for asthma or experiencing some symptoms in the past twelve 
months) (32, 33). There has been an increase in the prevalence of asthma in the past 15 
years and mostly in the westernized countries (2, 34). Prevalence rates tend to be higher 
in economically developed countries with temperate climate in comparison to rural and 
economically developing countries (27).  
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Although there is no clear explanation for the observed increasing incidence of 
asthma, it has been proposed that it may be the result of some alterations in the everyday 
life-styles (35). The early exposure to various allergens during pregnancy and childhood 
may influence the development of the immune system (2). In genetically predisposed 
individuals, the altered immune system may result in an increased allergic response to 
foreign substances and in this way predispose the child to asthma (2). Possible factors 
include changes in nowadays housing conditions with greater exposure to indoor 
aeroallergens, such as cats, house dust mites, cockroaches, and moulds, changes in diet, 
environmental changes such as outdoor pollution and indoor poor air quality as a result of 
more insulated home constructions (2, 35). The known risk factors related to developing 
asthma (incidence) are (23, 30, 36-40):  
 
• A family history of asthma or allergic reaction (eczema, allergic rhinitis), 
• Exposure to high levels of aeroallergens during infancy, 
• Exposure to environmental tobacco smoke both prenatally and postnatally  
• Exposure to chemical irritants in the workplace  
• Extensive vaccination programmes 
• Changes in diet  
o Food preservation 
o Adding antibiotic to the food 
• Inappropriate use of broad-spectrum antibiotics  
• Changes in life style;  
o Better insulated and more energy efficient homes which result in a warm 
and humid environment with low ventilation rate 
o More indoor living pets  
 
 
 
3.1.2. Pathology of asthma 
The pathology of asthma is characterized by various changes in the respiratory 
tract (27). In a normal airway, the lumen is free of mucus, there are few eosinophils in the 
bronchial wall and a layer of ciliated epithelial cells protects the bronchial wall (23, 28). 
However, on postmortem examination of patients with asthma, several changes have been 
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identified including hypertrophy of smooth muscles, thickening of the basement 
membrane due to collagen deposition, filling up of the airways by mucus and 
inflammatory cells, and engorgement of the vessels and microvascular leakage (23, 27, 
30). The swelling and the mucus plugging inside the airways lead to chronic airways 
narrowing which makes it hard for the air to pass through resulting in distressed breathing 
(23, 30).  
 
3.1.3. Pathophysiology of asthma 
The aetiology of asthma is not completely known, but it is suggested that 
bronchial inflammation or its consequences plays an important role in the pathogenesis 
and persistence of asthma (25). Generally, asthma is classified into two major categories 
based on the presence or absence of an underlying immune reaction (23, 25, 28, 30).  
 
The Extrinsic asthma (allergic) occurs in atopic individuals who show allergic 
reaction to foreign bodies such as  house dust mites, grass pollen, and cat and dog dander 
(history of allergic disease) (23, 28). The term ‘extrinsic’ implies that an inhaled allergen 
is the cause of the initiation of the broncho-spasm. Allergic or atopic asthma is the most 
common type of asthma and type I hypersensitivity reaction explains the cause of the 
bronchial inflammation in this group of patients (25). The type I hypersensitivity or 
immunoglobulin E (IgE) mediated hypersensitivity is caused by inappropriate production 
of IgE to specific allergens (23, 30, 41). In allergic asthma, IgE binds tightly on the 
surface of the mast cells, which result in mast cell degranulation and rapid releasing of 
histamine and other inflammatory mediators (Figure 1) (28, 30).  The inflammatory 
mediators induce bronchial smooth muscle contraction, mucus hyper secretion and 
increased vascular permeability (2, 23, 27, 28).  
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The Intrinsic asthma often exhibits in middle-age individuals and the cause of 
bronchial inflammation is much less clear in this type of asthma (23, 25, 28). Generally, 
the non-immunological mechanisms contribute to initiate bronchospasm responsible for 
other symptoms (23, 25, 27, 28).  The common non-allergic triggers are occupational 
exposures to chemical irritants, respiratory tract viral infection, cold weather, air 
pollution, tobacco smoke, strong odours, drugs such as Acetylsalicylic acid (ASA) and 
other nonsteroidal anti-inflammatory drugs (NSAIDs), antiadrenergic and cholinergic 
drugs (e.g. beta blockers and bethanechol), physical exercise, and psychological stress 
(23, 25, 28, 30). In clinical practice, making a clear distinction between extrinsic and 
intrinsic asthma is often difficult.  
 
 
Figure 1. Pathogenesis of asthma. A. Immunologically mediated asthma. Allergens 
interact with IgE on mast cells, either on the surface of the epithelium or, when there is 
abnormal permeability of the epithelium, in the submucosa. Mediators are released and 
may react locally or by reflexes mediated through the vagus (From Rubin R., Strayer D. 
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Rubin’s Pathology. Wolters Kluwer, Lippincott Williams & Wilkins; 2008, with 
permission from the editors (28).  
 
Airway remodeling 
When asthma is poorly controlled, the persistent inflammation can result in the 
airway remodeling. Damage to the protective endothelial layer allows infiltration of 
inflammatory mediators into the mucosa and can yield permanent airway abnormalities 
due to subbasement membrane collagen deposition and fibrosis (23, 27, 30). These 
changes provide the grounds for proposing prompt and continuous use of corticosteroid 
in the treatment of asthma (23, 27). 
 
3.1.4. Diagnosis of asthma 
The clinical diagnosis of asthma is based on a complete medical history, physical 
examination and lung function tests (35). A family history of asthma or atopic disease, 
the presence of typical asthma symptoms that improve with asthma medication, objective 
evidences of variability in lung function over time and evidences of hyper-responsiveness 
of the airways using a provocation challenge test can help to make an accurate asthma 
diagnosis (2, 27, 39). Generally, an increase of 15% or more in FEV1 (an absolute 
improvement of at least 200 ml) after inhaling a bronchodilator (short-acting beta-2 
agonist) is considered as a significant response and is a confirmation of the diagnosis of 
asthma (23, 41, 42).
 
 
 
Asthma symptoms 
The principal asthma symptoms are wheezing, dyspnea, chest tightness, cough, 
tachypnea (usually during an acute asthma exacerbation) and difficulty in sleeping (23, 
24, 30, 39, 43). The duration and frequency of these symptoms vary from patient to 
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patient and can change over time (41). Symptoms are frequently nocturnal or occur in 
early morning and from one acute asthma exacerbation to another one, patients may be 
asymptomatic (30). Significant sputum production is present in about 30% to 50% of 
patients with asthma (41). The microscopic examination of the sputum manifests large 
amount of eosinophils (41).  
 
Objective measurements 
Lung function measurements reflect the degree of airway obstruction and may be 
normal between exacerbations. Performing these measurements are required to confirm 
the diagnosis of asthma and the severity of the disease (30, 44). A spirometer is used to 
objectively measure the volume of air inhaled and exhaled, and to determine how 
effectively and how quickly the lungs can be emptied and filled again (23, 30). In clinical 
practice, the following tests are usually carried out  to measure the lung function, the 
forced expiratory volume in the first second (FEV1), the peak expiratory flow (PEF) and 
the provocation test (24, 30).  
 
FEV1 is the maximum volume of air expired in the first second of maximal 
expiration after a full inspiration and is a useful measure of how quickly full lungs can be 
emptied (23). PEF is the maximal flow rate achieved during expiration and this occurs 
very early in the forced expiratory manoeuvre (23). The PEF and FEV1 are both 
decreased in asthma and during an acute asthma exacerbation as result of increased 
airway resistance (23, 24, 30). The PEF variation greater than 20% during the day 
suggests airway hyperresponsivenesss and poorly controlled asthma (30). PEF and FEV1 
with
 
less than 50% of predicted value (or personal best value) are  signs of respiratory 
distress and severe asthma exacerbation (24, 30).  
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Broncho-provocation challenge testing with methacoline or histamine is 
conducted in patients whose pulmonary function tests are normal, but the diagnosis of 
asthma is not completely ruled out (30, 44). Changes in patient’s lung function (usually 
FEV1) are measured after inhalation of incremental doses of stimulant (methacoline or 
histamine) (23). The concentration of stimulant that causes a 20% decrease in the 
patient’s FEV1 is known as the Pc20 and a Pc20 of less than 4 mg/ml  methacoline is 
highly suggestive of  diagnosis of asthma (23). 
 
3.1.5. Management of asthma 
   According to Canadian guidelines, treatment should be determined on the basis 
of frequency and severity of symptoms, occurrence of acute exacerbations, activity 
limitation, degree of airway obstruction and response to medication (2, 26, 39). The main 
objectives in the treatment of chronic asthma are to prevent irreversible airway damage 
and to control asthma (23). The control of asthma is usually defined as reducing airway 
inflammation to achieve minimal symptoms during the day and night, to achieve normal 
lung function (PEF or FEV1 greater than 80% of the predicted value or personal best 
value), and normal daily activity including sports (23, 39, 43). ICSs are very effective at 
suppressing inflammation in asthma; however, symptoms and airway obstruction usually 
recur when the drugs are discontinued (27).  
 
Lifestyle management  
Medication is not the only way to control asthma. Non-pharmacological options 
such as environmental control approaches are also important to avoid or eliminate known 
exacerbating allergens like pollens that induce or trigger asthma (24, 41). In addition, 
management of asthma involves prophylactic measures such as smoking cessation, 
avoiding ASA and other NSAIDs, and patient education about a self-management plan 
and using the peak flow meter to adjust their therapy (2, 24, 41).   
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Pharmacological management of asthma 
According to the Canadian Asthma Consensus Conference Guidelines for asthma 
management, there are two types of medication to treat persistent asthma; controllers and 
relievers (39). The controller medications or preventers (anti-inflammatory and some 
bronchodilators) should be used on a regular basis to control the underlying inflammation 
and prevent bronchospasm symptoms and attacks. The relievers (short-acting 
bronchodilators) are used to relieve airway constriction and its accompanying acute 
symptoms, only on demand and at the minimum required dose and frequency.  (2). 
 
The choice of medication is based on the severity of the disease and may vary 
over the time as symptoms change (2, 41). Since persistent asthma is a chronic condition, 
patients have to take long-term anti-inflammatory medication daily to control the 
underlying inflammation and to prevent symptoms and attacks (23, 41). Most asthma 
guidelines propose a stepwise approach, which ranges from administrating short-acting 
inhaled beta agonists for very mild intermittent asthma to oral corticosteroids for severe 
asthma (23, 24, 27, 41). Therapy is preferably given by inhalation to deliver the drugs to 
the desired site of action with a much smaller dose and lower systemic drug 
concentrations which reduces systemic adverse effects (24, 27, 39, 41).  
 
Pharmacologic agents (39, 45)  
1. Relievers 
a. Bronchodilators 
• Inhaled short-acting beta2 agonists medications are the best choices for 
treatment of acute exacerbations and prophylaxis of exercise-induced asthma, 
they can produce almost immediate bronchodilating effect (24, 30, 44). 
Salbutamol, terbutaline, fenoterol and orciprenaline are available in Canada 
(24). 
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• Anticholinergic agents such as Ipratropium bromide are recommended for 
patients who present tremor or tachycardia with SABA, or are unresponsive to 
these agents or suffer from bronchospasm induced by a beta-blocker (24, 44). 
Ipratropium bromide is administrated by inhalation and has a delayed onset of 
action comparing to inhaled beta2 agonists, but its bronchodilator effect lasts 
longer (23, 30).  
 
 
2. Controllers 
a. Anti-inflammatory agents 
• Corticosteroids decrease the airway hyper responsiveness via their anti-
inflammatory properties (24, 44). They should be used regularly to achieve  
maximum effect (30).  
 
o Inhaled corticosteroids have less systemic and side effects than oral 
steroids (24, 44). Inhaled budesonide, beclomethasone dipropionate, 
fluticasone propionate and ciclesonide block the late phase of asthma 
and are recommended for chronic asthma prophylaxis (24). 
 
o Oral corticosteroids are helpful in managing acute exacerbations and 
their regular use may be necessary in severe asthma (30, 39). 
Improvement in pulmonary function may begin within 1-3 hours after 
their administration; however, the maximum effect could achieve 
about 6-9 hours later (23, 44). To avoid their significant side effects, 
the treatment should be administered on short periods (one to two 
weeks) (23).   
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• Inhaled Nonsteroidal agents such as Cromolyn sodium and Nedocromil 
sodium prevent both the early and late phase of asthma exacerbation (24, 44). 
They could be used for prophylaxis of exercise-induced asthma or be used 
regularly in conjunction with other asthma therapy or as an alternative to ICS 
in less severe asthma cases (30, 44). However, ICSs are more effective and 
used more commonly than these medications. 
 
• Leukotriene receptor antagonists (LTRAs) have anit-inflammatory and 
bronchodilator properties and are equivalent to low dose of ICS (30, 46). 
Zafirlukast and montelukast, currently available in Canada are usually used as 
an add-on therapy in patients who are inadequately controlled by ICSs (23, 44, 
46).  
 
b. Bronchodilators 
• Inhaled long-acting beta2 agonists are used regularly twice a day and 
considered as an add-on therapy for patients who already taking ICSs without 
achieving the desired control of asthma (24, 44). Salmeterol and formoterol 
are available in Canada (24, 44).  
 
• Theophylline compounds such as theophylline, aminophylline and 
oxtriphylline are the third-line therapy (24, 30, 44). Due to their systemic 
toxicity and their mild clinical effect, these medications are only 
recommended if patients cannot tolerate or are unresponsive to other 
bronchodilators (30).  
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3.2. Asthma in pregnancy 
The prevalence of asthma among pregnant women is estimated between 4 to 7% 
and it is known as one of the most frequent chronic diseases encountered during 
pregnancy (3-5, 7, 47). In a recent study, Known et al investigated the trends in asthma 
prevalence during pregnancy in the United States (US) over the past decades and they 
concluded that the prevalence of self-reported asthma in the US was between 8.4% and 
8.8% (48). In the same study the authors assessed international reports of asthma in 
pregnancy using standardized definitions of asthma within a shared time frame. They 
found significant differences in asthma prevalence during pregnancy worldwide, and an 
overall increasing prevalence of asthma during pregnancy over time (48). In addition, 
these percentages are probably underestimated because, in many cases, either the women 
do not report their previously diagnosed asthma or they are simply undiagnosed 
beforehand (49). The increasing prevalence of asthma during pregnancy necessitates a 
better understanding of the pathophysiology of asthma during pregnancy, and the 
reciprocal effect of asthma and pregnancy.  
 
3.2.1. Pathophysiology of asthma during pregnancy 
Several physiological respiratory alterations occur normally in pregnant women 
(50). Estrogen changes in pregnancy affect the upper respiratory tract and the airway 
mucosa resulting in mucosal edema, hypersecretion and capillary congestion (23, 50). 
Also, the increasing abdominal growth during pregnancy induces an elevation of the 
diaphragm which is associated with pulmonary function changes (23, 50). As a result, the 
expiratory reserve volume is reduced, however, the total lung capacity and FEV1 remains 
unchanged (50, 51). Increased circulating levels of progesterone and its stimulatory 
impact on the respiratory center induce an increase in minute ventilation (the total amount 
of gas expelled from the lungs per minute) and, consequently, a relative hyperventilation 
(23, 50-52). As a result, respiratory alkalosis occurs which induces secondary 
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compensation through renal loss of bicarbonate (50, 52). Thus, during pregnancy, normal 
blood gases reveal a higher pO2 (100 to 106 mmHg) and a lower pCO2 (28 to 30 mmHg) 
than in the non-pregnant state and pCO2 > 35 mmHg or pO2<70 mmHg associated with 
bronchial obstruction represent more severe respiratory failure during pregnancy 
compared to the same blood gas measurements in the nongravid state (50-52).  
 
Normal fetal oxygen pressure of placental blood flow is 30 to 37 mmHg (51, 52). 
To compensate this low level of pO2 in the fetus comparing to the adult (about one third), 
the fetus shows some adaptations: high fetal cardiac output, high affinity of fetal 
haemoglobin for oxygen, high fetal haemoglobin concentration (about 15 to 20 g per L) 
and a system of vascular shunts which directs available blood oxygen to high priority 
organs (liver, heart and brain) (50-52).  
 
Asthma during pregnancy can induce hypoxia combined with acute or 
compensated respiratory acidosis, as well as potentially an acute respiratory alkalosis that 
decreases the placental blood flow , increases systemic and pulmonary vascular resistance 
and decreases cardiac output (52-54). Asthmatic pregnant women who suffer from acute 
asthma exacerbations during their pregnancy can experience hypoxia and hypercapnia 
(28). Consequently, to obtain a reduction in oxygen consumption, the fetus may reduce 
breathing and body movements to redistribute oxygen to high priority organs (50, 51). In 
fetus suffering from lack of oxygen, the rate of oxygen extraction by fetal tissues may 
increase and can lead to perinatal long term effects of hypoxia including intrauterine 
growth retardation (IUGR), preterm birth, neonatal hypoxia or perinatal morbidity and 
mortality (50, 51, 55, 56).  
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3.2.2. Management of asthma during pregnancy 
The goal of asthma therapy in pregnancy is to provide adequate oxygenation to 
the mother and baby. Concerns about teratogenicity of asthma medications during 
pregnancy might lead women to stop or reduce their use, but this fear must be balanced 
against the risk of asthma exacerbations and their potential adverse effects on the mother 
and the developing fetus.  
 
The National Asthma Education Program (NAEP) in the US has issued guidelines 
for the treatment of asthma during pregnancy which recommend to treat asthma as 
aggressively in pregnant women as in non pregnant women (57). ICS are recommended 
as the first line maintenance therapy in women with persistent asthma during pregnancy 
and different studies have shown that ICS can be used with relative safety with minimal 
systemic absorption and few side effects (39, 57, 58). Inhalation has advantages as means 
of giving drugs during pregnancy because the therapeutic action can be achieved with 
minimum pharmacological effect to the fetus (24). The relatively low molecular weight 
and high lipidosolubility of budesonide predicts its substantial placental transfer. (59). 
However, the actual amount of active budesonide reaching the fetus may be small 
because of the low systemic bioavailability after inhalation and extensive placental 
metabolism to inactive compounds (59). In addition, it has been reported that ICS taken 
at recommended doses during pregnancy were associated with a reduction in the risk of 
congenital malformations (60). Systemic treatment should not be withheld if indicated, 
because the risk of asthma exacerbations and their potential adverse effects on the mother 
and the developing fetus is important and they should be treated rapidly. Prednisolone is 
an appropriate corticosteroid for oral use since very little of the drug reaches the fetus 
(24).  
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Indeed, none of the drugs usually used to treat asthma has been shown to cause 
congenital malformations (61-67). However, using the systemic corticosteroids should be 
kept only for severe cases of asthma exacerbation during pregnancy because it has been 
reported that the risk of cleft lip and palate may increase up to 3 folds by these 
medications (62, 65). A significant higher incidence of congenital abnormalities in the 
children of asthmatic women comparing to non-asthmatic ones has been reported by a 
few studies (aOR ranging from 1.10 to 1.37) (14, 68, 69) however, the results of some 
preceding studies were not the same (21, 22, 70). Therefore, it is important that concerns 
about teratogenicity of asthma medications be balanced against the risk of asthma 
exacerbations and their potential adverse effects on the developing fetus.  
 
 Leukotriene modifiers should be avoided during pregnancy because limited 
safety information is available for this situation (27, 65, 71). The pharmacologic and 
toxicologic profiles of inhaled long-acting beta2 agonist are similar to the short-acting 
beta2 agonists, with the exception of their prolonged retention in the lungs (71). However, 
they should be used only if there is no other alternative because limited data are available 
on their use during pregnancy (71-73). ICSs are the cornerstone of therapy in asthma 
during pregnancy and in fact, different studies have shown that ICS can be used with 
relative safety and minimal side effects during pregnancy (39, 57, 58).  
 
Under-treatment of asthma during pregnancy remains one of the main problems in 
the management of pregnant asthmatic women and the most important reasons leading to 
uncontrolled asthma during pregnancy, which may contribute to the increased risk of 
adverse maternal and perinatal outcomes (57, 74). In a study, done by Belanger et al., 
they reported under treatment with ICS in 65% of asthmatic women (N=761) for at least 
3 months during their pregnancy (75). Also, a published survey conducted in 2003 with 
501 asthmatic women 18 to 44 years old  reported that 39% of women who had been 
pregnant before the survey discontinued or reduced their asthma medications during 
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pregnancy (76). Of this subset, a third did so without first discussing it with their 
prescribing physician or obstetrician.  
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3.3. Impact of pregnancy on asthma 
Pregnancy could influence the course of asthma. A few studies have shown that 
asthma worsened during pregnancy in about 33% of women, improved in about 33% and 
stay unchanged in about 33% (77, 78). Both the variable nature of the disease as well as 
the asthma variability due to pregnancy could explain in part the change in the course of 
asthma during pregnancy (79). However, the mechanisms of these changes have not been 
well clarified and in general the course of asthma during pregnancy is not predictable 
(79). It was shown that the first trimester and the last month of pregnancy are relatively 
free of exacerbation and the second and third trimester have more potential for increased 
symptoms and the need for medications (77, 78, 80, 81). The course of asthma during 
pregnancy is influenced by the severity of the pre-existing asthma and severe asthma is 
more likely to worsen during pregnancy than mild asthma (77, 78, 82). The majority of 
women who experience increased severity of asthma during one pregnancy will have 
increased severity during subsequent pregnancies (83).  
 
3.3.1. Impact of fetal gender on maternal asthma exacerbation 
A few studies have suggested that fetal gender could influence the course of 
asthma during pregnancy (8-10). These studies have concluded that asthmatic mothers 
pregnant with female fetus reported more symptoms and had slightly lower lung function 
than mothers pregnant with male fetus (8-11).   
 
In a review of case series three mothers who had been followed in successive 
pregnancies reported more asthma attacks when pregnant with a female fetus than when 
they were carrying a male fetus (11).  
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In a blind-controlled prospective study (n=34), Beecroft et al. have found that 
asthmatic women pregnant with a female fetus reported significantly more shortness of 
breath (72% vs. 31%), nocturnal awakening (55% vs. 37%), and general asthma 
symptoms (50% vs. 31%) than women pregnant with a male fetus (8).  
 
Dodds et al. have evaluated steroids use during pregnancy among a sample of 817 
pregnant asthmatic women without having specific data on asthma severity or symptoms 
and found an increased usage of steroids during pregnancy among mothers of a female 
fetus as compared to mothers of a male fetus (20% vs. 14%) (9). This outcome is difficult 
to interpret since it is unclear whether or not it includes only oral corticosteroids or both 
inhaled and oral formulations, which in the later case would not necessarily reflect 
uncontrolled asthma. Moreover, no conclusion on the statistical significance of this 
difference can be made since no statistical inference was reported in the article. 
 
In a recent study, Kwon et al. used a prospective cohort design to assess the 
association between fetal gender and maternal airway lability among pregnant asthmatic 
women (10). Among 702 pregnant women with asthma, they measured an objective 
outcome i.e. peak expiratory flow (PEF). The PEF was assessed at enrolment and at 21, 
29, and 37 weeks of gestation. The 10% reported difference in log diurnal variation of the 
PEF between pregnancies of male and female fetuses reached statistical significance, but 
the clinical significance of the observed difference is questionable (10). 
  
Conversely, Baibergenova et al. did not find any significant association between 
fetal gender and visits to an emergency department (ED) for asthma during pregnancy 
between pregnancies of male and female fetuses (84). This study was based on a large 
cohort of 109,173 live singleton deliveries reconstructed from a hospital and an 
ambulatory care administrative database provided by the Canadian Institute for Health 
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Information (CIHI). From this cohort, Baibergenova et al. first identified all patients who 
visited an ED during pregnancy and then found that 0.49% and 0.48% of those ED visits 
were for asthma among women pregnant with a female and a male fetus, respectively (p-
value > 0.05).  
 
Among the hypotheses put forward to explain the mechanisms behind the 
association between fetal gender and maternal asthma control during pregnancy, the one 
related to the regulation of placental glucocorticoid and immune response in asthmatic 
pregnancies seems the most plausible (8, 10, 84). Indeed, Clifton and Murphy and their 
research teams have reported that female fetus alters maternal asthma during pregnancy 
by upregulating maternal inflammatory pathways (85-88) and thus if asthma-associated 
inflammatory pathways are not treated with inhaled steroids during pregnancy, the 
mother could suffer asthma exacerbation.  
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3.4. Impact of asthma on pregnancy 
Asthma could affect pregnancy outcomes. Asthma in pregnancy has been 
associated with maternal and fetal morbidity (16, 21, 89). It has been reported that 
pregnant asthmatic women have an increased risk of vaginal bleeding (16), pregnancy-
induced hypertension (16, 89), cesarean section (90, 91) and complicated labor (90) 
comparing to non-asthmatic women . However, it seems that the magnitude of these 
adverse outcomes is related to the degree of control and severity of maternal asthma (49). 
The association between maternal asthma and adverse perinatal outcomes has been 
evaluated by several studies; however, the literature reports inconsistent results.  
 
3.5. Impact of asthma on adverse perinatal outcomes 
Studies comparing adverse perinatal outcomes such as preterm birth, LBW infant 
or SGA infant between pregnancies of asthmatic women and non-asthmatic women are 
summarized in Table1. Different study designs were used in 36 studies presented in Table 
1. There are 14 prospective studies, 5 case series, 14 retrospective studies, 2 case-control 
studies, and one cross-sectional survey. The results of one other systematic review (meta-
analysis) are also presented in this table. The sample size of asthmatic group ranged from 
32 (92) to 36,985 (93) pregnancies and the sample size of non-asthmatic group ranged 
from 77 (94) to 1,320,000 (93) pregnancies. Among these studies, 27 adjusted for diverse 
potential confounding variables, but only 14 studies adjusted for smoking. 
 
In Table 1, for each study, general information regarding the study design, the 
period of data collection, the sample size of the asthmatic and non-asthmatic groups and 
the list of confounding variables are presented.  The magnitude of the risk for the adverse 
perinatal outcomes and its statistical significance are also presented in this table.  
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3.5.1.  Small for gestational age 
Most of the older studies evaluated the impact of maternal asthma on adverse 
perinatal outcomes did not assess the risk of delivering SGA infant in asthmatic women 
compared to non-asthmatic women. Among 13 studies that evaluated the risk of this 
adverse perinatal outcome among asthmatic women, 5 large studies reported a significant 
association between maternal asthma and the risk of SGA infants (adjusted relative risk 
(aRR) ranged from 1.16 to1.50) (14, 17, 95-97). However, 8 other studies found no 
significant increased risk of SGA associated with asthma (21, 63, 91, 94, 98-101). Lack 
of adjustment for several potential confounders and lack of power due to small sample 
sizes probably explain the differences in results.  
 
3.5.2.  Preterm birth 
Preterm birth, occurring prior to 37 weeks of gestation was evaluated in 29 studies 
and 10 of them have reported a significant increase of risk in asthmatic women that 
ranged from 1.15 to 4.00. Risk of preterm birth has been reported to be significantly 
increased in asthmatic women as compared to non-asthmatic women in 5 large studies 
(asthmatic population size > 2000) that adjusted for several potential confounders (aOR: 
1.11-1.78) (14, 17, 19, 93, 97). In addition, 4 other smaller studies (asthmatic population 
size < 500) reported a significant increased risk of preterm birth with ORs ranging from 
1.48 to 4.00 (16, 91, 102, 103). The fourfold significant increased risk of preterm delivery 
has been reported by Perlow et al. in asthmatic women receiving regular non-steroid 
medication (91). However, 18 studies have not found a significant increased risk of 
preterm birth in asthmatic women versus non-asthmatic women (7, 15, 20, 21, 61, 90, 92, 
94, 96, 98, 100, 104-110). Four other studies reported no significant difference in mean 
gestational age between asthmatic and non-asthmatic pregnant women (22, 95, 111, 112). 
Moreover, in a recent meta-analysis, conducted by Murphy and al, the asthmatic women 
 28 
 
with and without asthma exacerbation during pregnancy were compared to non asthmatic 
women (113). The authors found no significant increased risk of preterm delivery in 
women who had (RR: 1.46, 95%CI: 0.77-2.78) and those who did not have an asthma 
exacerbation during pregnancy (RR: 0.93, 95% CI: 0.74-1.17). 
 
3.5.3. Low birth weight 
Among 22 studies which evaluated the impact of maternal asthma on the risk of 
LBW infant (weight<2500 g at birth), 7 reported a statistical significant 1.15 to 9.36 
increase in the incidence of LBW. Bahna et al were the first authors who reported a 
significant increased risk of LBW (OR: 1.92) in asthmatic women (16). This increased 
risk was later confirmed in 3 large studies (asthmatic population size > 2000) conducted 
retrospectively and adjusted for some potential confounders including smoking (OR: 1.15 
to 1.32) (14, 93, 97). Two other smaller studies also reported a significant increased risk 
of LBW ranging from 2.95 to 9.36 (90, 114). No significant differences in the risk of 
LBW was observed among asthmatic women as compared to non-asthmatic women in 15 
other studies (7, 15, 20, 21, 61, 63, 91, 92, 94, 95, 105, 106, 109, 115, 116). In addition, 
Murphy et al investigated the effect of asthma and asthma exacerbation on LBW through 
a meta-analysis using data from three studies (113). They observed a significantly 
increased risk in women who had (RR: 2.54, 95% CI:1.52-4.25) but no increased risk in 
those who did not have an asthma exacerbation during pregnancy (RR: 1.12, 95% CI: 
0.89-1.40) (113).  
 
 
 
 Table 1. Description of studies that assessed the impact of maternal Asthma on SGA, preterm birth and LBW 
 Author, year 
of publication 
(Ref number) 
Study design 
(period of data 
collection) 
Source of data 
Sample size (pregnancy) OR / RR (95% Confidence Interval) or incidence % Adjustment for any 
confounders Asthmatic Non-
asthmatic SGA Preterm <37 wk LBW 
Schaefer et al. 
1961 (115) 
Case series  
 (1953-1959) 
New-York 
Lying-in 
hospital 
293  30,000  NE NE 1.10 NS No adjustment 
Gordon et al. 
1970 (15) 
Retrospective 
Cohort 
(unknown) 
Collaborative 
Study of 
neurological 
diseases (USA) 
277  30,861  NE 0.80 NS 1.33 NS No adjustment 
Bahna et al. 
1972 (16) 
Retrospective 
Cohort  
(1967-1968) 
Medical birth 
registry of 
Norway 
365 108,622 NE 1.48 (p<0.01) 1.92 (p<0.001) No adjustment 
Schatz et al. 
1975 (107)  
Case series  
 (1975) 
3 Medical 
Centers (USA) 70 
General 
population NE 1.50 NS NE No adjustment 
Fitzsimmons et 
al. 1986 (61) 
Case series  
(1981-1984) 
North-western 
University 
Allergy Service 
56 General population  NE 1.30 NS 2.53NS No adjustment 
Dombrowski et 
al. 1986 (111) 
Prospective 
(1982-1985) 
Medical records 
in Hutzel 
Hospital (USA)  
153  116  NE 
NS difference in 
mean gestational 
age (39weeks vs. 
39weeks) 
NS difference in 
mean birth weight 
(3000g vs. 3050g) 
Matched for parity 
Stenius et al. 
1988 (22) 
Prospective 
 (1978-1982) 
Helsinki 
University 
Central Hospital  
198  198  NE 
NS difference in 
mean gestational 
age (278days vs. 
276days) 
NS difference in 
mean birth weight 
(3479g vs. 3483g) 
Matched for age, 
parity and time of 
delivery 
Greenberg et 
al. 1988 (106) 
Case series 
(1981-1987) 
North-western 
University 
Allergy Service 
80 General population NE 1.03 NS 2.17 NS No adjustment 
Schatz et al. 
1988 (105) 
Prospective 
 (1978-1984) 
San Diego 
Kaiser-
Permanente 
Medical Care  
 
259 295 NE 2.22 NS 1.93 NS Matched for age and 
smoking 
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 Author, year 
of publication 
(Ref number) 
Study design 
(period of data 
collection) 
Source of data 
Sample size (pregnancy) OR / RR (95% Confidence Interval) or incidence % Adjustment for any 
confounders Asthmatic Non-
asthmatic SGA Preterm <37 wk LBW 
Lao et al. 1990 
(90) 
Retrospective  
(1984-1987) 
Hospital, Hong 
Kong 87  87  NE 3.09 NS 9.36 (p<0.01) 
Matched for age and 
parity 
Mabie et al. 
1992 (98) 
Case series 
(1986-1989) 
Hospital, 
Tennessee 200  22,651  0.87 NS 0.90 NS NE No adjustment 
Perlow et al. 
1992 (91) 
Retrospective  
 (1985-1990) 
Long Beach 
Memorial 
Medical Center 
Hospital 
150 130 5.6 (0.8-40.2) 4.0 (1.1-15.5) 3.4 (0.9-12.1) No adjustment 
 Doucette et al. 
1993 (92)  
Prospective 
(1980-1982) 
Yale-New 
Haven Hospital 32  3,850  NE 1.78 (0.53-6.02) 0.73 (0.1-5.29) 
Adjusted for 
education, race, 
vaginal bleeding, 
smoking in 2nd 
month 
Schatz et al. 
1995 (21) 
Prospective 
Cohort 
(1978-1990) 
San Diego 
Kaiser-
Permanente 
Medical Care 
486 486 1.33 (p=0.33) 1.65 (p=0.14) 1.64 (p=0.16) 
Matched for age, 
smoking, parity, year 
of delivery 
Stenius et al. 
1995 (108) 
Prospective 
(1982-1990) 
Helsinki 
University 
Central Hospital 
and Helsinki 
Maternity 
Hospital  
504  237  NE 1.15 NS NE Matched for age and parity 
Jana et al. 1995 
(20) 
Prospective 
(1983-1992) 
Nehru hospital, 
India 182  364  NE p>0.05 p>0.05 
Matched for age and 
parity 
Corchia et al. 
1995  (114) 
Cross-Sectional 
Survey 
(1987) 
3 areas of Lazio 
Region, Italy 55 2,871 NE NE 
Smoking  
6.62 (1.75-25.07) 
No smoking 
1.17 (0.28-4.99) 
Adjusted for  infant 
gender, and maternal 
education within each 
level of smoking 
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 Author, year 
of publication 
(Ref number) 
Study design 
(period of data 
collection) 
Source of data 
Sample size (pregnancy) OR / RR (95% Confidence Interval) or incidence % Adjustment for any 
confounders Asthmatic Non-
asthmatic SGA Preterm <37 wk LBW 
Kramer et al. 
1995 (102) 
Case-Control 
 (1990-1992) 
3 McGill 
University-
affiliated 
hospitals 
among cases 
244 
341 
among cases 
200 NE 
2 2.32 (1.38-3.89) 
3 2.42 (1.44-4.08) NE 
Matched for race, and 
smoking prior and 
during pregnancy 
Stenious et al. 
1996 (104) 
Prospective 
Cohort  
(1982-1992) 
Helsinki 
University 
Central Hospital 
4457 237 NE 1.0 NS NE Matched for age and parity 
 Alexander et 
1998 al. (7)  
Retrospective 
Cohort 
(1991-1993) 
Nova Scotia 
Perinatal 
Database 
5N: 375 
6B: 303 
7S: 139 
13,709 NE 
5N: 1.0 (0.5-1.7) 
6B: 1.0 (0.5-1.8) 
7S: 1.4 (0.6-3.0) 
5N: 0.9 (0.5-1.5) 
6B: 1.4 (0.8-2.2) 
7S: 1.0 (0.4-2.5) 
Adjusted for age, 
previous delivery of 
LBW, parity, pre-
delivery weight, and 
smoking 
Demissie et 
1998 al. (14) 
Retrospective 
Cohort  
(1989-1992) 
Administrative 
databases of 
New Jersey 
Hospitals 
2,289 9,156 
Crude 
1.33 (1.17-1.51) 
Adjusted 
1.26 (1.10-1.45) 
Crude 
1.59 (1.40-1.80) 
Adjusted 
1.36 (1.18-1.55) 
Crude 
1.57 (1.34-1.86) 
Adjusted 
1.32 (1.10-1.58) 
Adjusted for age, 
education, marital 
status, parity, race, 
chronic &gestational 
diabetes, chronic  
HTA, smoking, 
alcohol and drug use 
Kallen et al. 
2000 (93) 
Retrospective 
Cohort  
(1984-1995) 
The Sweden 
Medical Birth 
Registry 
All 
36,985 
Severe 
1,396  
81,320,000 NE 
All 
1.15 (1.09-1.21) 
Severe 
1.56 (1.27-1.90) 
All 
1.21 (1.14-1.29) 
Severe 
1.98 (1.52-2.59) 
Adjusted for year of 
delivery, age, and 
smoking 
Wen et al. 2001 
(19) 
Retrospective 
Cohort 
(1990-1996) 
Hospital 
discharge data 
from Canadian 
Institute for 
Health 
Information 
8,672 34, 688 NE 
Crude 
1.83 (1.57-2.11) 
Adjusted  
1.78 (1.53-2.07) 
NE 
Adjusted for age, 
chronic and 
gestational diabetes, 
chronic  and 
gestational  HTA, and  
caesarean delivery 
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 Author, year 
of publication 
(Ref number) 
Study design 
(period of data 
collection) 
Source of data 
Sample size (pregnancy) OR / RR (95% Confidence Interval) or incidence % Adjustment for any 
confounders Asthmatic Non-
asthmatic SGA Preterm <37 wk LBW 
Minerbi-
Codish et al. 
1998 (94) 
Prospective 
Cohort 
(1993-1994) 
Medical Center 
(Israel) 101 77 
No statistically 
significant 
difference 
No statistically 
significant 
difference 
No statistically 
significant 
difference 
Matched for age and  
ethnic origin 
Liu et al. 2001 
(17) 
Retrospective 
Cohort 
(1991-1996) 
Med-Echo 
database 
(Quebec)  
2,193 8,772 
Crude 
1.19 (1.02-1.37) 
Adjusted 
1.16 (1.00-1.35) 
Crude 
1.59 (1.35-1.87) 
Adjusted 
1.40 (1.18-1.66) 
NE 
Adjusted for age, 
chronic and 
gestational diabetes, 
chronic  HTA, and 
caesarean delivery 
Olesen et al. 
2001 (63) 
Retrospective 
Cohort 
(1991-1996) 
Hospital 
Discharge 
Registry and 
North Jutland 
Prescription 
Database 
(Denmark) 
9303 108,717  higher among 
exposed one  NE 
 higher among 
exposed one  
Adjusted for age, co-
habitation status, 
smoking and child 
gender 
Sobande et al. 
2002 (112) 
Prospective 
Cohort 
(1997-2000) 
Maternity 
Hospital (Saudi 
Arabia)  
88 106 NE 39.41 vs. 39.43 (p>0.05) 
2,855g vs. 3,051g 
(p=0.006) No adjustment 
Sorensen et al. 
2003 (103) 
Nested case-
control 
(1994-1995) 
Healthcare 
network of 
Swedish 
Medical center, 
(Seattle, USA) 
among cases 
20 
among cases 
292 NE 
Crude 
2.03 (1.01-4.09) 
Adjusted 
2.37 (1.15-4.88) 
NE 
Adjusted for age, 
race, parity, Medicaid 
status and smoking  
Bracken et al. 
2003 (99)  
Prospective 
Cohort 
(1996-2001) 
56 obstetric 
practices and 15 
clinics 
(Connecticut, 
Massachusetts) 
873 1,333 
Crude 
1.22 (0.89-1.68) 
Adjusted 
1.15 (0.79-1.67) 
Crude 
1.49 (1.07-2.08) 
Adjusted 
1.36 (0.92-2.00) 
NE 
Adjusted for age, 
marital status, race, 
education, pre-
pregnancy weight, 
height, smoking, 
daily caffeine, parity 
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 Author, year 
of publication 
(Ref number) 
Study design 
(period of data 
collection) 
Source of data 
Sample size (pregnancy) OR / RR (95% Confidence Interval) or incidence % Adjustment for any 
confounders Asthmatic Non-
asthmatic SGA Preterm <37 wk LBW 
Mihrshahi et 
al. 2003 (109) 
Prospective data 
collection 
(2003) 
Questionnaires 
to women 
identified in 
antenatal clinics 
of 6 Sydney 
hospitals 
340 271 NE 2.13 NS 1.47 NS 
Adjusted for age, 
parity, nulliparous, 
socioeconomic 
factors, exposure to 
smoking 
Dombrowski et 
al. 2004 (100) 
Prospective 
Cohort 
(1994-1999) 
16 centers of 
Maternal-Fetal 
Medicine Unit 
Network (USA) 
Mild: 873 
Moderate-
Severe:866 
Severe: 52 
881 
Mi:1.2 (0.8-1.7) 
MS:1.2 (0.8-1.8) 
Sev: 1.6 (0.6-4.4) 
Mi: 1.0 (0.6-1.8) 
MS: 0.9 (0.5-1.6) 
Sev: 2.2 (1.2-4.2) 
NE 
Adjusted only for 
analyses of severe 
patients for previous 
preterm, smoking, 
race, BMI  
ACS et al. 2005 
(116) 
Retrospective 
(1980-1996) 
Hungarian 
Congenital 
Abnormality 
Registry 
757 37,394 NE 
1.56  
statistical 
significance not 
reported 
1.61 
Statistical 
significance not 
reported 
Adjusted for age, 
birth order, 
employment status. 
Anti-asthmatic drugs  
Sheiner et al. 
2005 (95) 
Retrospective 
Cohort 
(1988-2002) 
Soroka 
University 
Medical center 
(Israel) 
1,963 137,205 1.5 (1.1-1.9) No difference in 
mean  
1.10 NS 
Adjusted for failure 
to progress in labour, 
mal-presentation 
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 Author, year 
of publication 
(Ref number) 
Study design 
(period of data 
collection) 
Source of data 
Sample size (pregnancy) OR / RR (95% Confidence Interval) or incidence % Adjustment for any 
confounders Asthmatic Non-
asthmatic SGA Preterm <37 wk LBW 
Murphy 2006 
(113) 
Meta analyse, 
 (2006) 
3 studies for 
evaluating LBW 
and 4 studies for 
evaluating 
preterm birth  
 
No- 
exacerbation
855 
Exacerbation 
79 
 
No- 
exacerbation 
1,312 
Exacerbation 
126 
For No- 
exacerbation 
31,662 
For 
Exacerbation 
31,285 
 
For No-
exacerbation 
31,662 
For 
Exacerbation 
31,899 
NE 
No-exacerbation 
vs. non-asthmatic 
0.93 (0.74-1.17) 
 
Exacerbation vs. 
non-asthmatic  
1.46 (0.77-2.78) 
 No-exacerbation 
vs. non-asthmatic 
1.12 (0.89-1.40) 
 
Exacerbation vs. 
non-asthmatic  
2.54 (1.52-4.25) 
LBW:  
(15),  (20), (21) 
 
Preterm birth: 
(15), (20), (21), (104) 
Enriquez et al. 
2007 (96) 
Retrospective 
cohort 
(1995-2003) 
Tennessee 
Medical 
Program 
Asthmatic 
9,154  
Exacerbation 
2,105 
No- 
Exacerbation 
7,049 
 
131,145 
Asthmatic vs. 
Non-asthmatic 
1.19 NS 
 
very SGA 
1.20 (p< .0001) 
Asthmatic: Ns 
Exacerbation: NS 
No-exacerbation: 
NS 
Asthmatic: Mean  
3,131g vs. 3,173g 
(p< .0001) 
 
Exacerbation 
1.22 (< .0002) 
 
No-exacerbation 
1.16 (< .0002) 
Adjusted for race, 
age, smoking, 
education, 
comorbidity and 
adequacy of prenatal 
care 
 
Clark et al. 
2007 (101) 
Prospective; 
Clinic 
 (2001-2003) 
Antenatal 
clinics of 
Manchester 
Children’s 
University 
Hospitals 
370 No med. 
170 ICS& β2 
178 β2 only 
718 
ICS& β2 
Boys:  
1.56 (p=.011) 
Girls:  
0.95 (p=.56) 
NS (other group) 
NE 
ICS& β2  
↓ in mean birth 
weigh 
-112 (-193, -30.7) 
NS for other 
groups 
Adjusted for 
smoking, race, parity, 
gestational age 
 35 
 
 Author, year 
of publication 
(Ref number) 
Study design 
(period of data 
collection) 
Source of data 
Sample size (pregnancy) OR / RR (95% Confidence Interval) or incidence % Adjustment for any 
confounders Asthmatic Non-
asthmatic SGA Preterm <37 wk LBW 
Kallen et al. 
2007 (97)  
Retrospective 
cohort  
(1995-2004) 
Swedish 
Medical Birth 
Registry 
23,988 
All birth 
registered 
846,635 1.16 (1.07-1.26) 1.11 (1.05-1.18) 1.15 (1.07-1.23) No adjustment 
mentioned 
 
NS: statistically non significant 
NE: not evaluated  
HTA: hypertension 
1Receiving chronic medication but non-steroid dependent 
2history of Asthma 
3Physician diagnosed asthma 
4No acute attack of asthma during the study period 
5N: No asthma medication use 
6B: beta agonist use only 
7S: Steroid use 
8All birth during study period 
9Receiving at least one prescription for asthma during pregnancy 
10Buying no drug prescription during pregnancy 
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The differences between these results could be partly explained by important 
differences between studies in: 
• The study sample sizes,  
• Study designs,  
• Asthmatic definition, 
• Non-asthmatic  definition, 
• Data collections,  
• Control for confounders,  
• Asthma severity during pregnancy, 
•  Adequacy of control of asthma during pregnancy. 
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3.6. Asthma severity and asthma control 
Control and severity of asthma are two different but complementary concepts 
(117). In fact, one can have severe asthma but adequately controlled and another one can 
have mild asthma but poorly controlled. The severity of asthma could influence the 
control over time. Canadian experts have recommended that the dose of ICS necessary to 
obtain good control of asthma should be included when evaluating severity (39). The 
accurate classification of asthma severity and control is a definite challenge both in 
clinical practice and in research since they are conceptually related and some of the 
criteria used in their assessment overlap.  
 
3.6.1.  Asthma control  
Current series of criteria in the assessment of the control of asthma were 
established by the Global Initiative for Asthma (GINA) and the Canadian Asthma 
Consensus Guidelines (39, 43). They include daytime and nocturnal symptoms, physical 
activity limitations, the occurrence of asthma exacerbations, the need for inhaled SABA, 
school or work absenteeism, and forced expiratory volume in the first one second (FEV1) 
or peak respiratory flow (PEF) values. The optimal control of asthma based on Canadian 
Asthma Consensus Guidelines has been defined by the presence of minimal respiratory 
symptoms, no physical activity limitation, normal respiratory function, and absence of the 
need for rescue bronchodilator more than recommended (see table 2) (39). 
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Table 2. Indications of asthma control 
From Canadian asthma consensus report, 1999 (39) 
 
Parameter 
 
Frequency or value 
Daytime symptoms < 4 days/week 
Night-time symptoms <1 night/week 
Physical activity Normal 
Exacerbations Mild, infrequent 
Absence from work or school None 
Need for short-acting β2-agonist <4 doses/week * 
FEV1or PEF > 85% of personal best, ideally 90% 
PEF diurnal variation† < 15% of diurnal variation 
FEV1= forced expiratory volume in 1 second; PEF = peak expiratory flow obtained with a portable peak flow meter. 
*May use 1 dose/day for prevention of exercise-induced symptoms. 
† Diurnal variation is calculated by subtracting the lowest PEF from the highest and dividing by the highest PEF 
multiplied by 100. 
 
3.6.2. Asthma severity  
Different methods are advocated by various guidelines for the assessment of 
asthma severity (39, 43, 118). The GINA guidelines as well as the US National Asthma 
Education and Prevention Program Consensus guidelines relative to the assessment of 
severity rely upon the evaluation of the disease’s clinical features (asthma symptoms, 
occurrence of asthma exacerbation and respiratory function) prior to the initiation of any 
anti-asthmatic treatment (43, 118). However, the Canadian Asthma Consensus Guidelines 
assess asthma severity once the treatment has been instigated and rely upon a 
combination of factors, many of which overlap with measures of asthma control. These 
include pulmonary function tests, the treatment required to obtain asthma control, the 
history of hospital admissions, and life-threatening asthma attacks (see table 3) (39).  
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Table 3: Levels of asthma severity based on treatment needed to obtain control  
From Canadian asthma consensus report, 1999 (39) 
 
Asthma severity Symptoms Treatment required 
Very mild Mild-infrequent None, or inhaled SABA 
rarely 
 
Mild Well-controlled  SABA (occasionally) and 
low-dose ICS 
 
Moderate Well-controlled SABA and low to moderate 
doses of ICS with or 
without additional therapy 
 
Severe Well-controlled SABA and high doses of 
ICS and additional therapy 
 
Very Severe May be controlled or not 
well-controlled 
SABA and high doses of 
ICS and additional therapy 
and OCS 
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3.7. Impact of adequately controlled asthma during 
pregnancy on adverse perinatal outcomes 
Poorly controlled asthma is potentially dangerous to the fetus since hypoxia 
combined with respiratory alkalosis decrease placental blood flow and potentially 
impaired fetal oxygenation (50, 52, 57, 119). Decreased fetal blood oxygen could result 
in abnormal growth and development of the fetus (120).  Jana et al. found that maternal 
uncontrolled severe asthma (ED visit and systemic corticosteroids use during pregnancy) 
leads to fetal growth retardation (mean birth weight: 2469g vs 2842g; p<0.05) and low 
birth weight (53.3% vs 20.5%; p<0.01) more often than women with adequately 
controlled asthma during pregnancy (20). These results have also been confirmed in other 
studies (56, 61, 106).  
 
The question is whether better controlled asthma lead to improve fetal growth. To 
our knowledge, only one study evaluated directly whether or not women with adequately 
controlled asthma are at higher risk of perinatal outcomes than non-asthmatic women. In 
a prospective controlled study comparing women with actively managed asthma during 
pregnancy and non-asthmatic women, Schatz et al observed relative risks as large as 1.65 
for perinatal outcomes, but concluded that there was no difference between the groups 
since the relative risks were not statistically significant (21). In two other studies, 
Stenius-Aarniala et al and Jana et al. came to the same conclusion, although the 
association between the control of asthma and perinatal outcomes was only indirectly 
evaluated (20, 22). 
 
In a prospective study conducted between 1978-1990, Schatz et al assessed 
perinatal outcomes in 486 actively managed pregnant asthmatic women as compared with 
486 non asthmatic pregnant women matched for age, smoking, parity and year of 
delivery (21). All asthmatic women had a history of asthma or asthma symptoms with a 
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reconfirmation of their diagnostic of asthma at the entry to the study and they were 
managed in the allergy clinic to prevent acute asthmatic episodes and asthma symptoms 
that interfere with sleep or normal activity. Moreover, all women received routine 
obstetric care. The authors reported a RR of 1.33 for SGA (p value =0.33), a RR of 1.64 
for LBW (p=0.16), and a RR of 1.65 (p=0.14) for preterm births. However, they 
concluded that there was no difference between the groups since these RRs were not 
found to be statistically significant (21).  
  
Jana et al. compared the perinatal outcomes in 182 pregnancies from asthmatic 
women with those of  364 non-asthmatic women matched for age and parity between 
1983-1992 (20). The asthmatic women were followed in an Obstetric-Medical Disorder 
Clinic and there were close cooperation between the obstetrician and chest physician in 
the patient’s management. The asthmatic women were advised to continue anti-asthmatic 
medication throughout pregnancy and they were provided with instructions in the case of 
acute exacerbation of asthma.  
 
In this study, the authors investigated the risk of adverse perinatal outcomes in 
women who required emergency hospitalization and was managed with high flow of 
oxygen, high doses of inhaled β2-agonists, intravenous corticosteroids and aminophylline 
infusion during the study period (severe asthmatic patients) as compared with non-
asthmatic controls (20). Moreover, they compared women who had used oral and/or 
parental β2-agonists, theophylline, aminophylline, corticosteroids, and inhaled salbutamol 
and beclomethasone during the study period (mild asthmatics) to non-asthmatic ones for 
adverse perinatal outcomes. In summary, the authors investigated the effect of asthma 
severity level on adverse perinatal outcomes and they concluded indirectly regarding well 
controlled asthma without any clear distinction between asthma severity and control.  
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In another study, Stenius-Aarniala et al. prospectively followed 198 pregnancies 
of asthmatic women and 198 pregnancies of non-asthmatic women matched for age, 
parity and time of delivery from 1978 to 1982 (22). In this study, asthmatic women were 
divided into four severity groups based on the treatment necessary to control asthma 
during pregnancy and the occurrence of acute asthma exacerbation. The authors 
examined the risk of adverse perinatal outcomes in each severity group as compared to 
the non-asthmatic women and they concluded that there is no difference in adverse 
perinatal outcomes between well controlled asthmatic women and healthy women (22). 
 
 
  
 3.8. Impact of maternal asthma severity on adverse 
perinatal outcomes 
Although studies have reported associations between severe exacerbations 
requiring hospitalization during pregnancy and adverse perinatal outcomes (20, 61, 106), 
there is little evidence on the impact of the level of asthma severity on perinatal 
outcomes. Only a few small studies investigated the association between the level of 
asthma severity during pregnancy and perinatal outcomes and yielded inconsistent 
results. Studies comparing adverse perinatal outcomes such as preterm birth, LBW infant 
or SGA infant between pregnancies of women with moderate to severe asthma and 
women with mild asthma are summarized in Table4. 
 
3.8.1.  Small for gestational age 
Fitzsimmons et al. and Mabie et al. reported a significant increased risk of SGA 
infants associated with severe asthma as compared with mild asthma (p=0.02 and p<0.05 
and  respectively) (61, 98). However, their definition of severe asthma was quite  
restrictive including only patients who were hospitalized for status asthmaticus, had 
mechanical ventilation or required chronic maintenance therapy with oral prednisone (61, 
98). In another study, Schatz et al. reported a significant  increase in the ponderal indices 
< 2.2 (suggestive of asymmetric intrauterine growth retardation) (p=0.04) in women who 
had lower mean percent predicted FEV1 during pregnancy (56). However, in this study 
the authors did not evaluate directly SGA infants but they examined the ponderal 
index<2.2 which is considered to be indicative of IUGR (56). Among these three studies, 
only Schatz et al. adjusted their results for some potential confounding variables 
including smoking (56).  
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A few other studies found a non-significant increased risk of SGA among women 
with severe asthma compared to women with mild asthma (99, 106, 121). Bracken et al 
found that IUGR (defined as below the tenth percentile of birth weight for gestational 
age) was more common among infants of mothers with mild to moderate persistent 
asthma as compared to those with no symptoms or medication use (OR ranged from 1.74 
to 1.98)  (99). However, they reported no significant increased risk among women with 
severe persistent asthma (aOR=1.57; 95% CI: 0.72-3.45) as compared to asthmatic 
women with no symptoms or medication use (99). Perlow et al. and Dombrowski et al. 
also found no increased risk of SGA associated with severe asthma (91, 100).  
 
3.8.2. Preterm birth 
There are several studies that have evaluated the association between markers of 
severe asthma and the risk of preterm delivery (Table 4.). Three studies found a 
significant increased risk of preterm delivery associated with severe asthma which ranged 
from 1.38 to 7.5 (91, 121, 122). Perlow et al. defined severe asthma as the mother being 
corticosteroid dependent during pregnancy (91). This definition is quite restrictive, 
identifies the most severe asthmatic and corresponds to only a small proportion of women 
with severe asthma. However, in two other studies, severe asthma was defined as women 
who had mean FEV1<80% during study period (121) or women who had asthma 
symptoms during the prior 2 weeks before each interview that interfere with sleep or 
activity occasionally, frequently or constantly (122). 
 
Some other studies have found non-significant increase in the risk of preterm birth 
associated with asthma severity (20, 61, 99, 106, 108, 123). However, all of them had a 
small sample size and except one (99) all suffered from the lack of adjustment for 
important confounding variables, including cigarette smoking during pregnancy. Five 
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other studies have not found any association between asthma severity and preterm birth 
(22, 90, 98, 100, 104).  
 
3.8.3. Low birth weight 
A significant increase in LBW (OR:5.1, 95%CI: 1.6-17.0) was found by Perlow et 
al among infants of corticosteroid dependent mothers as compared to non-corticosteroids 
dependent mothers (91). Also, Jana et al found a significantly higher incidence of LBW 
among infants of 15 mothers requiring as compared to 167 mothers not requiring 
emergency admission during pregnancy (53.3% vs. 20.5%; p<0.01) (20). Moreover, 
Schatz et al. reported a 36% significant increased risk of LBW among pregnant women 
having a mean FEV1<80% during pregnancy as compared with women with higher mean 
FEV1 during pregnancy (121). 
 
Greenberg et al and Fitzsimmons et al have found a significant decrease in mean 
birth weight (ranging from 300 to 500 g) among women who were hospitalized for 
asthma during pregnancy (61, 106). However, these authors found no significant 
increased risk of LBW among women who were hospitalized for asthma during 
pregnancy. On the other hand, Stenius-Aarniala et al found no difference in birth weight 
between mothers with moderate-to-severe asthma and mothers with very mild-to-mild 
asthma (3418 vs. 3479 g) (22). Moreover, Lao et al. found no association between level 
of asthma severity and the risk of LBW (90).  
 Table 4. Description of studies that assessed the impact of asthma severity during pregnancy on adverse perinatal outcomes 
 
 Author, year 
of publication 
(Ref number) 
Study 
design 
(period of 
data 
collection) 
Source of 
data 
Severity definition Sample size (pregnancy) 
OR / RR (95% Confidence Interval) or incidence 
% Adjustment for 
any confounders Severe 
asthmatic 
Mild 
asthmatic 
Severe 
asthmatic 
Mild 
asthmatic SGA 
Preterm <37 
wk LBW 
Fitzsimmons 
et al., 1986 
(61) 
Case series  
(1981-1984) 
North-
western 
University 
Allergy 
Service 
Emergency 
therapy 
No 
emergency 
therapy  
17 41 OR, *NR (p=0.08) 1.87 (p=0.55) 2.42 (p=0.12) No adjustment 
Fitzsimmons 
et al. 1986 
(61) 
Case series  
(1981-1984) 
North-
western 
University 
Allergy 
Service 
Status- 
asthmaticus 
No 
emergency 
therapy 
8 41 OR, NR (p=0.02) †NE 
2,764g vs. 
3,284g 
(p=0.03) 
No adjustment 
Stenius et al. 
1988 (22) 
Prospective 
 (1978-1982) 
Helsinki 
University 
Central 
Hospital  
Exacerbation 
and hospital 
admission 
No 
exacerbation 
or hospital 
admission 
91  109  NE 
‡NS difference 
in mean 
gestational age 
(272d vs. 278d) 
NS difference 
in mean birth 
weight 
(3,418g vs. 
3,479g) 
Matched for age, 
parity and time of 
delivery 
Greenberg et 
al. 1988 (106) 
Prospective 
Cohort 
(1981-1987) 
North-
western 
University 
Allergy 
Service 
Emergency 
therapy 
No 
emergency 
therapy  
25  55 OR, NR (p=0.16) 2.11(p=0.23) 2.97(p=0.06) No adjustment 
Greenberg et 
al. 1988 (106) 
Prospective 
Cohort 
(1981-1987) 
North-
western 
University 
Allergy 
Service 
Status- 
asthmaticus 
No 
emergency 
therapy 
16 55 5.75 (p=0.05) NE -434g (p=0.02) No adjustment 
Schatz el al. 
1990 (56) 
Prospective; 
(1978-1984) 
Kaiser-
Permanente 
Medical 
Care 
Individual 
mean % 
predicted 
FEV1<83% 
Individual 
mean % 
predicted 
FEV1>99% 
 
89 91 
SGA, NE 
1IUGR 
(p=0.04)  
NS 
NS for LBW 
mean birth 
weight 
(p=0.002) 
Adjusted for age, 
parity, smoking 
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 Author, year 
of publication 
(Ref number) 
Study 
design 
(period of 
data 
collection) 
Source of 
data 
Severity definition Sample size (pregnancy) 
OR / RR (95% Confidence Interval) or incidence 
% Adjustment for 
any confounders Severe 
asthmatic 
Mild 
asthmatic 
Severe 
asthmatic 
Mild 
asthmatic SGA 
Preterm <37 
wk LBW 
Lao et al. 
1990 (90) 
retrospective  
(1984-1987) 
Hospital, 
Hong Kong 
with 
treatment 
without 
treatment 54  33  NE 0.31 NS 0.31NS 
Matched for age 
and parity 
 
Mabie et al. 
1992 (98) 
Case series 
(1986-1989) 
Hospital, 
Tennessee 
At least one 
hospitalization 
or OCS 
therapy or 
mechanical 
ventilation   
No OCS 
therapy or 
hospital 
admission 
31  169  4.54 (p<0.05) 1.01 NS NE No adjustment 
Perlow et al. 
1992 (91) 
retrospective  
 (1985-1990) 
Long Beach 
Memorial 
Medical 
Center 
Hospital 
Steoid-
dependent 
Non-steroid-
dependent 31 50 0.8 (0.1-5.5) 7.5 (2.3-25.2) 5.1 (1.6-17.0) No adjustment 
Stenius et al. 
1995 (108) 
Prospective 
(1982-1990) 
Helsinki 
University 
Central 
Hospital and 
Helsinki 
Maternity 
Hospital  
theophylline 
users 
Non-
theophylline 
users 
212  292  NE 1.39 NS NE Matched for age 
and parity 
Jana et al. 
1995 (20) 
Prospective 
(1983-1992) 
Nehru 
hospital, 
India 
 
hospitalizati
on 
No ER visits 15  167  NE 1.61 NS 2.60 (p<0.01) Matched for age 
and parity 
Stenious et al. 
1996 (104) 
Prospective 
Cohort  
(1982-1992) 
Helsinki 
University 
Central 
Hospital 
 
Exacerbation  No 
exacerbation  47 457 NE 1.1 NS NE 
Match for age and 
parity 
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 Author, year 
of publication 
(Ref number) 
Study 
design 
(period of 
data 
collection) 
Source of 
data 
Severity definition Sample size (pregnancy) 
OR / RR (95% Confidence Interval) or incidence 
% Adjustment for 
any confounders Severe 
asthmatic 
Mild 
asthmatic 
Severe 
asthmatic 
Mild 
asthmatic SGA 
Preterm <37 
wk LBW 
Bracken et al. 
2003  (99)  
Prospective 
Cohort 
(1996-2001) 
56 obstetric 
practices and 
15 clinics 
(Connecticut
Massachuset
ts) 
  80 94 
Crude 
1.39 (0.69-2.77) 
 
Adjusted 
1.57 (0.72-3.45) 
Crude 
1.67 (0.74-3.81) 
 
Adjusted 
1.88 (0.73-4.82) 
NE 
Adjusted for age, 
marital status, 
race, education, 
pre-pregnancy 
weight, height, 
smoking, daily 
caffeine, parity, 
and vitamin use 
Dombrowski 
et al. 2004 
(100) 
Prospective 
Cohort 
(1994-1999) 
16 centers of 
Maternal-
Fetal 
Medicine 
Unit 
Network 
(USA) 
 
Moderate 
and severe 
 866 873 
7.1% vs. 6.9% 
Statistical sig 
NE 
15.8% vs. 
16.1% 
Statistical sig 
NE 
NE _______ 
Murphy et al. 
2005  (123) 
Prospective 
Cohort 
(1997-2003) 
John Hunter 
Hospital 
antenatal 
clinic 
 
Severe 
exacerbation 
No severe 
exacerbation 52 92 NE 2.66  (p>0.05) 7.06 (p>0.05) No adjustment 
Schatz et al. 
2006 (121) 
Prospective 
Cohort 
(1994-2000) 
16 centers of 
MFMU 
network of 
National 
Institute of 
Child health 
and human 
development 
 
Mean 
FEV1<80% 
Mean 
FEV1>80% 
354 1,769 1.06 NS 1.38 (P<0.01) 1.36 P<0.05 
Adjusted for age, 
parity, smoking, 
race, pre-
pregnancy weight, 
ER or hospital 
visit, OCS 
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 Author, year 
of publication 
(Ref number) 
Study 
design 
(period of 
data 
collection) 
Source of 
data 
Severity definition Sample size (pregnancy) 
OR / RR (95% Confidence Interval) or incidence 
% Adjustment for 
any confounders Severe 
asthmatic 
Mild 
asthmatic 
Severe 
asthmatic 
Mild 
asthmatic SGA 
Preterm <37 
wk LBW 
Bakhireva et 
al. 2008 (122) 
Prospective 
Cohort 
(1998-2003) 
Multicenter 
prospective 
study of 
asthma 
medication 
use in 
pregnancy 
2Poor to fair 
asthma 
symptom 
control < 20 
gestational 
weeks 
Adequate 
asthma 
symptom 
control < 20 
gestational 
weeks 
308 396 NE 1.83 (1.04-3.25) NE 
Adjusted for age, 
BMI, gravidity, 
parity, 
socioeconomic 
status, smoking, 
ethnicity, use of 
OCS 
 
*NR: not reported 
†NE: not reported  
‡NS: statistically non significant 
1IUGR: ponderal index<2.2 
2Poor to fair asthma symptom control < 20 gestational weeks: the presence of asthma symptoms during the prior 2 weeks that interfere with sleep or activity 
occasionally, frequently or constantly  
 
 
 3.9. Risk factors for SGA, LBW infants or preterm birth 
3.9.1. SGA Babies  
Preeclampsia, a history of stillbirth, spontaneous abortion in preceding 
pregnancies, vaginal bleeding, and multiple gestations are reported in the literature to be 
risk factors of SGA babies (124-131). Marital status, maternal age, maternal height and 
body mass index, pregnancy weight gain, maternal birth weight and parity are also known 
to be risk factors for SGA (125, 128, 129, 132-137). The other factors which are known 
in the literature to be strongly associated with intrauterine growth restriction are maternal 
smoking, alcohol intake or being exposed to environmental tobacco smoke during 
pregnancy (131, 138-148). Whereas, maternal diabetes (OR, 0.7; 95% CI, 0.6-0.9), and 
being overweight or obese offered protection against SGA (128, 129, 135). Socio-
demographic risk factors like low income level, unemployment, low maternal education 
and black race are also known to increase SGA new borns (126, 128, 129, 137, 149). 
 
3.9.2. Preterm Birth 
Alcohol intake before and during the three trimesters of pregnancy has been 
significantly associated with an increased risk of preterm birth (OR=2 for the first 
trimester) (146, 147, 150, 151). Cigarette smoking and illicit drug use during pregnancy 
has also been significantly associated with an increased risk of preterm birth (126, 131, 
144-148, 150-154). Hypertension during pregnancy is strongly associated with preterm 
birth (adjusted OR=17.5 among SGA babies and adjusted OR=3.11 among non-SGA 
babies) (125). After adjustment for marital status, education level and adequacy of 
prenatal care, it is shown that younger mothers (13 to 17 years of age) in comparison to 
mothers who were 20 to 24 years old had a significantly higher risk of preterm delivery 
(RR: 1.9, 95%CI: 1.7-2.1) (132). Previous preterm delivery is also strongly associated 
with an increased risk of preterm delivery in a subsequent pregnancy (155, 156). 
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Maternal anemia, bacteriuria, bacterial vaginosis or systemic infection, vaginal bleeding, 
prior abortions, and multiple gestation are known to be risk factors for preterm birth (124-
126, 131, 155-158). Advanced maternal age, low or high maternal body mass index, and 
poor maternal weight gain have also an increased risk effect on preterm births (126, 132, 
135, 136, 158).  
 
3.9.3. Low Birth Weight 
Smoking during pregnancy has been strongly associated with  low birth weight, as 
well as an overall 150-250 g reduction in mean birth weight (125, 142, 155, 159-161). 
The relation between exposure to environmental tobacco smoke in pregnant women and 
low birth weight have also been shown in several studies (138-143). Less than 6 to 9 
months or more than 120 months between pregnancies are risk factors for low birth 
weight (162, 163). In addition, maternal birth weight and that of the siblings are 
independent predictors of the low birth weight of a newborn (134). 
 
The summary table of other risk factors for SGA, LBW infants or preterm birth is 
shown in table 5.  
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Table 5: Summary of Risk factors for SGA, LBW infants and preterm birth 
Risk factors SGA LBW Preterm birth 
Socio-demographic risk factors     
Maternal age   (125, 129, 132) (164, 165)  (126, 132, 158) 
Race/ethnicity  (148) (166, 167)  
Low socio-economic level  (128, 168)  (169)  
Low educational level   (128, 129)  (170)  
Unemployment  (137)   
Marital status  (128, 129, 137)  (171)  
    
Medical and obstetrical 
complications 
   
Preeclampsia (125, 127, 128, 137)  (172)  (125) 
Gestational diabetes  (128)   
Vaginal bleeding  (124, 126, 131)  (173)  (124, 126, 131) 
Prior abortions  (130)   (126) 
Prior history of preterm delivery    (155-157) 
History of stillbirths  (126)   (156, 158) 
Multiple pregnancies  (131)  (174)  (131) 
Anemia   (175)  (176) 
Infections   (177, 178)  (179, 180) 
Birth intervals  (128)  (162, 163)  
Placental anomalies   (181)  
    
Maternal risk characteristics    
Pregnancy weight gain  (128, 129)   (136) 
Body mass index  (125, 128, 137)  (182)  (135) 
Height  (129)   
Maternal birth weight  (135)  (133, 134)  
Parity  (128, 129)   (126) 
    
Environmental and behavior risks    
Maternal tobacco smoking (128, 137, 142, 145) (125, 142, 155, 
159-161) 
(126, 144, 145, 148) 
Environmental tobacco smoke 
exposure 
(138-141, 143) (138-141, 143)  
Alcohol consumption  (146, 148)  (146, 147, 150, 151) 
Illicit drug consumption    (152-154) 
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4. Method 
4.1. Study Design  
As it is shown in Table 6., to achieve the proposed objectives we used a cohort 
design for the two first studies (183). Moreover, the two-stage sampling cohort design 
(balanced selection) was used for the three last studies (184, 185). This design is 
recommended for observational studies when data on the main exposure and outcomes 
are available for a large number of subjects but the data on confounding variables can be 
retrieved only for a subset of the study subjects (when data collection is time and cost-
consuming) (184). 
 Table 6. Summary of five studies included in the present thesis  
 Objective Study Design Exposure Outcomes Sample Size Statistical 
analyses 
Study 
1 
Development and 
validation of a 
database index of 
asthma control and a 
database index of 
asthma severity 
Cohort (asthma clinic) 
Levels of 
asthma 
severity and 
control 
A. Differences in 
mean FEV1 
 
B. Differences in 
mean FEV1/FVC 
71 asthmatic patients 
35: mild 
21: moderate 
15: severe 
 
38: adequately 
controlled 
33: poorly controlled 
Student’s 
t- test for 
independent 
samples 
Study 
2 
Impact of fetal gender 
on maternal asthma 
Cohort 
(administrative 
databases) 
Fetal gender 
A. Maternal asthma 
exacerbation during 
pregnancy 
B. SABA use during 
pregnancy 
C. ICS use during 
pregnancy 
11,257 pregnancies 
5,529: female fetus 
5,728: male fetus 
Logistic 
regression 
Study 
3 
Impact of maternal 
asthma on adverse 
perinatal outcomes 
2-stage sampling 
Cohort: balanced 
selection 
(administrative 
databases and a 
mailed questionnaire) 
 
Asthma 
during 
pregnancy 
A. SGA infant, 
B. LBW infant, 
C. Preterm birth 
40,788 pregnancies 
13,007: asthmatic 
27,781: non-asthmatic 
GEE 
(logistic 
link) 
Study 
4 
Impact of severity of 
asthma during 
pregnancy on adverse 
perinatal outcomes 
2 stage sampling 
Cohort: balanced 
selection 
(administrative 
databases and a 
mailed questionnaire) 
Level of 
asthma 
severity 
during 
pregnancy 
A. SGA infant, 
B. LBW infant, 
C. Preterm birth 
13,007 pregnancies 
10,737: mild asthmatic 
1,618:  moderate 
asthmatic 
652: severe asthmatic 
GEE 
(logistic 
link) 
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 Objective Study Design Exposure Outcomes Sample Size Statistical 
analyses 
Study 
5 
Impact of adequately 
controlled maternal 
asthma on adverse 
perinatal outcomes 
2 stage sampling 
Cohort: balanced 
selection 
(administrative 
databases and a 
mailed questionnaire) 
Adequately 
controlled 
asthma 
during 
pregnancy vs. 
non-asthmatic 
women 
A. SGA infant, 
B. LBW infant, 
C. Preterm birth 
36,115 pregnancies 
8,334: controlled 
asthmatic 
27,781: non-asthmatic 
GEE 
(logistic 
link) 
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4.2. Sources of data 
The historical data from the administrative databases of the province of Quebec as 
well as data obtained from a postal questionnaire that was sent to a sample of the study 
subjects were our sources of data.  
 
4.2.1. Administrative databases 
To construct our cohort, we worked with three administrative databases from the 
province of Quebec, i.e. the Régie de l’Assurance Maladie du Quebec (RAMQ) database, 
the MED-ECHO database and the Fichier des événements démographiques du Québec 
(birth and death registries) managed by the Institut de la statistique du Québec (ISQ).  
 
The RAMQ databases provide information on medical services dispensed to all 
residents of Quebec and on prescribed medications filled in community pharmacies by 
residents covered by the RAMQ’s Public Drug Insurance Plan. Approximately 43% of 
the population of Quebec is covered by the RAMQ’s Public Drug Insurance Plan, most 
notably the elderly and social assistance beneficiaries since 1980. Furthermore, since the 
enactment of mandatory drug coverage in 1997, the RAMQ’s Public Drug Insurance Plan 
now provides coverage for an additional 1.7 million adherents, mainly workers and their 
families who have no access to a group drug insurance plan at work (186).  
 
The RAMQ Prescribed Medications database provides information on 
dispensed medications – i.e. date of filling, name, dose, quantity, dosage form and 
duration of the prescription and on the prescribing physician. The RAMQ Medical 
Services database provides information on medical services dispensed in a physician 
office, a clinic, an emergency department (ED), or a hospital; including information 
pertaining to date, diagnosis coded with 9th international classification of diseases (ICD-
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9), where the service was dispensed and who was the physician in charge. Also RAMQ 
database provides information on socio-demographic data such as age, gender, social 
assistance status, area of residence, and, where relevant, date of death. Data recorded in 
the RAMQ Public Prescribed Medications database and asthma diagnoses recorded in the 
RAMQ Medical Services database have been formally evaluated and found to be valid 
(187, 188). Data from the RAMQ was obtained for 2 years preceding conception and 
during pregnancy, for each pregnancy included in the cohort.  
 
The MED-ECHO database is a provincial database which records data on acute 
care hospitalizations and covers all residents of Quebec (187). MED-ECHO provides 
information on all acute care hospitalizations- i.e. deliveries, medical and obstetrical 
complications, neonatal complications, asthma-related hospitalizations, etc. For all 
hospitalizations, MED-ECHO provides data on primary and up to 15 secondary discharge 
diagnoses, date of entry, duration of hospital stay, and treatments received during the 
stay. For delivery-related hospitalizations, data on the gestational age and birth weight of 
the newborn are also available. Data from the MED-ECHO was obtained for each woman 
and baby included in the cohort. 
 
The Fichier des événements démographiques database provides information on 
all births and stillbirths in the province of Quebec. From this database we obtained 
demographic variables on the mother (date of birth, age, marital status, mother tongue, 
place of birth, area of residence, education level, number of live births, number of 
deliveries), on the father (date of birth, age, mother tongue, place of birth), and on the 
baby (sex, type of delivery, birth weight, gestational age, date of birth). 
 
 58 
 
4.2.2. Questionnaire 
Some additional information regarding siblings and maternal life styles during 
pregnancy which are not recorded in the administrative databases were retrieved from a 
mailed questionnaire completed by a number of selected women in a strategic way in 
order to capture the most information at the least cost. A 10$ compensation was given to 
women who completed the questionnaire.  
 
The questionnaire underwent prior testing by a sample of asthmatic and non-
asthmatic women for its clarity and also its facility to be understood and answered. 
Among the 40 women who pre-tested the questionnaire, some women were questioned 
about a pregnancy that occurred up to 25 years ago and they had no problem to remember 
their life style habits such as cigarette smoking during the pregnancy.  
 
The questionnaire provided us with data pertaining to life styles (including 
maternal cigarette smoking, maternal alcohol consumption, and paternal cigarette 
smoking), maternal characteristics, and pregnancy related variables that are not recorded 
in the administrative databases (for the list of the questions, see appendix A). Data 
collected through the questionnaire was linked anonymously to the cohort. 
 
4.3. Study Population 
4.3.1. Cohort of pregnant women and newborns, first stage of 
sampling 
The cohort used for our studies was reconstructed from the linkage of RAMQ, 
MED-ECHO and ISQ databases and formed of singleton deliveries (live births or still 
births) of asthmatic and non-asthmatic women. Pregnant women and newborns were 
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identified in the RAMQ and MED-ECHO databases using diagnostic and act codes 
related to prenatal care, pregnancy complications, and deliveries (189). All pregnancies 
corresponded to an abortion was eliminated.  
 
Inclusion criteria  
To be included in the cohort a woman should fulfill the following criteria:  
 
1. having at least one pregnancy ending in a delivery (live births and still births) 
between January 1st, 1990 and December 31st, 2002 in the province of Quebec 
(Canada);  
2. being 13-50 years old at the beginning of the pregnancy; 
3. being covered by the RAMQ Drug Insurance Plan for at least one year prior to 
and throughout the duration of the pregnancy.  
 
To be included in the cohort of asthmatic pregnancies, a woman should fulfill also 
the following criterion 
 
4. being asthmatic i.e. having at least one diagnosis of asthma (ICD-9 code 493, 
except 493.2 which corresponds to chronic obstructive asthma) and at least one 
dispensed prescription for an asthma medication (see appendix B for the list of 
asthma medications) recorded in any type of RAMQ database or MED-ECHO 
either two years before or during the first pregnancy that occurred after January 1, 
1990.  
 
Exclusion criteria  
A woman was excluded from the cohort if at least one of the following conditions 
was present: 
1. multiple pregnancy 
2. unavailable data regarding: 
a. newborn’s weight 
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b. newborn’s gender 
c. gestational age at birth 
 
Within the RAMQ database women and their children are paired to allow the link 
between them. A woman can have more than one pregnancy during the study period. We 
allowed a maximum of four pregnancies per woman to enter in the cohort and only the 
more recent ones were retained. For each pregnancy, the data from the RAMQ and MED-
ECHO databases were obtained one year before and during pregnancy. The gestational 
age and date of birth of the infant were obtained from the MED-ECHO, RAMQ and ISQ 
databases. This mother-child cohort was then linked with the Fichier des événements 
démographiques database to obtain information on socio-demographic variables for the 
mothers and the newborns.  
 
Final cohort details 
The original cohort composed of 41,691 pregnancies including 13,297 asthmatic and 
28,394 non-asthmatic pregnancies. The final cohort includes 13,007 asthmatic and 27,781 
non-asthmatic pregnancies after the exclusion criteria were applied (see Figure 2. for 
more details).   
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Figure 2. Summary of final cohorts of asthmatic and non-asthmatic pregnancies 
 
41,691 pregnancies (asthmatic and non-asthmatic) 
       
543 Multiple pregnancies    
       
     
 
194 Asthmatic pregnancies 349 Non-asthmatic pregnancies     
         
41,148 singleton pregnancies 
 
 
 
 
 
13,103 Asthmatic pregnancies   28,045 Non-asthmatic pregnancies 
 
     Pregnancies excluded                Pregnancies excluded 
    
 
    62 because the gestational age at birth was       193 because the gestational age   
    not available                       at birth was not available 
    9 because the newborn’s gender was not        10 because the newborn’s gender 
    Available             was not available 
    18 because the women had more than 4         38 because the woman had more  
    pregnancies during the study period                   than 4 pregnancies during the  
    7 because the newborn’s weight was not         study period 
    available            23 because the newborn’s weight  
             was not available 
     
13,007 Asthmatic pregnancies   27,781 Non-asthmatic pregnancies 
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4.4. Two-Stage Sampling 
A two-stage sampling cohort design was used for the three last studies (see table 
5.). This design was appropriate for these studies because some of the important risk 
factors of adverse perinatal outcomes such as maternal cigarette smoking and maternal 
weight gain during pregnancy were not available through administrative databases. 
However, we did not use this design for the second study because we could obtain the 
necessary data on confounding variables through administrative databases. 
 
4.4.1. Sub-cohort of selected pregnant women, second stage of 
sampling 
At the second stage of sampling, we used the balance sampling strategy to 
improve the statistical power (184, 185). A maximum of two pregnancies per woman 
were selected at this stage of sampling to avoid overloading women with more than two 
questionnaires. Selected women should be aged 18 years old or more at the beginning of 
their pregnancy to be eligible for the second stage of sampling due to ethical 
considerations (we were not allowed to contact women aged under 18 years).  
 
In the “balanced design” at the second stage of sampling, individuals should be 
selected according to their exposure/disease characteristics to have an equal number of 
individuals in each cell of the second stage cross table (184, 190). This strategy decrease 
the occurrence of small cells (responsible for large variance) by forcing an 
overrepresentation of individuals who belong to small groups in the exposure/disease 
cross-classification (184).  
 
First, we constructed the cross table of exposure-outcome based on pregnancies 
included in the first stage of sampling (see Table 7. for more details). 
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Table 7. Distribution of adverse perinatal outcomes per maternal asthma status at 
the first stage of sampling (N), the number of pregnancies selected per each 
exposure-outcome category (n) and the number of pregnancies of women who 
answered to the questionnaire (n) 
 
1N=Distribution of pregnancies of the first stage of sampling 
2
n=Distribution of pregnancies selected for the second stage of sampling 
3n= Distribution of pregnancies of women who answered to the questionnaire 
 
To select women at the second stage of sampling, we exhaustively sampled all 
pregnancies with the exposure (i.e. women with moderate to severe or poorly controlled 
asthma) and outcomes under study (i.e. SGA infant, preterm delivery or LBW infant). 
The total number of pregnancies selected in this way was 2,774 (ntotal=2,774) (see Table 
7. for more details). Then, we sampled an equal number of pregnancies per each 
exposure-outcome category from the remaining cells. In total, we selected 2,933 
pregnancies, to achieve the total number of 5,707 pregnancies that we were allowed to 
send the questionnaires. Thus, we selected an equal number of 419 pregnancies per cell 
from 7 remaining cells (ntotal=2,933) (see Table 7. for more details).  
 
 
Level of asthma severity 
and control 
SGA Non SGA 
Preterm birth Non- Preterm 
birth 
Preterm birth Non- Preterm 
birth 
LBW Non- 
LBW 
LBW Non- 
LBW 
LBW Non- 
LBW 
LBW Non- 
LBW 
Adequately  controlled 
mild asthmatic 
1N=77 
2n=77 
3n=28 
------- 
N=190 
n=190 
n=80 
N=638 
n=638 
n=239 
N=265 
n=265 
n=89 
N=305 
n=305 
n=112 
N=10 
n=10 
n=4 
N=5269 
n=419 
n=172 
Poorly controlled mild 
asthmatic 
N=9 
n=9 
n=1 
------- 
N=44 
n=44 
n=10 
N=147 
n=147 
n=58 
N=58 
n=58 
n=18 
N=64 
n=64 
n=20 
N=1 
n=1 
n=1 
N=1043 
n=419 
n=171 
Non-asthmatic 
N=144 
n=144 
n=45 
------- 
N=515 
n=515 
n=153 
N=2030 
n=419 
n=132 
N=643 
n=419 
n=162 
N=825 
n=419 
n=139 
N=25 
n=25 
n=8 
N=2195 
n=419 
n=167 
Adequately  controlled 
moderate to severe 
asthmatic 
------ ------- 
N=3 
n=3 
------- 
N=6 
n=6 
n=1 
N=3 
n=3 
------- 
N=1 
n=1 
------- 
N=1 
n=1 
------- 
N=30 
n=30 
n=15 
Poorly controlled 
moderate to severe 
asthmatic 
N=10 
n=10 
n=6 
------- 
N=38 
n=38 
n=13 
N=113 
n=113 
n=54 
N=35 
n=35 
n=12 
N=41 
n=41 
n=9 
N=1 
n=1 
------- 
N=719 
n=419 
n=161 
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4.4.2. Sample constructed based on RAMQ data 
As described in the previous section, we first selected 5,324 women (5,707 
pregnancies) from the cohort of pregnant women and newborns (first stage of sampling). 
Then, we sent their encrypted NAM to the RAMQ in order to obtain women’s current 
address. RAMQ provided us with the current postal addresses and spoken language of 
only 5,021 women (303 addresses were unknown to the RAMQ).  The final sample 
included 5,384 pregnancies which corresponded to 3,168 asthmatic and 2,216 non-
asthmatic pregnancies (see Table 8. for more details).  
 
Table 8. Details regarding the sample of selected women at the second stage of 
sampling and final sample constructed after receiving RAMQ data 
 
 
Date N of 
women 
N of 
pregnancy 
N of 
asthmatic 
pregnancies 
N of women 
with 1 child 
N of women 
with 2 children 
Sending Encrypted 
NAM of selected 
women to the RAMQ 
14 
December 
2006 
5,324 5,707 3,347 4,941 383 
Receiving women’s 
addresses from RAMQ 
(final cohort)  
16 
January 
2007 
5,021* 5,384 3,168 4,658 363 
*303 addresses were unknown to the RAMQ 
 
4.4.3. Mailing procedure 
During the first phase of mailing, we sent 4,658 questionnaires (see appendix A) 
to women with one live delivery during the study period. 4,143 questionnaires were in 
French and 515 were in English. The remaining questionnaires were sent to 363 women 
who had two live births during the study period. Among them 327 spoke French and 36 
spoke English. About two months later, during the second phase of mailing, a total of 
3,555 questionnaires were sent as a reminder to women who did not answer to the first 
questionnaire (see Table 9. for more details).  
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Of the 5,384 sent questionnaires, we received 2,119 completed questionnaires and 
the notice of move for 314 women. The Ascii & Élite Services Informatiques seized 
2,117 questionnaires (2 questionnaires were removed because they were not lisible). The 
questionnaires’ data were recorded in a computerized database, using a double-checking 
entry method to improve the data quality. After reviewing the recorded data, 37 
questionnaires were removed mostly because of the errors found in them. The data of 
2080 questionnaires were kept and used for our second stage analyses. These 
questionnaires corresponded to 806 and 1,274 pregnancies from non-asthmatic and 
asthmatic women (see Table 9. for more details).  
 
 
Table 9. Summary of two phases of mailing; Questionnaires sent and received 
 
First phase of mailing Second phase of mailing 
Date 2 March 2007 16 May 2007 
N of women 5,021 3,328 
N of pregnancy 
(questionnaires sent) 5,384 3,555 
N of women with 1 child 4,658 3,098 
N of women with 2 children 363 230 
N of questionnaire received 1,5711 5712 
N of questionnaires seized by 
Elite Services   1,570 547 
Questionnaires retained for our 
cohort of 2nd stage 1543
3 5374 
 
1One questionnaire was deleted and not seized by firm because of non consistency of the answers 
2 19 were the double, 1 was torn and 3 was received after the end of the study 
327 questionnaires were deleted after reviewing the data  
410 questionnaires were deleted after reviewing the data   
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4.5. Outcomes definition 
4.5.1. Small for gestational age 
To construct a Canadian valid fetal growth reference, Kramer et al. have 
developed a gender-specific reference of birth weight for gestational age based on all 
births contained in the linked files of live birth and infant death occurring in the 
provinces and territories of the Canada (with the exception of Ontario) born between 
1994-1996 (191). The results of their study was a tabular presentation of means, standard 
deviations, and the 3rd, 5th, 10th, 50th (median), 90th, 95th, and 97th percentiles of birth 
weight (g) for gestational age, for males and female singleton (191).  
 
In our studies, SGA was defined as a birth weight below the 10th percentile for 
gestational age and gender, (the conventional SGA cutoff) (191). This definition is based 
on new Canadian standards and considers the Canadian growth pattern in its definition. 
Algorithms based on data obtained from the MED-ECHO database or from the Birth and 
death registry (ISQ) were used to measure the birth weight and gestational age at birth. 
Vilain et al. evaluated the validity of gestational age at birth and birth weight recorded in 
administrative databases of Quebec using patient medical charts as the gold standard 
among 726 asthmatic pregnant women who delivered in 1990-2000 (192). They found 
that these variables are highly valid with Pearson correlation coefficients of 0.972 for 
gestational age at birth and 0.979 for birth weight (192).  
 
4.5.2. Preterm birth 
 Preterm birth was defined as a birth before completing 37 weeks of gestation. In 
the MED-ECHO and ISQ databases, the gestational age at birth was reported as the 
completed gestational weeks. According to the algorithm that was constructed to measure 
the gestational age, we compared the gestational age recorded at the databases and we 
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kept the value that was the more frequent.  In case of missing values or inconsistencies, 
the following algorithm was used to determine the gestational age: 1) If the gestational 
age was recorded in the MED-ECHO-Mother (mother data) database then this value was 
retained; 2) If the gestational age was missing at the MED-ECHO-Mother and recorded 
at ISQ-Infant (infant’s data) then the ISQ value was retained; and 3) If the gestational age 
was missing at the MED- ECHO-Mother and ISQ-Infant, the value recorded at MED-
ECHO-Infant (infant’s data) was retained. If the gestational age was not recorded in any 
of the three databases, the pregnancy was excluded. 
 
4.5.3. Low birth weight 
LBW was defined as birth weight lower than 2,500g. For each infant, we had data 
relating to his birth weight in three databases; ISQ, MED-ECHO-Infant and MED- 
ECHO-Mother. In case of inconsistency between values in three databases, the following 
priority algorithm was used to determine the birth weight: 1) ISQ; 2) MED-ECHO-Infant 
and 3) MED- ECHO-Mother. If the birth weight was not recorded in any of the three 
databases, the pregnancy was excluded. 
 
4.5.4. Moderate to severe maternal asthma exacerbations 
Based upon the criteria used in the Canadian Asthma Consensus Guidelines, 
asthma exacerbations were defined as a short (< 14 days) course  of oral corticosteroids 
dispensed by a pharmacy, an emergency department (ED) visit for asthma, or a 
hospitalization for asthma (39). To avoid the overestimation of the number of 
exacerbations, all the aforementioned events occurring within a 15-day period accounted 
for one exacerbation. Asthma diagnosis recorded in the RAMQ databases have been 
formally evaluated and found to be valid (193). 
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4.5.5. ICS or SABA use during pregnancy 
The mean daily dose of ICS and the mean weekly dose of SABA during 
pregnancy, calculated using data from the RAMQ’s database using validated algorithms 
based upon the name, dose, formulation and quantity of the dispensed medication, 
duration of the prescription and time intervals between renewals (189, 194). The 
equivalencies of the mean daily dose of ICS into beclomethasone-CFC were calculated 
using the equivalency table published in the Canadian Asthma Consensus Guidelines 
(39). The equivalencies for SABA were established by the pharmacist collaborating with 
this research project; for example, one dose of SABA was equivalent to two inhalations 
of salbutamol from a metered-dose inhaler (100µg/inhalation) (194). 
 
4.6. Exposures definition 
4.6.1. Fetal Gender 
The gender of the baby was extracted from the RAMQ database and was checked 
for consistency with that recorded in the ISQ and MED-ECHO databases. In case of 
missing values or inconsistencies, the following algorithm was used to determine the 
gender: 1) If the gender of the baby was recorded in the RAMQ database then this value 
was retained; 2) If the gender of the baby was missing at the RAMQ and recorded at ISQ 
then the ISQ value was retained; and 3) If the gender of the baby was missing at the 
RAMQ and ISQ, the value recorded at MED-ECHO was retained. If the gender of the 
baby was not recorded in any of the three databases, the pregnancy was excluded. Fetal 
gender has been formally evaluated and found to be highly valid as compared to the 
information recorded in the medical chart of the mother with specificity and sensitivity 
higher than 0.97 (195). 
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4.6.2. Asthma during pregnancy 
Asthma during pregnancy is defined as having at least one diagnosis of asthma 
(ICD-9 code 493, except 493.2 which corresponds to chronic obstructive asthma) and at 
least one dispensed prescription for an asthma medication (see appendix B for the list of 
asthma medications) recorded in the RAMQ or MED-ECHO databases either two years 
before or during the pregnancy. 
 
4.6.3. Asthma severity during pregnancy 
The level of severity of maternal asthma during pregnancy measured with an 
index that we had developed and validated in study 1 (196). This index is based on 
dispensed prescriptions of asthma medications (controller therapies, short-acting beta2-
agonists, oral corticosteroids) as well as acute care for asthma (ED visits and 
hospitalizations) recorded in the RAMQ and MED-ECHO databases. This severity index 
covers three categories, mild, moderate, and severe, and is based upon the definitions 
provided in the Canadian Asthma Consensus Guidelines (26). Details of the severity 
index are provided in the first article included in the present thesis.  
4.6.4. Asthma control during pregnancy 
Asthma control during pregnancy was measured with an index that we had 
developed and validated in study 1 (196). This control index is based upon the definition 
provided in the Canadian Asthma Consensus Guidelines (26). Two levels of asthma 
control during pregnancy were defined based on the average number of doses of short-
acting beta2-agonists (SABA) per week and the presence of markers of moderate-to-
severe asthma exacerbations – a filled prescription of oral corticosteroids (less than 14 
days), an ED visit for asthma, or a hospitalization for asthma (197). Patients were 
considered adequately controlled if they had no marker of moderate-to-severe asthma 
exacerbation and no more than three doses of SABA per week for mild asthma and ten 
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doses of SABA per week for moderate and severe asthma (196). Details of the index of 
control are provided in the first article included in the present thesis. 
 
4.7. Confounding variables  
The large number of confounding variables that we adjusted for are known risk 
factors for outcomes under study. For the complete list of risk factors, see the literature 
review section. 
 
4.7.1. Risk factors for maternal asthma exacerbation during 
pregnancy 
Variables retrieved from the administrative databases  
Asthma-related variables 
• Respiratory specialist visit during pregnancy (yes/no), 
• ICS use during pregnancy (yes/no), 
• Pre-conception asthma severity (mild, moderate, severe) (details of the index of 
severity are provided in the first article included in the present thesis), 
• Pre-conception asthma control (adequately controlled, poorly controlled) (details 
of the index of control are provided in the first article included in the present 
thesis).  
 
4.7.2. Risk factors for adverse perinatal outcomes 
Variables retrieved from the administrative databases  
Maternal characteristics  
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• Age at the beginning of the pregnancy (recorded in the RAMQ database) (< 18, 
18-34, > 34 years),  
• Receiving social assistance benefits in the year before or during pregnancy 
(recorded in the RAMQ database) (yes/no),  
• Urban residency at delivery (recorded in the RAMQ or ISQ databases) (yes/no),  
• Being primiparous (recorded in the RAMQ database) (yes/no).  
Pregnancy-related variables  
• High risk pregnancies (ICD-9 codes V23 except V238,  6932, 6938, 6939, 6941, 
9157 and 9167 recorded in the RAMQ or MED-ECHO databases) (yes/no), 
• Gestational diabetes (algorithm developed by Amélie Forget, Marie-Josée Martel 
and Dr. Lucie Blais based on data recorded in the RAMQ databases) (yes/no) (for 
details of algorithm, see appendix C),  
• Pregnancy-induced hypertension (algorithm developed by Amélie Forget, Marie-
Josée Martel and Dr. Lucie Blais based on data recorded in the RAMQ databases) 
(yes/no) (for details of algorithm, see appendix D),  
• A gynecologist or obstetrician visit during pregnancy (recorded in the RAMQ or 
MED-ECHO databases) (yes/no),  
• Number of prenatal visits (recorded in the RAMQ database) (≤5, 6-14, >14).  
Maternal co-morbidities  
• Diabetes mellitus (recorded in the RAMQ database) (yes/no) and  
• Chronic hypertension (recorded in the RAMQ database) (yes/no). 
 
Variables retrieved from the questionnaire  
Maternal characteristics  
• Maternal education (highest level reached: elementary school, high school, 
college & University),  
• Annual family income during pregnancy (<$18,000, $18,000-$46,000, >$46,000)  
•  Birth weight (<2.5, 2.5-5, >5 kg) 
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Pregnancy-related variables 
• Maternal weight gain during pregnancy (<8, 8-16, >16 kg),  
• Maternal body mass index (BMI) (<18.5, 18.5-24.9, 25-29.9, >29.9) at beginning 
of pregnancy 
• Another preterm or LBW infant prior to the current delivery (yes/no)   
Life style habits  
• Maternal and paternal cigarette smoking during pregnancy (yes/no) and  
• Maternal alcohol consumption during pregnancy (yes/no).  
 
4.8. Statistical analysis 
Details regarding statistical analysis used in the five studies were described in the 
five articles included in the present thesis. A summary of these analyses was also 
reported in Table 5. in the beginning of the Method section. In all studies, the unit of 
analysis was the pregnancy and not the woman, since a non negligible proportion of 
women contributed to two or more pregnancies in the analysis. 
 
In study 1, using the Student’s t- test for independent samples, two-tailed pair 
wise comparisons were performed to compare the differences in mean FEV1 (percent 
predicted value) between the levels of asthma severity and control within the sample of 
patients recruited at the asthma clinics (for more details, see first article included in the 
present thesis).  
 
In study 2, logistic regression models were used to obtain crude and adjusted odds 
ratios of maternal asthma exacerbation during the whole pregnancy and for each trimester 
separately comparing pregnancies of female with male fetus (for more details, see second 
article included in the present thesis).  
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In the three last studies, descriptive statistics were used to report the 
characteristics of the exposed and non-exposed women included in the cohort (first stage 
of sampling) and for those selected at the second stage of sampling. Also, descriptive 
statistics were used to calculate the distribution of the variables retrieved from 
administrative databases for women who answered the questionnaire and women who did 
not. A woman could contribute up to four pregnancies during the study period at the first 
stage of sampling and up to two pregnancies at the second stage of sampling. In these 
studies, we calculated the prevalence of the study outcomes (i.e. SGA infant, preterm 
births and LBW infant) for exposed and non-exposed women, separately for the first and 
second stage of sampling. Crude and adjusted odds ratios (OR) for the study outcomes 
comparing exposed to non- exposed women were then estimated for the first stage of 
sampling using Generalized Estimation Equation (GEE) models (198).  
 
4.8.1. GEE for Logistic Regression 
The method of GEE, introduced by Liang and Zeger  in 1986, is a generalization 
of generalized linear models (GLM) to analyze correlated data (198, 199). The data sets 
for the GEE models can come from longitudinal studies with repeated measurements or 
multilevel studies (clustering). The GEE analysis is implemented with a repeated 
statement in which the clustering information regarding the correlation of successive 
measurements is specified (200).  
 
The GEE using a logit link estimates the same model as the standard logistic 
regression (dichotomous dependent variable), however, unlike in logistic regression, GEE 
logit allows for dependence within clusters, such as in longitudinal data (201). The GEE 
logit can estimate the effect of independent variables, including the main exposure and 
confounding variables, on dichotomous outcomes such as the presence or the absence of 
SGA, with a logit function as well as take into account the fact that a woman could 
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contribute more than one pregnancy to the analysis by estimating the correlation between 
consecutive pregnancies.  
 
In the three last studies, the GEE models were used to take into account the fact 
that some women had two pregnancies or more during the study period (i.e. correlation 
between the different pregnancies of a woman) and all potential confounders. The models 
were first constructed using the subjects drawn from the second stage of sampling for 
which we have information on all variables, including confounding variables collected 
with the questionnaire. The estimates was then adjusted to reflect the sampling fractions 
and the first stage of sampling (202, 203). Missing values for variables retrieved from the 
questionnaire were included in the reference category for modeling purposes since the 
proportion of missing values was low. The best reduced models were found using a 
backward selection strategy, keeping in the model only covariates that were found to act 
as a confounder or those that were significantly associated with the outcome (p-value < 
0.05). 
 
4.8.2. Two stage sampling analyses 
To study the association between exposure and outcomes in the three last studies, 
we used the methodology proposed by Collet et al (184). This methodology is based on a 
statistical analysis that takes into account the fact that certain cells of the outcome/main 
exposure cross table have been over sampled and provide unbiased estimates of the 
association under study (184). 
 
In the three last studies, the stage 2 confounding variables (obtained from 
questionnaires) was combined with that already available for stage 1 (obtained from 
administrative databases) to obtain confounder-adjusted estimates and its confidence 
interval (184). First, we obtained adjusted OR estimates for each outcome based on 
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pregnancies selected at the second stage of sampling by the GEE models that adjusted for 
confounding variables collected at the first (administrative databases) and second 
(questionnaire) stages of sampling. The final adjusted OR estimates were then obtained 
by correcting the second stage adjusted OR with the second stage sampling fractions and 
the adjusted OR found at the first stage of sampling using the methodology proposed by 
Collet et al (see Figure 3. For more details) (184).  
 
Figure 3. Summary of statistical methods of Collet et al. to correct the logistic regression 
estimate and its variance for two-stage sampling design (184) 
 
Stage 1 
                             Outcome 
 
Exposure 
Yes No 
Yes N1 N2 
No N3 N4 
 
Stage 2 
                             Outcome 
 
Exposure 
Yes No 
Yes n1 n2 
No n3 n4 
 
Sampling fraction of stage 2 
S1= n1/N1 
S2= n2/N2 
S3= n3/N3 
S4= n4/N4 
Where N represents the number of observations at the first stage of sampling and n 
represents the number of observations at the second stage of sampling. 
 
Correction of logistic regression estimate and its variance (184) 
βcorrected  = βadjusted + ln (N1 N4 n2 n3 / N2 N3 n1 n4) 
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OR 
βcorrected  = βadjusted + ln S2 + ln S3 - ln S1 - ln S4 
Var βcorrected = Var βadjusted – [ (Sum 1/n) – (Sum 1/N) ] 
 
 
4.9. Ethic consideration 
The linkage between data obtained from the RAMQ, MED-ECHO and ISQ 
databases, and the filled questionnaires as well as the request of the name and the mailing 
address of selected women at the second stage of sampling was approved by the 
Commission d’accès à l’information du Quebec (CAI). This research project was also 
approved by the ethics committee of the Hôpital du Sacré-Cœur de Montréal prior to 
proceeding with the studies. 
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5. Results 
The five papers presenting the results of five studies included in this thesis are the 
contents of the chapter 5: 
 
1. Development and Validation of Database Indexes of Asthma Severity and 
Control 
Faranak Firoozi, Catherine Lemière, Marie-France Beauchesne, Amélie Forget, 
Lucie Blais 
Published in Thorax 2007; 62:581-7. 
 
2. Effect of Fetal Gender on Maternal Asthma Exacerbations in Pregnant 
Asthmatic Women 
Faranak Firoozi, Francine M Ducharme, Catherine Lemière, Marie-France 
Beauchesne, Sylvie Perreault, Amélie Forget, Lucie Blais 
Published in Respiratory Medicine, 2009; Volume 103, Issue 1, Pages 144-151.  
 
3. Impact of maternal asthma on perinatal outcomes  
Faranak Firoozi, Catherine Lemière, Marie-France Beauchesne, Sylvie Perreault, 
Amélie Forget, Lucie Blais,  
Submitted to ERJ 
 
4. Effect of maternal moderate to severe asthma on perinatal outcomes  
Faranak Firoozi, Catherine Lemière, Francine M Ducharme, Marie-France 
Beauchesne, Sylvie Perreault, Anick Bérard, Ema Ferreira, Amélie Forget, Lucie 
Blais,  
Submitted to Respiratory Medicine 
 
     5.    Does Good Asthma Control in Pregnant Women Annihilate the Risk of 
Perinatal Outcomes?  
Faranak Firoozi, Catherine Lemière, Marie-France Beauchesne, Francine M 
Ducharme, Sylvie Perreault, Amélie Forget, Lucie Blais,  
Submitted to Annals of Allergy, Asthma & Immunology 
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5.1. First article 
 
Titre: Development and Validation of Database Indexes of Asthma Severity and 
Control 
 
Published in Thorax 2007; 62:581-7. 
Included in the present thesis by the permission of the co-authors and editors. 
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The role of each author 
Faranak Firoozi, Catherine Lemière, Marie-France Beauchesne, and Lucie Blais 
participated in the design of the study. The same authors and Amélie Forget conducted 
the study. The statistical analyses were done by Faranak Firoozi, and Amélie Forget. The 
article was written by Faranak Firoozi and all the authors revised this article. 
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Abstract 
Background 
The use of administrative databases to perform epidemiologic studies in the field of 
asthma has expanded in recent years. The unavailability of clinical parameters to measure 
the level of asthma severity and control is considered as one of the major limitations of 
database studies. The aim of our study was to develop and validate two database indexes, 
one to measure the control of asthma and the other to measure asthma severity.  
 
Methods 
The database index of asthma severity (3 categories) and the database index of asthma 
control (2 categories) were derived from the definitions found in the Canadian Asthma 
Consensus Guidelines and were based upon dispensed prescriptions (controller therapies, 
short-acting beta2-agonists, oral corticosteroids) as well as the medical services for 
asthma (ED visits and hospitalizations), which were recorded in two large administrative 
databases from the Canadian province of Quebec; Régie de l’Assurance Maladie du 
Quebec (RAMQ) and MED-ECHO over 12 months. For validation purposes, 71 
asthmatic patients were randomly selected from two asthma clinics and their spirometric 
lung function measures were retrieved from their medical chart. For these patients, we 
also obtained data on prescriptions and medical services from the aforementioned 
databases. The database indexes of asthma severity and control were validated against the 
pulmonary function test results using t-tests. Our database indexes of asthma severity and 
control were also applied in the Quebec cohort which was comprised of 139 283 person-
years of follow-up of asthmatic patients who were selected from RAMQ and MED-
ECHO databases between January 1st 1997 and December 31st 2004. 
 
Results 
According to the database indexes, 49.3%, 29.6% and 21.1% of patients recruited at the 
asthma clinics were found to respectively have mild, moderate and severe asthma while 
53.5% were found to have controlled asthma. The mean predicted value of forced 
expiratory volume in one second (FEV1) ranged from 89.8% for mild asthma to 61.5% for 
severe asthma (p-value<0.001) whereas the range from controlled to uncontrolled asthma 
was 89.5% to 67.3% (p-value<0.0001). The ratio of the FEV1 to the forced vital capacity  
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(FEV1/FVC ratio) was measured for 56 patients and ranged from 75.8% for mild asthma 
to 61.8% for severe asthma (p-value of pairwise comparison=0.030) whereas the range 
from controlled to uncontrolled asthma was 75.3% to 65.7% (p-value =0.0009).  
 
Conclusions 
In the absence of clinical data, our database indexes could be used in epidemiologic 
studies using administrative databases that record data on dispensed prescriptions and 
medical services for asthma to reasonably assess the severity and control of asthma. 
 
Keywords: Asthma severity, asthma control, administrative databases, validity 
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Introduction 
The accurate classification of asthma severity and control is a definite challenge since 
they are conceptually related and some of the criteria used in their assessment overlap. 
The optimal control of asthma has been defined by the presence of minimal respiratory 
symptoms, no activity limitation, normal respiratory function, and absence of the need for 
rescue bronchodilator (39, 43, 118). Current series of criteria in the assessment of the 
control of asthma were established by the Global Initiative for Asthma (GINA) and the 
Canadian Asthma Consensus Guidelines (39, 43) and they include daytime and nocturnal 
symptoms, the occurrence of asthma exacerbations, the need for inhaled short-acting 
beta2-agonists (SABA), physical activity, absenteeism, and forced expiratory volume in one 
second (FEV1) or peak expiratory flow (PEF) values.  
 
Different methods are advocated by various guidelines in the assessment of asthma 
severity (39, 43, 118). The GINA guidelines as well as the US National Asthma 
Education and Prevention Program Consensus guidelines relative to the assessment of 
severity rely upon the evaluation of the disease’s inherent symptoms in the patient and his 
or hers lung function before instigating any treatment relative to the assessment of its 
severity (43, 118). However, the Canadian Asthma Consensus Guidelines assess asthma 
severity once the treatment has been instigated and rely upon a combination of factors, 
many of which overlap with measures of symptom control. These include pulmonary 
function tests, the treatment required to obtain asthma control, the history of hospital 
admissions, and life-threatening asthma attacks (39). 
 
The use of administrative health databases to perform epidemiologic studies in the field 
of asthma has widely expanded in recent years (204-206). The unavailability of clinical 
parameters to measure the level of asthma severity and control has always been 
considered as one of the limitations of using administrative databases in this field of 
research. Therefore, the development of an index of asthma severity and an index of 
asthma control based on electronically-available data seems necessary. Indeed, it is 
important to be able to measure asthma severity and control separately since, for 
example, in some studies it might be required to evaluate the control of asthma following 
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a new treatment strategy, while in other studies it might be required to measure the level 
of severity of asthma before starting a new treatment. 
 
Several validated multidimensional indexes of asthma control and severity have been 
developed for use in epidemiologic and clinical studies (207-212). These indexes are 
usually based on one or several factors that are considered clinically important in the 
assessment of asthma severity and control; for example, frequency, duration & intensity 
of symptoms, and pulmonary function tests. However and to the best of our knowledge, 
none of these indexes rely solely on data that are usually recorded in administrative 
health databases. 
 
Therefore, the aim of this study was to develop and validate two database indexes, one to 
measure the control of asthma and the other to measure the severity of asthma in 
currently treated asthmatics using information related to dispensed asthma medications 
and medical services, which were obtained from the administrative healthcare databases 
of the Canadian province of Quebec. 
 
Method 
Source of Data 
Our database indexes of asthma severity and control are based upon variables that were 
recorded in two administrative databases of the Province of Quebec, Canada; Régie de 
l’Assurance-Maladie du Québec (RAMQ) and MED-ECHO. The RAMQ database 
provides information on medical services dispensed to all residents of Quebec and on 
prescribed medications provided to residents covered by the RAMQ’s Prescription Drug 
Insurance Plan. Approximately 43% of the population of Quebec are covered by the 
RAMQ’s Prescription Drug Insurance Plan and mainly include the elderly, social aid 
recipients since 1980, and about 1.7 million new adherents since 1997, mostly workers 
and their families who in socio-economic terms, represent the average population (186). 
The RAMQ’s Prescription Drug Insurance Plan database provides information on 
dispensed medications (date of filling, name, dose, quantity, dosage form and duration of 
the prescription) while the RAMQ’s Medical Services database provides information on 
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medical services dispensed in a clinic, an emergency department (ED), or a hospital  
(date, and diagnosis coded with ICD-9). The RAMQ’s databases also provide socio-
demographic data such as age, gender, social aid status and where relevant, date of death. 
Data recorded in the RAMQ’s Prescription Drug Insurance database and asthma 
diagnoses recorded in the RAMQ’s Medical Services database have been formally 
evaluated and deemed valid (188, 213).  
 
The MED-ECHO database is a provincial database, which records data on acute care 
hospitalizations and covers all residents of Quebec. For each hospitalization, we obtained 
data on primary & up to 15 secondary discharge diagnoses, date of admission, duration of 
hospital stay as well as the treatments received during the hospitalization (213).  
 
Description of the Database Indexes of Asthma Severity and Control  
The database indexes of asthma severity and control that we developed are based upon 
the criteria detailed in the Canadian Asthma Consensus Guidelines for the assessment of 
the severity and control of asthmatic patients, who are already taking anti-asthmatic 
medications (39). Three levels of asthma severity and two levels of asthma control were 
defined over a 12-month period based upon the following: the average daily dose of 
inhaled corticosteroid (ICS) in beclomethasone-chloroflurocarbon (CFC) equivalent, the 
use of additional controller therapies defined as at least 6 filled prescriptions of inhaled 
long-acting beta2-agonists, theophylline, or leukotriene-receptor antagonists within a 12-
month period, the average number of doses of SABA per week, and the presence of 
markers of moderate to severe asthma exacerbations – a filled prescription of oral 
corticosteroids, an Emergency Department (ED) visit for asthma, or a hospitalization for 
asthma (197). The details of the two database indexes are presented in Table 1. Briefly, 
the mild asthma category corresponds to doses of ICS ranging from 0 to 500 µg per day 
for patients who do not have an additional controller therapy, and doses of ICS ranging 
from 0 to 250 µg per day for patients who have an additional controller therapy. 
Moreover, in order to be classified in this mild category, a patient must not have had a 
marker of a moderate to severe asthma exacerbation and nor have used more than an 
average of 3 doses of SABA per week during the 12-month period under study. The 
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moderate asthma category corresponds to ICS doses larger than 500 µg per day for 
patients who do not have an additional controller therapy, and doses larger than 250 µg 
per day for patients who have an additional controller therapy, except for patients with 
high use of SABA and moderate to severe asthma exacerbations. Severe asthma is mainly 
characterized by doses of ICS that are greater than 1000 µg per day, except for patients 
with both markers of uncontrolled asthma; for example, patients who are taking more 
than 10 doses of SABA per week and a marker for a moderate to severe asthma 
exacerbation.  
 
Patients were considered as controlled if they had no marker for moderate to severe 
asthma exacerbation and were taking no more than 3 doses of SABA per week for mild 
asthma and 10 doses of SABA per week for moderate and severe asthma.  
 
Using data from the RAMQ’s databases, an algorithm was developed to calculate the 
mean daily dose of ICS and the mean weekly dose of SABA on the basis of prescription 
renewals, quantity of medication dispensed, duration of the prescription, and time 
intervals between renewals (189, 214). In order to calculate the equivalence of the mean 
daily dose of ICS into beclomethasone-CFC, we used the equivalency table published in 
the Canadian Asthma Consensus Guidelines (39). The pharmacist established the 
equivalencies for SABA; for example, one dose of SABA was equivalent to two 
inhalations of salbutamol from a metered-dose inhaler (100µg/inhalation) (215).  
 
Validation of the Database Indexes of Asthma Severity and Control 
In order to validate the database indexes of asthma severity and control, we applied the 
indexes of severity and control that we had created to the administrative database 
information available for a sample of asthmatic patients recruited in two different asthma 
clinics. We then compared the actual mean pulmonary function test values for these 
patients across the classification categories to determine if pulmonary function 
corresponded with our indexes of severity and control. All the patients had a confirmed 
diagnosis of asthma with no diagnosis of a chronic obstructive pulmonary disease 
(COPD). From the Montreal Chest Institute, we recruited 56 asthmatic patients between 
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May 2001 and February 2002. The most recent measures of FEV1 (predicted value) and 
FEV1/FVC were retrieved from their medical charts. From the asthma clinic of the 
Hôpital du Sacré-Coeur de Montréal (HSCM), we recruited 15 asthmatic patients 
between January 2003 and March 2003. The patients’ most recent value of FEV1 was 
obtained from their medical chart. However and for this set of patients, the FEV1/FVC 
values were unavailable. 
 
The information concerning the use of prescribed medications, the history of 
hospitalizations, and ED visits for asthma was obtained from the RAMQ and MED-
ECHO databases for all patients. The data obtained from the RAMQ and MED-ECHO 
provided us with the necessary information to classify the severity and control of each 
patient using our database indexes. 
 
Application of the Database Indexes of Asthma Severity and Control 
Our database indexes of asthma severity and control were applied in a cohort of asthmatic 
patients from Quebec in order to obtain the distribution of asthma severity and control as 
classified by our indexes at a population level. The Quebec cohort was comprised of 
139 283 person-years of follow-up of asthmatic patients aged from 14 to 44 years old, 
who were selected from RAMQ and MED-ECHO databases between January 1st 1997 
and December 31st 2004. In order to be included in the cohort, patients had to have been 
diagnosed with asthma at least once between January 1st 1997 and December 31st 2004. 
Furthermore, their medications must have been covered by the RAMQ Prescription Drug 
Insurance Plan for at least one year prior and one year after the index date; which was 
defined as, the coming January 1st after having been diagnosed with asthma. Based upon 
the aforementioned conditions, we found all the non-overlapping one-year periods that 
fulfilled our criteria. Therefore, a patient could contribute more than one episode of one 
year of follow-up into the cohort. The level of asthma severity and control was evaluated 
for each one-year period included in the cohort using our database indexes. The RAMQ 
provided us with the data on dispensed medications, medical services, and socio-
demographic data while MED-ECHO provided us with data related to hospitalizations for 
all patients included in the cohort. 
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Comparison of the Distribution of Asthma Severity Levels across Different Study 
Populations and Severity Indexes 
For validation purposes, the distribution of the severity levels found in the Quebec cohort 
using our database index of severity was compared to the distribution of the severity 
levels found in different populations worldwide using other severity indexes. The first 
severity index with which we compared ours was based on the GINA classification of 
symptoms and FEV1 that was then applied in a sample of 4,333 asthmatic patients (51% 
female) aged from 16-45 years old, who had been examined by clinical specialists in 
private practice throughout France (216). The second severity index with which we 
compared ours was also based on the measure of asthma severity reported in the GINA 
guidelines – frequency of symptoms – and was applied to a sample of 2509 asthmatic 
patients identified in the Asthma Insights and Reality (AIR) survey conducted in the 
United States (217). The third severity index with which we compared ours was based on 
patient’s reported daily medication usage and was applied to a sample of 1279 asthmatic 
patients, who had completed a telephone questionnaire and had filled inhaler 
prescriptions in community pharmacies in Ontario, Canada (207).  
 
Statistical Analysis 
The differences in mean FEV1 (percent predicted value) were compared between the 
levels of asthma severity and control within the sample of patients recruited at the asthma 
clinics. The comparison of the FEV1/FVC ratio between levels of asthma severity and 
control was only completed for patients recruited at the Montreal Chest Institute. We also 
performed the same analysis stratified by age: < 45 and > 45 years old. Using the 
Student’s t- test for independent samples, two-tailed pair wise comparisons were 
performed and p-values smaller than 0.05 were considered significant. No adjustment for 
multiple testing was done. The distribution of the levels of asthma severity and control 
using our database indexes was estimated among the Quebec cohort of asthmatic patients. 
All statistical analyses were performed using SAS version 8.02. 
 
Ethical consideration 
The link between the data obtained from the RAMQ database, the MED-ECHO database 
and the medical chart was approved by the Commission d’accès à l’information du 
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Québec. This research project was approved by the ethic board of the Hôpital du Sacré-
Cœur de Montréal and the Montreal Chest Institute. 
 
Results 
Study Population Characteristics  
In Table 2, we present the characteristics of the populations under study; i.e. patients 
from the asthma clinics and the Quebec cohort. Mean age of 139 283 person-years of 
asthmatic patients of the Quebec cohort was lower (30.3 yrs) than those from the asthma 
clinics (49.0 yrs). Patients from the asthma clinics used more ICS than those from the 
Quebec cohort (71.8% vs. 63.0%). The use of more than 10 doses of SABA per week was 
higher among patients from the asthma clinics than patients in the Quebec cohort (26.8% 
vs. 24.0%). In the sample of patients from the asthma clinics, 11.3% had at least one ED 
visit and 4.2% had at least one hospitalization for asthma over a 12-month period, while 
these figures were 18.1% and 6.2% for patients in the cohort. 
 
Application of our Database Index of Asthma Severity and Control 
In Table 3, we present the distribution of the levels of asthma severity and control based 
on our database indexes for the sample of 71 patients from the asthma clinics and the 
Quebec cohort. In patients from the asthma clinics, we found that 35 (49.3%), 21 (29.6 
%), and 15 (21.1%) of them respectively had mild, moderate and severe asthma. Overall, 
in the asthma clinic sample, we classified 46.5% of patients as having poorly controlled 
asthma, and we found that of those we classified as mild, moderate or severe, 20.0 %, 
57.1 % and 93.3 % respectively had poorly controlled asthma by our criteria. When this 
sample was stratified by age, we observed that younger patients were more likely to have 
mild asthma and controlled asthma than older patients. In the Quebec cohort, we found 
that 63.4%, 22.6%, and 14.0% respectively had mild, moderate and severe asthma and 
that 54.5 % had uncontrolled asthma.  
 
Validation of the Database Indexes of Asthma Severity and Control  
In Table 4, we present the results of the analyses performed to validate our database 
indexes against pulmonary function measures. With respect to the index of severity, 
among the 71 patients from the asthma clinics, the mean predicted value of FEV1 was 
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found to be 89.8% for mild, 74.1 % for moderate, and 61.5 % for severe asthma. All pair 
wise comparisons of FEV1 between the three levels of asthma severity were found to be 
statistically significant (P-value=0.0066 for moderate vs. mild, < 0.0001 for severe vs. 
mild and 0.0333 for severe vs. moderate respectively). In the sample of 56 patients from 
the Montreal Chest Institute, the FEV1/FVC ratio ranged from 75.8 % for mild to 61.8 % 
for severe asthma. Pair wise comparisons of the ratio were found to be statistically 
significant when mild patients were compared to moderate (P-value=0.0056) and severe 
patients (P-value=0.0302), but the observed difference between moderate and severe 
patients was not found to be statistically significant (P-value=0.2049).  
 
With respect to the index of control, we found that patients we classified as well 
controlled had a mean FEV1 of 89.5 % and a FEV1/FVC ratio of 75.3% while 
corresponding figures were 67.3 % and 65.7 % for those we classified as poorly 
controlled, using different subsets of clinic patients for the FEV1 and FEV1/FVC 
comparisons as described in methods. Differences between controlled and uncontrolled 
patients were found to be statistically significant (P-value=< 0.0001 for differences in 
FEV1 and P-value=0.0009 for differences in FEV1/FVC ratio).  
 
In Table 5, we present the results of the analysis comparing FEV1 across the different 
levels of asthma severity and control stratified by age (< 45 and > 45 years old). 
Statistically significant differences were observed for all pair wise comparisons between 
severity levels except for the moderate to severe comparison in younger patients and the 
mild to moderate comparison in the older patients. Differences in FEV1 between 
controlled and uncontrolled patients were found to be statistically significant in both 
subgroups. 
 
Comparison of the Distribution of Asthma Severity among Different Populations 
The comparison of the distribution of asthma severity in the Quebec cohort assessed 
against our database index and the distribution of asthma severity in other populations 
worldwide assessed against other severity indexes is presented in Table 6. In the Quebec 
cohort, the distribution of severity levels was 63%, 23%, and 14% for mild, moderate and 
severe respectively. This distribution was similar to those of two of the three study 
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populations: between 59% and 66% for mild, around 22% for moderate, and between 
13% and 19% for severe. However, the Ontarian population had quite a different 
distribution of severity with 28% of mild, 49% of moderate, and 23% of severe patients. 
  
Discussion 
We have demonstrated that our database indexes of asthma severity and control correlate 
well with lung function measures, such as the FEV1 and the FEV1/FVC ratio, which are 
reliable indices reflecting asthma severity and control (39, 118). Moreover, the 
application of our database severity index to a population-based cohort of asthmatic 
patients led to a distribution of asthma severity similar to that found with other severity 
indexes applied in two of the three comparison samples.  
 
The need to adjust for the level of asthma severity and control to minimize confounding 
is encountered in most of the epidemiologic studies carried out in the field of asthma. 
However, these disease characteristics are not always easy to measure because of the lack 
of clinical data, especially in the case of studies performed with administrative databases. 
To the best of our knowledge, our indexes of asthma severity and control are the first of 
this kind to be entirely based on data available from health administrative databases, and 
it will be possible to use them in future epidemiologic studies in the field of asthma.  
 
Differences in the distribution of asthma severity and control found in the populations 
that we studied are worthy of comments. Patients followed in asthma clinics of tertiary 
healthcare centers are more likely to have moderate or severe asthma and are more 
properly controlled due to the fact that they benefit from follow up from respiratory 
specialists. Our results do reflect this since the percentage of controlled patients in each 
level of severity was greater among the patients from the asthma clinics than those from 
the Quebec cohort. Moreover, we found that patients treated in the asthma clinics more 
commonly suffer from severe asthma, according to our criteria, than patients in the 
Quebec cohort.  
 
Our results also demonstrated that the distribution of the level of asthma severity 
obtained by applying our database index to the Quebec cohort was close to the 
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distribution found within two of the three asthma severity indexes based upon the 
symptoms and pulmonary function that have been applied in other populations, France 
and the United States (216, 217). The distribution of severity found in the study 
conducted in Ontario was different from the one found in the Quebec cohort and this 
might be due to differences in how we define severity. According to the Ontarian index, 
patients were classified as having mild asthma if they had only bronchodilators to treat 
asthma, and they were classified as having moderate or severe asthma when they were 
prescribed ICS, while in our index of severity, patients with a low dose of ICS could be 
classified as having mild asthma. Indeed, the other two indexes resemble more than the 
Ontarian one to our indexes. 
 
This study has some limitations that should be kept in mind when interpreting the results. 
First, with our database indexes it could, in some cases, be difficult to precisely 
distinguish the difference between asthma severity and control since the markers of 
exacerbations and use of rescue medications were used in both definitions. The overlap in 
the definitions of asthma severity and control could also result in an asthma that is more 
uncontrolled among severe patients than mild ones. This overlap could also have played a 
role in the validation against FEV1 and FEV1/FVC measures for the asthma clinic sample 
since these pulmonary function values may reflect both severity and control. However, 
the difficulty in making a clear distinction between asthma severity and control is not 
specific to our indexes and is also encountered in clinical practice (218). Second, our 
database index of severity was developed to measure disease severity among patients 
already treated for asthma and is at least in part based on the level of medication needed 
to attain control (39). Moreover, our indexes were validated among patients likely to be 
compliant to their treatment, because they were under the care of respiratory specialists. 
However and with respect to general clinical practice, a proportion of patients will not 
attain control and this might reduce the capacity of our severity index to accurately 
classify patients. Third, our database index of control cannot detect short-term changes 
since it is based on medications and health care services dispensed over a one-year 
period. Fourth, another limit of our study concerns the use of a single measure of lung 
function to validate the indexes. Only one measure of lung function might not be optimal 
to assess a parameter that can fluctuate over time. Fifth, patients included in the Quebec 
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cohort are not fully representative of the population since they do not include patients 
with private drug insurance plans and tend to over represent patients with a low to 
moderate socio-economic status. 
 
This study has also several strengths. The database indexes can assess asthma severity 
and control among patients already treated for asthma and are at least in part based on the 
use of acute care for asthma, which are well-recognized markers of asthma severity and 
lack of control (39). Moreover, the data obtained from the Prescription Drug Insurance 
database regarding the mean dose of ICS and SABA are considered to be good reflection 
of usual dosage (219-223). Our indexes were validated against pulmonary function 
measures that are well established measures of asthma severity and control. Moreover, 
the age-stratified analysis allowed us to assess the validity of our database index across 
different age groups. Finally, the distribution of asthma severity found with our database 
index when applied to the Quebec cohort was found to be comparable to the distribution 
of severity assessed with other indexes applied to two of the three different population 
samples we used for comparison.  
 
In conclusion, we have demonstrated that the database indexes that we developed based 
on dispensed asthma medications and medical services are valid to the extent we could 
test this and could adequately classify currently treated asthmatic patients into categories 
of severity and control. In the absence of clinical data, our database indexes could be 
used in epidemiologic studies using administrative databases to reasonably assess the 
severity and control of asthma among adult patients and thus, improve the quality of 
database studies in the field of asthma. Further research will be needed to confirm these 
findings, and to adapt and validate these database indexes for use in special populations 
including pregnant women, the elderly or pediatric patients.  
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Table 1. Definition of the Database Indexes of Asthma Severity and Control 
Developed According to the Canadian Asthma Consensus Guidelines 
 
Asthma severity 
and control 
*ICS daily dose 
(µg) 
**Other 
controller 
therapy 
+SABA doses 
per week 
++ Marker of 
moderate to severe 
exacerbations 
Mild      
        Controlled 0-500 No 0-3 No 
 
0-250 Yes 0-3 No 
        Uncontrolled 0-250 Yes 0-3 Yes 
 
0-500 No 0-3 Yes 
 
0-250 Yes 4-10 No 
 
0-500 No 4-10 No 
Moderate     
         Controlled 251-500 Yes 0-10 No 
 
501-1000 Yes/No 0-10 No 
 
>1000 Yes/No 0-3 No 
        Uncontrolled 0-250 Yes 4-10 Yes 
 
0-500 No 4-10 Yes 
 
0-250 Yes >10 No 
 
0-500 No >10 No 
 
251-500 Yes >10 No 
 
251-500 Yes 0-10 Yes 
 
501-1000 Yes/No >10 No 
 
501-1000 Yes/No 0-10 Yes 
Severe     
        Controlled >1000 Yes/No 4-10 No 
        Uncontrolled 0-1000 Yes/No >10 Yes 
 
>1000 Yes/No 0-10 Yes 
 
>1000 Yes/No >10 Yes/No 
 
*ICS daily dose in beclomethasone-CFC equivalent over a 12-month period 
** Other controller therapy: at least 6 prescriptions of long-acting beta2-agonist (LABA), 
theophylline or leukotriene-receptor antagonists dispensed over a 12-month period 
+SABA: Average number of inhaled short-acting beta2-agonist doses per week calculated 
over a 12-month period 
++ An emergency department visit for asthma, a hospitalization for asthma or a filled 
prescription of an oral corticosteroid over a 12-month period. 
 97 
 
Table 2. Characteristics of the Study Population over a 12-Month Period 
 
 
Patients selected from 
the asthma clinics 
(n=71) 
*Quebec cohort of 
asthmatic patients 
(n=139 283 person-
years) 
Mean age ± s.d, years  49.0 ±  17.8 30.3 ± 8.7  
Female, % 62.9 62.2 
**ICS use, µg per day, %   
              0 28.2 37.0 
              1-250 15.5 34.3 
              251-500 18.3 11.9 
              501-1000 18.3 10.9 
              > 1000 19.7 5.9 
+SABA, number of doses per 
week, % 
  
              0-3 57.7 53.6 
              4-10 15.5 22.4 
               > 10 26.8 24.0 
++LABA use, % 54.9 23.4 
Theophyline use, % 9.9 2.3 
Anti-leukoterienes use, % 21.1 7.7 
Oral corticosteroids use, % 31.0 16.5 
Respiratory physician visit, % 98.6 12.3 
ED care for asthma, % 11.3 18.1 
Hospital care for asthma, % 4.2 6.2 
* On average, patients contributed 2.1 episodes of one year into the cohort. The cohort 
correspond the asthmatics selected from January 1st 1997 to December 31st 2004 
** ICS daily dose in beclomethasone-CFC equivalent over a 12-month period 
+SABA: Average number of inhaled short-acting beta2-agonist doses per week calculated 
over a 12-month period 
++LABA: inhaled long-acting beta2-agonist  
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Table 3. Distribution of the Levels of Asthma Severity and Control 
  
 
All patients from 
asthma clinics 
(n=71) 
Patients aged 
45 ys old or 
less (n=34)  
Patients  aged 
more than 45 
ys old (n=37) 
Quebec cohort of 
asthmatic patients 
(n=139 283 
person-years) 
 
 Numbers (Percent) 
Mild 35 (49.3) 20 (58.8) 15 (40.5)  88 250 (63.4) 
           Controlled 28 (80.0) 17 (85.0) 11 (73.3) 57 529 (65.2) 
           Uncontrolled 7 (20.0) 3 (15.0) 4 (26.7) 30 721 (34.8) 
Moderate 21 (29.6) 9 (26.5) 12 (32.4) 31 552 (22.6) 
           Controlled 9 (42.9) 4 (44.4) 5 (41.7) 5 488 (17.4) 
           Uncontrolled 12 (57.1) 5 (55.6) 7 (58.3) 26 064 (82.6) 
Severe 15 (21.1) 5 (14.7) 10 (27.0) 19 481 (14.0) 
           Controlled 1 (6.7) 0 (0.0) 1 (10.0) 377 (1.9) 
           Uncontrolled 14 (93.3) 5 (100.0) 9 (90.0) 19 104 (98.1) 
Controlled 38 (53.5) 21 (61.8) 17 (45.9) 63394 (45.5) 
Uncontrolled 33 (46.5) 13 (38.2) 20 (54.1) 75889 (54.5) 
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Table 4. Comparison of the Database Indexes of Asthma Severity and Control 
against Lung Function Measures  
 
Asthma severity 
N=71 
Variable N Mean P-value 
Mild FEV1 predicted % 35 89.8  
Moderate FEV1 predicted % 21 74.1 *0.0066 
Severe FEV1 predicted % 15 61.5 **< 0.0001 
 
   ***0.0333 
N=56     
Mild FEV1 /FVC 30 75.8  
Moderate FEV1 /FVC 18 68.1 *0.0056 
Severe FEV1 /FVC 8 61.8 **0.0302 
 
   ***0.2049 
 
    
Asthma control 
N=71 
    
Controlled FEV1 predicted % 38  89.5  
Uncontrolled FEV1 predicted % 33 67.3 < 0.0001 
N=56     
Controlled FEV1 /FVC 33 75.3  
Uncontrolled FEV1 /FVC 23 65.7 0.0009 
* Moderate vs. Mild  
**Severe vs. Mild  
*** Severe vs. Moderate 
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Table 5. Age Stratified Comparison of the Database Indexes of Asthma Severity and 
Control and FEV1 Measures 
 
Asthma severity Variable N Mean P-value 
< 45 ys old N=34     
        Mild FEV1 predicted % 20 95.2  
        Moderate FEV1 predicted % 9 68.7 *0.0016 
        Severe FEV1 predicted % 5 61.1 **0.0018 
 
   ***0.5193 
>45 ys old N=37     
        Mild FEV1 predicted % 15 82.6  
        Moderate FEV1 predicted % 12 78.1 *0.5523 
        Severe FEV1 predicted % 10 61.6 **0.0261 
 
   ***0.0146 
 
    
Asthma control     
< 45 ys old N=34     
      Controlled FEV1 predicted % 21 92.0  
      Uncontrolled FEV1 predicted % 13 68.9 0.0044 
>45 ys old N=37     
      Controlled FEV1 predicted % 17 86.4  
      Uncontrolled FEV1 predicted % 20 66.2 0.0041 
* Moderate vs. Mild  
**Severe vs. Mild  
*** Severe vs. Moderate 
 
 
Table 6. Comparison of the Distribution of Asthma Severity Based on Different 
Indexes Applied to Different Populations 
 
 *Cohort of 
asthmatic patients, 
Quebec, Canada 
(n=139 283 person-
years) 
**Cohort of 
asthmatic patients, 
France (20)  
(n= 4333)  
***AIR America 
survey, United 
States (21)  
(n=2509)  
****Cohort of  
asthmatic patients, 
Ontario, Canada (7) 
(n=1279)  
 Percent 
Mild asthma 63 66 59 28 
Moderate asthma 23 21 22 49 
Severe asthma 14 13 19 23 
 
*The index is based on dispensed medications and medical services for asthma 
**The index is based on symptoms and FEV1. 
***The index is based on symptoms and the current state of asthma management. 
****The index is based on reported daily medication use. 
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Summary 
Recent studies have found that asthmatic women pregnant with a female fetus reported 
more symptoms and had slightly lower lung function than women pregnant with a male 
fetus. In order to further investigate this association, we studied the effect of fetal sex on 
maternal asthma exacerbations and the use of asthma medications during pregnancy. A 
large cohort of pregnant asthmatic women and their babies was reconstructed between 
1990 and 2002 from the linkage of three administrative databases of the Canadian 
province of Quebec. Asthma exacerbations were defined as a filled prescription of oral 
corticosteroids, an emergency department visit, or a hospitalization for asthma. Women 
pregnant with a female fetus were compared to women with a male fetus with respect to 
their rate of asthma exacerbation, their weekly doses of inhaled short-acting beta2-
agonists (SABA), and their daily dose of inhaled corticosteroids (ICS) during pregnancy. 
Logistic and linear regression models were used to obtain effect measures adjusted for 
several potential confounders such as, asthma severity and control prior to pregnancy. 
The cohort included 5529 pregnancies with a single female fetus and 5728 pregnancies 
with a single male fetus. No significant differences were found between mothers of a 
female and male fetus as to the occurrence of asthma exacerbations (adjusted rate 
ratio=1.02; 95% CI: 0.92 to 1.14), the daily dose of ICS (adjusted mean difference 
(AMD): 2.46 µg; 95% CI: -4.01 to 8.93), and the weekly dose of SABA (AMD: 0.004 
dose; 95% CI: -0.23 to 0.24). Based on the results, we conclude that fetal gender is 
unlikely to affect maternal asthma during pregnancy to the point where acute care and 
medications are more often required among women pregnant with a female fetus. 
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Introduction:  
The prevalence of asthma among pregnant women varies between 4 and 7% and it is 
known as one of the most frequent chronic diseases encountered during pregnancy (3-5, 
7, 47). The course of asthma may remain unchanged, improve or worsen during 
pregnancy and usually returns to the pre-pregnancy state within three months after 
delivery (77, 78). The control of asthma during pregnancy can be influenced by several 
factors, namely physiologic hormonal changes that are triggered during pregnancy (78).  
 
A few studies have suggested that a pregnant woman’s asthma may worsen when 
carrying a female fetus (8-11). In a review of case series, (11) three mothers who had 
been followed in successive pregnancies reported more asthma attacks when pregnant 
with a female fetus than when they were carrying a male fetus. Moreover and in 
comparison with mothers carrying a male fetus, Beecroft et al. observed that pregnant 
asthmatic mothers with a female fetus had reported an increase in asthma symptoms (8) 
while Dodds et al. (9) observed that they had an increased usage of steroids. More 
recently, Kwon et al. assessed the association between fetal gender and airway lability 
among pregnant asthmatic women and found a 10 percent significant reduction in peak 
expiratory flow rate (PEF) among mothers with a female fetus. Conversely, 
Baibergenova et al. did not find any significant association between fetal gender and 
visits to an emergency department (ED) for asthma during pregnancy (84). Among 
hypotheses put forward to explain the mechanisms behind the association between fetal 
gender and maternal asthma control during pregnancy, the one related to the regulation of 
placental glucocorticoid and immune response in asthmatic pregnancies seems the most 
plausible (8, 10, 84). Indeed, Clifton and Murphy and their research teams have reported 
that female fetus alters maternal asthma during pregnancy by upregulating maternal 
inflammatory pathways (85-87, 224) and thus if asthma-associated inflammatory 
pathways are not treated with inhaled steroids during pregnancy, the mother could suffer 
asthma exacerbation.  
 
Although studies have reported possible associations between fetal gender and maternal 
asthma control during pregnancy, methodological issues such as the measure of the 
outcome and the absence of statistical inference, as well as the questionable clinical 
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significance of some of the results make it difficult to conclude with a reasonable degree 
of certainty that women pregnant with a female fetus are more likely to have uncontrolled 
asthma. Using Canadian administrative databases, we planned a large cohort study to 
further evaluate the effect of fetal gender on the risk of uncontrolled maternal asthma 
through the study of exacerbations, use of inhaled short-acting beta2-agonists (SABA) 
and inhaled corticosteroids (ICS) during pregnancy. 
 
Materials and Methods 
Source of data 
The data for our study came from three administrative databases of the Canadian 
province of Québec; the Régie de l’Assurance Maladie du Québec (RAMQ), MED-
ECHO, and the Fichier des événements démographiques du Québec (birth and death 
registries) managed by the Institut de la statistique du Québec (ISQ). RAMQ databases 
provide information on the medical services dispensed to all residents of Québec and on 
prescribed medications filled in community pharmacies by residents covered by the 
RAMQ’s Public Drug Insurance Plan. Approximately 43% of the population of Quebec 
is covered by the RAMQ Public Drug Insurance Plan, most notably the elderly and social 
aid beneficiaries since 1980 and since 1997, 1.7 million of new adherents, mainly 
workers and their families who have no access to a private drug insurance plan (186). The 
RAMQ’s Prescription Drug Insurance database provides information on dispensed 
medications – i.e. date of filling, name, dose, quantity, dosage form and duration of the 
prescription – while the RAMQ’s Medical Services database provides information on 
medical services dispensed in a clinic, an emergency department (ED) or a hospital (date, 
diagnosis coded with ICD-9, where the service was dispensed, etc.). The RAMQ 
databases also provide socio-demographic data such as age, gender, social assistance 
status and where relevant, date of death. Data recorded in the RAMQ Prescription Drug 
Insurance database and asthma diagnoses recorded in the RAMQ Medical Services 
database have been formally evaluated and found to be valid (187, 188). The MED-
ECHO database is a provincial database which records data on acute care hospitalizations 
and covers all residents of Quebec. For each hospitalization, data on primary and up to 15 
secondary discharge diagnoses, date of entry, duration of hospitalization, and treatments 
received during the hospitalization are available (187). The Fichier des événements 
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démographiques provides information on all births and still births in the province of 
Québec. 
 
Study Design and Population 
A large cohort of pregnant asthmatic women and their babies was reconstructed between 
1990 and 2002 from the linkage of the three administrative databases. Pregnant women 
were identified using diagnostic and act codes related to prenatal care, pregnancy 
complications, abortions and deliveries (189). To be included in our cohort, a women 
should have had: 1) one or more singleton pregnancy ending in a delivery (life birth or 
still birth) between January 1, 1990 and December 31, 2002; 2) being between 13-50 
years of age at conception; 3) in the two years prior to, or during pregnancy, a diagnosis 
of asthma (9th international classification of diseases (ICD-9) code 493, except 493.2 
which relates to COPD disease) and one or more prescription for an asthma medication 
(ICS , oral corticosteroids, SABA, long-acting beta2-agonists (LABA), theophyllines, 
leukotriene-receptor antagonists, inhaled short-acting anticholinergic, cromoglycate or 
nedocromil) dispensed; 4) coverage with the RAMQ drug insurance plan for at least one 
year prior to, and throughout the duration of the pregnancy; and 5) no other pregnancy of 
more than 14 weeks in the year prior to conception. The length of gestation was obtained 
mainly from the MED-ECHO database, which was calculated based upon the date of the 
last menstruation. To assess the date of conception, we subtracted the length of gestation 
from the date of the delivery. The unit of analysis was the pregnancy; a woman could 
contribute more than one pregnancy in the cohort. 
 
For each included woman, data from RAMQ and MED-ECHO were obtained for the two 
years preceding conception, and the duration of the pregnancy. This mother-child cohort 
was then linked with the Fichier des événements démographiques databases to obtain 
information on socio demographic variables for the mothers and the newborns.  
 
Fetal Gender 
The gender of the baby was extracted from the RAMQ database and was checked for 
consistency with that recorded in the ISQ and MED-ECHO databases. In case of missing 
values or inconsistencies, the following algorithm was used to determine the gender: 1) 
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If the gender of the baby was recorded in the RAMQ database then this value was 
retained; 2) If the gender of the baby was missing at the RAMQ and recorded at ISQ then 
the ISQ value was retained; and 3) If the gender of the baby was missing at the RAMQ 
and ISQ, the value recorded at MED-ECHO was retained. If the gender of the baby was 
not recorded in any of the three databases, the pregnancy was excluded. Fetal gender has 
been formally evaluated and found to be highly valid as compared to the information 
recorded in the medical chart of the mother with specificity and sensitivity higher than 
0.97 (195). 
 
Primary and Secondary Outcomes 
The primary outcome was asthma exacerbations during pregnancy. Based upon the 
criteria used in the Canadian Asthma Consensus Guidelines, asthma exacerbations were 
defined as a short (< 14 days) course  of oral corticosteroids dispensed by a pharmacy, an 
ED visit for asthma, or a hospitalization for asthma (39). To avoid the overestimation of 
the number of exacerbations, all the aforementioned events occurring within a 15-day 
period accounted for one exacerbation. Asthma diagnosis recorded in the RAMQ 
databases have been formally evaluated and found to be valid (193). 
 
The secondary outcomes included the mean daily dose of ICS and the mean weekly dose 
of SABA during pregnancy, calculated using data from the RAMQ’s database using 
validated algorithms based upon the name, dose, formulation and quantity of the 
dispensed medication, duration of the prescription and time intervals between renewals 
(189, 194). The equivalencies of the mean daily dose of ICS into beclomethasone-CFC 
were calculated using the equivalency table published in the Canadian Asthma Consensus 
Guidelines (39). The equivalencies for SABA were established by a pharmacist (MFB); 
for example, one dose of SABA was equivalent to two inhalations of salbutamol from a 
metered-dose inhaler (100µg/inhalation) (194).  
 
Data Analysis 
Descriptive statistics were calculated by fetal gender for socio-demographic variables, 
antiasthmatic medication use, and health care services use for asthma during pregnancy. 
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Crude rates of maternal asthma exacerbation during the whole pregnancy and for each 
trimester separately were compared between pregnancies of a female and male fetus.  
 
Logistic regression models were used to obtain odds ratios of exacerbation adjusted for 
several potential confounders including socio-demographic variables such as, maternal 
age at conception (< 18, 18-34, > 34 years), social assistance benefits one year before or 
during pregnancy (yes/no), area of residency at delivery (rural or urban); pregnancy-
related variables such as being primiparous (yes/no), high risk pregnancy (yes/no), 
gestational diabetes (yes/no), diabetes mellitus (yes/no), pregnancy-induced hypertension 
(yes/no), chronic hypertension (yes/no), gynecologist or obstetrician visit during 
pregnancy (yes/no), number of prenatal visits (≤5, 6-14, >14); as well as asthma-related 
variables such as, a respiratory specialist visit during pregnancy (yes/no), ICS use during 
pregnancy (yes/no), and asthma severity and control prior to pregnancy. Asthma severity 
and control were measured with validated database indexes that we developed based on 
medication use and need for acute care for asthma (196). We used a backward 
elimination strategy to find final logistic regression models including covariates that 
changed the odds ratio associated with the gender of the baby by at least 10% and 
covariates that were found to be statistically associated with the outcome. Adjusted 
effects of fetal gender were estimated for the whole pregnancy and for each trimester 
separately. The first, second and third trimesters of pregnancy were defined as periods 
between 0 to 14 weeks of pregnancy, 15 to 28 weeks of pregnancy and from 29th week up 
to the end of pregnancy, respectively.  
 
Adjusted differences in the mean daily dose of ICS and mean weekly dose of SABA were 
estimated between all pregnancies of female and male fetuses using linear regression 
models and the aforementioned potential confounders. Adjusted differences were 
estimated for the whole pregnancy and for each trimester separately. 
 
One secondary analysis was performed on the primary outcome. For this analysis, we 
selected the women who had at least two pregnancies during the study period with fetuses 
of different sex. For these women, the rate of asthma exacerbations during the whole 
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pregnancy was compared between pregnancies of a female and male fetus using logistic 
regression models. All statistical analyses were performed using SAS version 8.02. 
 
Results 
Study Population Characteristics  
Among the 13 040 pregnancies included in the cohort of asthmatic women, 1774 were 
excluded because there was another pregnancy of 14 weeks or more in the year prior to 
conception and 9 pregnancies were excluded because the baby’s gender was unknown. 
The final cohort included 11 257 singleton pregnancies with 5529 female (49.1 %) and 
5728 male (50.9 %) fetuses. The rate of concordance for fetal gender between the three 
databases was 99%.  
 
In Table 1, we present the socio demographic and pregnancy related characteristics of the 
study women, by fetal gender. The female and male fetus groups showed comparable 
characteristics. In Table 2, we present the asthma related characteristics in the year before 
conception and during pregnancy, by fetal gender. All characteristics were distributed 
similarly among female and male fetus pregnancies for these two periods.  
 
Maternal Asthma Exacerbation during Pregnancy by Fetal Gender 
In Table 3, we present the proportion of women who had at least one asthma exacerbation 
within each trimester separately and during the entire pregnancy, by fetal gender. During 
the first trimester, 6.9% and 6.8% of women carrying a female and male fetus had at least 
one asthma exacerbation, respectively. In the second trimester, this proportion remained 
unchanged for the female fetus group, but increased modestly to 7.1% for the male fetus 
group. During the third trimester, the rate of maternal asthma exacerbations decreased to 
4.0% and 3.7% for mothers of female and male fetus, respectively. The final logistic 
regression models showed no statistically significant differences in the rate of 
exacerbation both during the entire pregnancy and for each trimester separately between 
mothers of female and male fetus after adjusting for all potential confounders listed in the 
data analysis section (adjusted rate ratio=1.02; 95% CI: 0.92-1.14 for the entire 
pregnancy). 
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Maternal SABA Use by Fetal Gender 
 
In Table 4, we present the results of the analyses performed to compare the use of SABA 
between women pregnant with female and male fetuses. The mean doses of SABA used 
per week in each trimester and during the entire pregnancy were similar in both groups. 
Moreover, the proportion of women who used at least one dose of SABA per week on 
average during the entire pregnancy was similar between the groups (62.5% for female 
and 62.6% for male fetuses). No statistically significant adjusted differences were found 
between mothers of female and male fetuses as to their use of SABA (adjusted mean 
difference: 0.004 dose/week; 95% CI: -0.23; 0.24 for the entire pregnancy)  
 
Maternal ICS Use by Fetal Gender 
In Table 5, we present the results of the analysis comparing the mean daily dose of ICS 
between women pregnant with female and male fetuses. Similar proportions of women 
used ICS in each trimester and during the entire pregnancy in both groups (41.6% in 
female and 41.0% in male fetuses during the entire pregnancy). Moreover, the daily doses 
of ICS were similar between the groups. No statistically significant adjusted differences 
were found between mothers of female and male fetuses as to their use of ICS (adjusted 
mean difference: 2.46 µg/day; 95% CI: -4.01; 8.93 for the entire pregnancy).  
 
Maternal Asthma Exacerbations in Successive Pregnancies with a Different Fetal Gender 
From the cohort of 11 257 asthmatic pregnant women, we identified 1674 women who 
had more than one pregnancy during the study period. Among them, 874 had one 
delivery with a girl and one delivery with a boy during the study period. There was no 
significant difference in the rate of asthma exacerbations during the entire pregnancy 
between the male and female fetuses (adjusted rate ratio=1.07; 95% CI: 0.81-1.42). 
 
Discussion 
In this large cohort study of 11 257 pregnancies of asthmatic women, we detected no 
significant increase in the rate of maternal asthma exacerbations, the use of ICS and 
SABA during pregnancy among mothers of female fetus, whether examined between or 
within mothers. 
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Our results concord with those of Baibergenova et al. who found no difference in ED 
visits for asthma between pregnancies of male and female fetuses. This study was based 
on a large cohort of 109 173 live singleton deliveries reconstructed from a hospital and an 
ambulatory care administrative database provided by the Canadian Institute for Health 
Information (CIHI). From this cohort, the investigators first identified all patients who 
visited an ED during pregnancy and then found that 0.49% and 0.48% of those ED visits 
were for asthma among women pregnant with a female and a male fetus, respectively (p-
value > 0.05). However, these results should be interpreted with caution since the authors 
did not take into account the number of asthmatic women among pregnancies of male and 
female fetuses. 
 
On the other hand, our results are not in accordance with those of three other smaller 
studies that found increased markers of uncontrolled asthma among pregnancies of 
female fetuses (8-10), but the choice of the outcome and the way it was measured can be 
put forward to explain the differences between studies. In their blind-controlled 
prospective study (n=34), Beecroft et al. have found that asthmatic women pregnant with 
a female fetus reported significantly more shortness of breath (72% vs. 31%), nocturnal 
awakening (55% vs. 37%), and general asthma symptoms (50% vs. 31%) than women 
pregnant with a male fetus (8). However, these self-reported asthma symptoms might not 
necessarily reflect asthma exacerbations. Moreover, Dodds et al. have evaluated steroids 
use during pregnancy among a sample of 817 pregnant asthmatic women without having 
specific data on asthma severity or symptoms and found that it was higher among 
mothers of a female fetus as opposed to a male fetus (20% vs. 14%) (9). This outcome is 
difficult to interpret since it is unclear whether or not it includes only oral corticosteroids 
or both inhaled and oral formulations, which in the later case would not necessarily 
reflect uncontrolled asthma. Moreover, we cannot conclude on the statistical significance 
of this difference since no statistical inference was reported in the article. Finally, Kwon 
et al. used a prospective cohort design to study an objective outcome among 702 pregnant 
women with asthma, i.e. PEF measures. The PEF was assessed at enrolment and at 21, 
29, and 37 weeks of gestation. The 10% reported difference in log diurnal variation of 
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PEF between pregnancies of male and female fetuses reached statistical significance, but 
we question the clinical significance of the observed difference (10). 
 
Our study must be interpreted in light of the following limitations. First, the obtained data 
from the administrative databases reflect medication dispensing and might not correspond 
exactly to medication intake. However, there is no reason to believe that the use of 
dispensed medications differed between mothers of female and male fetus. Secondly, the 
outcome was evaluated for either trimesters or the entire pregnancy and this precluded us 
to identify short-term changes in asthma control. Thirdly, we did not have access to 
clinical data, such as the frequency of asthma symptoms and lung function measures, and 
this precluded us to evaluate a milder lack of control that could be perceived by the 
mother.  
 
Our study has also several strengths. One of the biggest strength is its very large sample 
size, which provided a high power to detect small differences. Indeed, we had a 80% 
power to detect a relative difference of 16 % (i.e. RR=1.16) in the rate of asthma 
exacerbations between pregnancies of female and male fetus. Moreover, the data 
obtained from the databases allowed us to identify moderate to severe asthma 
exacerbations requiring medical attention, which is an outcome that objectively reflects 
an important aggravation of asthma symptoms. In addition, our cohort included mothers 
with pregnancies with alternate fetal gender allowing us to compare the outcome between 
pregnancies of female and male fetus of the same mother, eliminating inter-patient 
variability. 
 
In conclusion, we have shown that fetal gender had no significant impact on the rate of 
maternal moderate to severe asthma exacerbations, use of rescue medications, and ICS 
during pregnancy. Fetal gender might have a minor impact on maternal asthma 
symptoms, but this study provides evidence that these changes are not serious enough to 
lead to a moderate to severe exacerbation. According to our results, it is not recommended to 
adjust for fetal gender in epidemiologic studies in the field of asthma and pregnancy. Moreover, 
our results suggest that fetal gender should not be considered to plan the management of asthma 
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during pregnancy, and that the management should aim at asthma control regardless of the gender 
of the fetus.  
 
 
ACKNOWLEDGMENTS 
The authors want to thank Ms. Brigitte Morin from the Régie de l’assurance maladie du 
Quebec (RAMQ) for her assistance with the data and Mr. Hatch for the English revision 
of the manuscript. 
 
COMPETING INTERESTS 
The authors declare no competing interests for the submitted manuscript. 
 
FUNDING 
Lucie Blais and Sylvie Perreault are the recipients of a career salary award from the 
Fonds de la recherche en santé du Québec (FRSQ). Francine M Ducharme is the 
recipient of two career salary awards, namely the National Scientist Award from the 
FRSQ and the William-Dawson award from McGill University. Catherine Lemière is the 
recipient of a New Investigator Award for salary support from the Canadian Institutes for 
Health Research (CIHR). Lucie Blais and Marie-France Beauchesne hold the 
AstraZeneca Chair in Respiratory Health. Faranak Firoozi is the recipient of a Doctoral 
Training Award from the FRSQ. This study was funded through a grant from the CIHR. 
 
 
 
 115 
 
Table 1. Socio demographic and pregnancy related characteristics of study women 
by fetal gender  
 
 
Pregnancies of 
female fetus 
Pregnancies of 
male fetus 
Numbers 5529 5728 
Age at conception (years), mean ± s.d  25.0 + 5.6 24.9 + 5.6 
*Social assistance, % 78.9 78.3 
Urban residency at delivery, %  80.7 81.3 
Primiparous, % 36.9 37.3 
High risk pregnancy, % 35.6 36.3 
Gestational diabetes, % 8.1 7.6 
Chronic diabetes, % 2.3 2.7 
Pregnancy induced hypertension, % 7.0 6.7 
Chronic hypertension, % 2.6 2.3 
Gynecologist or obstetrician visit 
during pregnancy, % 
82.2 83.3 
Number of prenatal visits, %   
               ≤ 5 15.1 14.5 
               6-14  73.3 73.0 
               > 14 11.7 12.5 
Season of delivery, %  
                  Winter  24.4 23.9 
                  Spring 26.2 27.2 
                  Fall     24.0 23.9 
                  Summer 25.4 25.0 
*Recipient of social assistance in the year prior or during pregnancy  
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Table 2. Asthma related characteristics of study women by fetal gender  
 
 
In the year before conception During pregnancy 
 
Pregnancies 
of female 
fetus N=5529 
Pregnancies 
of male fetus 
N=5729 
Pregnancies 
of female 
fetus N=5529 
Pregnancies 
of male fetus 
N=5729 
*ICS use (µg per day), %     
                    0 56.0 55.3 58.4 59.0 
                 0-500 40.3 41.3 37.6 37.6 
                500-1000 2.6 2.4 3.0 2.2 
                > 1000 1.1 0.9 1.0 1.2 
**SABA use (number of 
doses per week), % 
    
                   0 33.4 32.9 37.5 37.5 
               > 0-3 34.9 34.8 32.4 32.8 
                > 3 31.7 32.3 30.1 29.7 
***LABA use, % 2.1 1.8 1.8 1.8 
Leukoteriene-receptor          
antagonists  use, % 
1.0 0.8 0.4 0.2 
Oral corticosteroids use, % 12.1 12.1 7.5 7.7 
 ≥ 1 respiratory physician 
visit, % 
6.0 7.0 5.9 5.9 
 ≥ 1 ED visit for asthma, % 13.5 13.3 12.6 12.4 
 ≥ 1hospitalisation for 
asthma, % 
1.2 1.2 1.5 1.5 
****Asthma severity, %     
                      Mild    81.5 82.1 82.2 82.3 
                      Moderate        13.4 12.6 12.7 12.3 
                      Severe 5.1 5.3 5.1 5.4 
****Asthma control, %     
                      Controlled       60.6 60.1 63.2 64.0 
                      Uncontrolled  39.4 39.9 36.8 36.0 
*ICS daily dose in beclomethasone-CFC equivalent over a 12-month period 
**SABA: short-acting inhaled beta2-agonist 
***LABA: long-acting inhaled beta2 -agonist 
****Measured with validated database indexes that we developed based on medication use and need for 
acute care for asthma (196) 
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Table 3. Occurrence of maternal moderate to severe asthma exacerbation in each 
trimester and during the entire pregnancy, by fetal gender 
 
 
F: female fetus, M: male fetus 
*Adjusted for respiratory specialist visit, asthma severity and asthma control in the year before pregnancy 
and ICS use in the first trimester of pregnancy. 
**Adjusted for socioeconomic status, gestational diabetes, respiratory specialist visit, asthma severity in the 
year before pregnancy, and ICS use in the second trimester of pregnancy. 
***Adjusted for gestational diabetes, respiratory specialist visit, asthma severity in the year before 
pregnancy, ICS use in the third trimester of pregnancy. 
****Adjusted for socioeconomic status, respiratory specialist visit during pregnancy, asthma severity and 
asthma control in the year before pregnancy and ICS use during pregnancy. 
 
 
N Total At least one 
exacerbation 
n (%) 
Crude OR 
F vs M 
Adjusted OR(95% CI) 
F vs M 
1st                      F  
trimester          M 
5519 
5721 
378 (6.9) 
391 (6.8) 
1.00  1.01 (0.86 to 1.18)* 
2nd                    F 
Trimester        M 
5519 
5721 
381 (6.9) 
408 (7.1) 
0.98 0.98 (0.84 to 1.14)** 
3rd                   F 
Trimester        M 
5474 
5667 
220 (4.0) 
211 (3.7) 
1.02 1.03 (0.85 to 1.24)*** 
During             F 
pregnancy       M 
5519 
5721 
846 (15.3) 
861 (15.1) 
1.02 1.02 (0.92 to 1.14)**** 
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Table 4. Use of SABA during the entire pregnancy and within each trimester, by 
fetal gender 
 
F: female fetus, M: male fetus 
*Adjusted for socioeconomic status, high risk pregnancy, and respiratory specialist visit during the first 
trimester of pregnancy and asthma severity and asthma control in the year before pregnancy  
**Adjusted for socioeconomic status and respiratory specialist visit during the second trimester of 
pregnancy and asthma severity and asthma control in the year before pregnancy 
***Adjusted for socioeconomic status, and respiratory specialist visit during the third trimester of 
pregnancy, and asthma severity and asthma control in the year before pregnancy 
****Adjusted for socioeconomic status, high risk pregnancy, pregnancy induced hypertension and 
respiratory specialist visit during pregnancy, and asthma severity and asthma control in the year before 
pregnancy  
 
 N 
Total 
At least one 
dose per week 
N (%) 
Mean  
number of 
doses per 
week  
Crude  mean 
difference 
F vs M 
Adjusted  mean difference 
(95% CI) 
F vs M 
1st               F  
trimester   M 
5529 
5728 
3083 (55.8) 
3200 (55.9) 
4.4 
4.3 
0.09 0.07 (-0.17 to 0.31)* 
2nd               F 
Trimester  M 
5529 
5728 
3058 (55.3) 
3172 (55.4) 
4.6 
4.5 
0.03 - 0.003 (-0.27 to 0.26)** 
3rd              F 
Trimester  M 
5484 
5674 
2864 (52.2) 
2972 (52.4) 
4.5 
4.5 
-0.02 -0.06 (-0.34 to 0.22)*** 
During       F 
pregnancy M 
5529 
5728 
3456 (62.5) 
3583 (62.6) 
4.5 
4.4 
0.03 0.004 (-0.23 to 0.24)**** 
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Table 5. Use of ICS during the entire pregnancy and within each trimester, by fetal 
gender 
 
 
F: female fetus, M: male fetus 
*Adjusted for maternal age at conception, area of residency at delivery, chronic diabetes, chronic 
hypertension, number of prenatal visits during the first trimester of pregnancy, respiratory specialist visit 
during the first trimester and asthma severity and asthma control in the year before pregnancy,  
**Adjusted for maternal age at conception, chronic diabetes, chronic hypertension, number of prenatal visit 
during the second trimester of pregnancy, respiratory specialist visit during the second trimester and asthma 
severity in the year before pregnancy 
***Adjusted for maternal age at conception, chronic diabetes, chronic hypertension, number of prenatal 
visit during the third trimester of pregnancy, respiratory specialist visit during the third trimester of 
pregnancy, and asthma severity in the year before pregnancy 
****Adjusted for maternal age at conception, area of residency at delivery, gestational diabetes, chronic 
diabetes, chronic hypertension, number of prenatal visit during pregnancy, respiratory specialist visit during 
pregnancy and asthma severity and asthma control in the year before pregnancy 
 
 
 N 
Total 
ICS use 
N (%) 
Mean  µg 
per day  
Crude  mean 
difference   
F vs M 
Adjusted  mean difference 
(95% CI) 
F vs M 
1st                F  
trimester   M 
5529 
5728 
1933 (35.0) 
1995 (34.8) 
76.5 
74.9 
1.55 1.17 (-5.33;7.67)* 
2nd               F 
Trimester  M 
5529 
5728 
1933 (35.0) 
1974 (34.5) 
87.1 
82.8 
4.36 3.63 (-3.82 to 11.09)** 
3rd              F 
Trimester  M 
5484 
5674 
1788 (32.6) 
1855 (32.7) 
99.3 
94.9 
4.36 3.01 (-6.28 to12.30)*** 
During       F 
pregnancy M 
5529 
5728 
2301 (41.6) 
2348 (41.0) 
85.7 
82.5 
3.17 2.46 (-4.01;8.93)**** 
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5.3. Third article 
 
Titre: Impact of maternal asthma on perinatal outcomes  
 
Submitted to the ERJ. 
Included in the present thesis by the permission of the co-authors. 
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Abstract 
 
Background/ Objectives 
The literature presents conflicting results concerning the impact of maternal asthma 
during pregnancy on perinatal outcomes. We investigated the effect of asthma during 
pregnancy on the risk of a small-for-gestational-age (SGA) infant, a low-birth-weight 
(LBW) infant, and preterm birth using a large population-based cohort. 
 
Methods 
A population-based cohort of 40,788 pregnancies from asthmatic and non-asthmatic 
women was reconstructed through the linking of three of Quebec’s (Canada) 
administrative databases covering the period between 1990 and 2002. A two-stage 
sampling cohort design was used to collect additional information on the women’s life-
style habits by way of a mailed questionnaire. The generalized estimation equation 
models were used to obtain adjusted odds ratios of SGA, LBW and preterm birth 
comparing pregnancies from asthmatic and non-asthmatic women. 
 
Results 
The cohort (first stage of sampling) included 13,007 pregnancies from asthmatic women 
and 27,781 pregnancies from non-asthmatic women. Final estimates showed that the risk 
of SGA (OR: 1.27, 95% CI: 1.14-1.41), LBW (OR: 1.41, 95% CI:1.22-1.63) and preterm 
delivery (OR: 1.64, 95%CI:1.46-1.83) was significantly higher among asthmatic than 
non-asthmatic women.  
 
Conclusions 
Mothers with asthma during pregnancy have a higher risk of having SGA, LBW, or 
preterm birth infants than non-asthmatic women.  
 
Keywords 
Asthma, perinatal outcomes, pregnancy, LBW, SGA, preterm birth, administrative 
databases, two stage sampling cohort 
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Introduction 
The prevalence of asthma among pregnant women is between 4 to 7% and is known as 
one of the most frequent chronic diseases encountered during pregnancy (3-5, 7, 47). 
Adverse perinatal outcomes, such as a preterm birth, a low-birth-weight (LBW) infant 
and a small-for-gestational-age (SGA) infant, have been reported to be higher in pregnant 
women with asthma when compared to women without asthma (14, 16, 17, 19, 93, 96, 
102, 103). However, some other studies do not confirm these results (7, 15, 20, 90, 92, 
98-100, 115). 
 
In a recent meta-analysis, conducted by Murphy and al., asthmatic women with and 
without asthma exacerbations during pregnancy were compared to non-asthmatic women 
for the risk of LBW infant and preterm delivery (113). The authors found no significant 
increased risk of preterm delivery among asthmatic women, but observed a significant 
increased risk of LBW in women who had an exacerbation (RR: 2.54) and no significant 
increased risk in women who did not have an asthma exacerbation during pregnancy 
(RR: 1.12) (113).  
 
Methodological differences between studies as well as the lack of power of some of them 
due to small sample sizes make it difficult to estimate, with any reasonable degree of 
certainty, the risk of adverse perinatal outcomes in pregnant women with asthma. To 
further investigate the potential effect of asthma during pregnancy on adverse perinatal 
outcomes including SGA infants, LBW infants, and preterm births, we performed a two-
stage sampling cohort study based on a cohort of 40,788 pregnancies from asthmatic and 
non-asthmatic women reconstructed by the linkage of three administrative databases from 
Quebec (Canada) between 1990 and 2002.  
 
Materials and Methods 
Source of Data  
The data for our study came from three administrative databases of the province of 
Quebec; the Régie de l’Assurance Maladie du Quebec (RAMQ), MED-ECHO, and the 
Fichier des événements démographiques du Québec (birth and death registries) managed 
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by the Institut de la statistique du Québec (ISQ). These data were supplemented by a 
mailed questionnaire completed by selected mothers. The RAMQ databases provide 
information on the medical services dispensed to all residents of Quebec and on 
prescribed medications filled in community pharmacies by residents covered by the 
RAMQ’s Public Drug Insurance Plan. Approximately 43% of the population of Quebec 
is covered by the RAMQ Public Drug Insurance Plan, most notably the elderly and social 
assistance beneficiaries since 1980. Furthermore, since the enactment of mandatory drug 
coverage in 1997, the RAMQ’s Public Drug Insurance Plan now provides coverage for 
an additional 1.7 million adherents, mainly workers and their families who have no 
access to a group drug insurance plan at work (186). The RAMQ Prescribed Medication 
database provides information on dispensed medications – i.e. date of filling, name, dose, 
quantity, dosage form and duration of the prescription – while the RAMQ Medical 
Services database provides information on medical services dispensed in a clinic, an 
emergency department (ED), or a hospital; including information pertaining to date, 
diagnosis coded with 9th international classification of diseases (ICD-9), where the 
service was dispensed, etc. Data recorded in the RAMQ Public Prescribed Medication 
database and asthma diagnoses recorded in the RAMQ Medical Services database have 
been formally evaluated and found to be valid (187, 188). The MED-ECHO database is a 
provincial database which records data on acute care hospitalizations and covers all 
residents of Quebec (187). The Fichier des événements démographiques provides 
information on all births and stillbirths in the province of Quebec. Some additional 
information regarding siblings and maternal life styles during pregnancy which are not 
included in the administrative databases were retrieved from a mailed questionnaire 
completed by a number of selected women.  
 
 
Study Design and Population 
A two-stage sampling cohort design (balanced selection) was used for this study (184, 
185, 190, 225). In our study, the first stage of sampling corresponds to a cohort formed of 
singleton pregnancies of asthmatic and non-asthmatic women ending in a delivery (live 
birth or stillbirth) between January 1st, 1990 and December 31st, 2002 in the province of 
Quebec (Canada). Pregnant women and newborns were identified in the RAMQ database 
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using diagnostic and act codes related to prenatal care, pregnancy complications, and 
deliveries (189). Moreover, to be included in our cohort, a woman must have been 
between 13-50 years of age at the beginning of her pregnancy as well as being covered by 
the RAMQ Public Prescription Drug Insurance Plan for at least one year prior to and 
throughout the duration of her pregnancy. Women were considered as having asthma if 
they had a diagnosis of asthma (ICD-9 code 493, except 493.2 which corresponds to 
chronic obstructive asthma), and one or more prescriptions for an asthma medication 
dispensed in the two years prior or during pregnancy. We allowed a maximum of four 
pregnancies per woman to enter in the cohort and only the more recent ones were 
retained. For each pregnancy, the data from the RAMQ and MED-ECHO databases were 
obtained one year before and during pregnancy. The date of the last menstruation was 
calculated using the gestational age and date of birth of the infant, obtained from the 
MED-ECHO and RAMQ databases. This mother-child cohort was then linked with the 
Fichier des événements démographiques database to obtain information on socio-
demographic variables for the mothers and the newborns.  
 
At the second stage of sampling, we selected, from the cohort, a sample of women to 
whom a questionnaire was sent by mail, using a balance sampling strategy (184, 190). 
This strategy oversamples women who had a SGA infant, a LBW infant, or a preterm 
delivery in order to increase the statistical power (184). A maximum of two pregnancies 
per woman were selected at this stage of sampling to avoid overloading women who had 
more than two live deliveries during our study period with questionnaires. Selected 
women had to be at least 18 years old at the beginning of their pregnancy to be eligible 
for the second stage of sampling due to ethical considerations. For all pregnancies 
selected at this stage, the RAMQ provided us with the current postal addresses of the 
mother as well as their spoken language.  
 
The questionnaire was used to obtain information pertaining life styles (including 
maternal cigarette smoking, maternal alcohol consumption, and paternal cigarette 
smoking), maternal characteristics, and pregnancy related variables that are not recorded 
in the administrative databases. The questionnaire underwent prior testing by about 40 
women for its clarity and also its facility to be understood and answered. By pretesting, 
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we also assessed the capacity of women to remember the events which happened up to 15 
years ago. First, we sent 5,384 questionnaires to selected women. A second questionnaire 
was sent a month and half later as a reminder. A 10$ compensation was given to women 
who completed the questionnaire. The questionnaires’ data were recorded in a 
computerized database, using a double entry method to improve data quality.  
 
The linkage between data obtained from the RAMQ, MED-ECHO and ISQ databases, 
and the filled questionnaires as well as the request of the name and the mailing address of 
selected women at the second stage of sampling was approved by the Commission 
d’accès à l’information du Quebec (CAI). This research project was also approved by the 
ethics committee of the Hôpital du Sacré-Cœur de Montréal (Montreal, Quebec, 
Canada). 
 
Exposure 
In this study, the main exposure variable is maternal asthma during pregnancy as 
previously defined in the section “Study design and Population”. Women with asthma 
during pregnancy were compared to non-asthmatic pregnant women.   
 
Outcomes 
The outcomes of interest included SGA infants, preterm births, and LBW infants. SGA 
was defined as a birth weight below the 10th percentile for gestational age and gender, 
using new Canadian standards (226, 227). Preterm birth was defined as a birth before 37 
weeks of gestation while LBW was defined as birth weight lower than 2,500g. Validated 
algorithms based on data recorded in the RAMQ, MED-ECHO or ISQ databases were 
used to measure these variables (195).  
 
Confounding Variables  
Four categories of variables were considered as potential confounding variables. 
Maternal characteristics derived from administrative databases include age at the 
beginning of the pregnancy (< 18, 18-34, > 34 years) (228), receiving social assistance 
benefits in the year before or during pregnancy (yes/no), urban residency at delivery 
(yes/no), and being primiparous (yes/no). Maternal characteristics derived from the 
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questionnaire include maternal education (highest level reached: elementary school, 
high school, college & University), annual family income during pregnancy (<$18,000, 
$18,000-$46,000, >$46,000) (228) and birth weight (<2.5, 2.5-5, >5 kg). Pregnancy-
related variables derived from administrative databases include high risk pregnancies 
(ICD-9 codes V23 except V238,  6932, 6938, 6939, 6941, 9157 and 9167 recorded in the 
RAMQ or MED-ECHO databases) (yes/no), gestational diabetes (yes/no), pregnancy-
induced hypertension (yes/no), a gynecologist or obstetrician visit during pregnancy 
(yes/no), and number of prenatal visits (≤5, 6-14, >14). Pregnancy-related variables 
derived from the questionnaire include maternal weight gain during pregnancy (<8, 8-
16, >16 kg), maternal body mass index (BMI) (<18.5, 18.5-24.9, 25-29.9, >29.9) at 
beginning of pregnancy and another preterm or LBW infant prior to the current delivery 
(yes/no) (229). Maternal co-morbidities derived from administrative databases 
include diabetes mellitus (yes/no) and chronic hypertension (yes/no). Life style habits 
derived from the questionnaire include maternal and paternal cigarette smoking during 
pregnancy (yes/no) and maternal alcohol consumption during pregnancy (yes/no).  
 
Data Analysis 
Descriptive statistics were used to report the characteristics of the asthmatic and non-
asthmatic women included in the cohort (first stage of sampling) and those selected at the 
second stage of sampling. In addition, the asthmatic related characteristics were reported 
for the asthmatic women. The maternal asthma severity and control level during 
pregnancy were measured with an index that we had previously developed and validated 
(196). These indexes are based on dispensed prescriptions of asthma medications as well 
as acute care for asthma recorded in the RAMQ and MED-ECHO databases. We also 
calculated the distribution of the variables measured at the first stage of sampling for 
women who answered the questionnaire and women who did not in order to investigate 
whether or not there is any difference between these two groups. The unit of analysis was 
the pregnancy, due to the fact that a woman could contribute up to four pregnancies 
during the study period at the first stage of sampling and up to two pregnancies at the 
second stage of sampling. 
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We calculated the prevalence of the study outcomes for asthmatic and non-asthmatic 
women, separately for the first and second stage of sampling. Crude and adjusted odds 
ratios (OR) for SGA infants, LBW infants and preterm births comparing asthmatic to 
non-asthmatic women were then estimated for the first stage of sampling using 
Generalized Estimation Equation (GEE) models (198). The GEE models can estimate the 
effect of independent variables, including the main exposure and confounding variables, 
on several types of outcomes, namely dichotomous outcomes such as the presence or the 
absence of SGA, LBW or preterm delivery with a logit function as well as take into 
account the fact that a woman could contribute more than one pregnancy to the analysis 
by estimating the correlation between consecutive pregnancies. The best reduced models 
were found using a backward selection strategy, keeping in the model only covariates that 
were found to act as a confounder or those that were significantly associated with the 
outcome (p-value < 0.05).  
 
We also obtained adjusted OR estimates for each outcome based on pregnancies selected 
at the second stage of sampling and GEE models that adjusted for confounding variables 
collected at the first (administrative databases) and second (questionnaire) stages of 
sampling. Missing values for variables retrieved from the questionnaire were included in 
the reference category for modeling purposes since the proportion of missing values was 
low. The final adjusted OR estimates were then obtained by correcting the second stage 
adjusted OR with the second stage sampling fractions and the adjusted OR found at the 
first stage of sampling using the methodology proposed by Collet et al (184). This 
methodology is based on a statistical analysis that takes into account the fact that certain 
cells of the outcome/main exposure cross table have been over sampled and provide 
unbiased estimates of the association under study. 
 
Results 
At the first stage of sampling, the cohort included 13,007 singleton pregnancies of 
asthmatic women and 27,781 singleton pregnancies of non-asthmatic women. At the 
second stage of sampling, we sent a total of 5,384 questionnaires to selected asthmatic 
(n=3,168) and non-asthmatic (n=2,216) women. We received 2,080 completed 
questionnaires (response rate: 38.6%): 1,274 questionnaires from asthmatic women 
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(response rate: 40.2%) and 806 questionnaires from non-asthmatic women (response rate: 
36.4%).  
 
In Table 1, we present the distribution of the variables retrieved from the administrative 
databases for all pregnancies of asthmatic and non-asthmatic women included in the 
cohort (first stage of sampling). We found that the prevalence of several characteristics 
was higher among the pregnancies of asthmatic than those of non-asthmatic women: 
recipients of social assistance (79.5% vs. 57.5%), high risk pregnancies (36.1% vs. 
29.3%), gestational diabetes (7.7% vs. 6.8%), pregnancy induced hypertension (6.5% vs. 
5.2%), maternal chronic diabetes (2.4% vs. 1.4%), and maternal chronic hypertension 
(2.3% vs. 1.3%).  
 
Table 2 shows the distribution of variables retrieved from the questionnaires among 
women selected at the second stage of sampling and who responded to the questionnaire. 
In this sample, asthmatic women had a lower education (15.2% vs. 28.0%, for college 
and university levels) and a lower annual family income (37.9% vs. 51.3%, for >$ 
18,000) than non-asthmatic women. However, the prevalence of several other 
characteristics was higher among asthmatic than non-asthmatic women: maternal birth 
weight <2.5 kg (19.5% vs. 15.4%), maternal weight gain >16 kg (40.6% vs. 30.4%), 
maternal BMI pre-pregnancy >29.9 (12.2% vs. 7.6%), preterm birth prior to the current 
delivery (16.5% vs. 13.8%), maternal cigarette smoking (63.2% vs. 49.0%), and paternal 
cigarette smoking (50.9% vs. 42.9%).  
 
Furthermore, we found that among asthmatic and non-asthmatic women, respondents 
(1,274 vs. 1,894, respectively) and non respondents (806 vs. 1,410) were quite similar 
except that there was a lower proportion of women who received social assistance (54.6% 
vs. 64.8% for non-asthmatics and 77.2% vs. 84.0% for asthmatics), and lived in an urban 
area (71.6% vs. 80.1% for non-asthmatics and 77.2% vs. 83.7% for asthmatics) among 
respondents. The details of this analysis are available in the electronic attachment.  
 
In Table 3, we present the distribution of asthma related variables among pregnancies of 
asthmatic women included in the first stage of sampling. We found that 82.6%, 12.4% 
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and 5.0% of pregnancies of asthmatic women included at the first stage of sampling were 
from women with mild, moderate and severe asthma, respectively. Among these women, 
3.6% used more than 500 µg of inhaled corticosteroids (ICS) per day, 29.5% used more 
than three doses of SABA per week during pregnancy and 34.0% filled no asthma 
medications during pregnancy.  
 
Table 4 shows the prevalence of SGA infants, LBW infants and preterm deliveries among 
pregnancies of asthmatic and non-asthmatic women at the first stage of sampling. In 
addition, in this table we present the first stage and the final crude and adjusted estimates 
of the ORs and corresponding 95% CIs for the three perinatal outcomes, comparing 
asthmatic to non-asthmatic women. The prevalence of the three perinatal outcomes was 
higher among pregnancies of asthmatic than those of non-asthmatic women (SGA: 14.5% 
vs. 10.6%, LBW: 9.2% vs. 5.7% and preterm births: 10.3% vs. 6.7%).  
 
The first stage adjusted ORs showed that the risk of the three adverse perinatal outcomes 
was significantly higher among asthmatic than non-asthmatic women. In the final 
models, all potential confounding variables were initially included, but only some of 
them remained in the final reduced models. The covariables were kept in the GEE models 
only if they were found to act as a confounder for the association between asthma and 
perinatal outcomes or if they were significantly associated with the outcome under study. 
Adjusted final estimates showed that the risk of the three adverse perinatal outcomes was 
significantly higher among asthmatic than non-asthmatic women. The risk was OR:1.27 
(95% CI: 1.14-1.41) for SGA, OR:1.41 (95% CI: 1.22-1.63) for LBW and OR:1.64 (95% 
CI: 1.46-1.83) for preterm births.  
 
Discussion 
We have found that asthma during pregnancy was significantly associated with an 
increased risk of SGA, LBW and preterm births. One of the possible mechanism causing 
these adverse outcomes is lack of oxygen to the fetus which can lead to intrauterine 
growth retardation, preterm birth, or neonatal hypoxia (55, 56).   
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Our results support the findings of Demissie et al, Liu et al and Enriquez et al who 
reported a significant association between maternal asthma and the risk of SGA infants 
with relative risk estimates ranging between 1.16 and 1.20 (14, 17, 96). On the other 
hand, our results differ from those of Perlow et al, Bracken et al and Dombrowski et al 
who found no significant increased risk of SGA associated with asthma (91, 99, 100). 
Lack of adjustment for several potential confounders and lack of power due to small 
sample sizes probably explain the differences in results. 
 
Murphy et al investigated the effect of asthma and asthma exacerbation on LBW and 
preterm births through a meta-analysis using data from three and four studies, 
respectively (113). The authors found no significant increased risk of preterm delivery in 
women who had (RR: 1.46, 95%CI: 0.77-2.78) and in women who did not have an 
asthma exacerbation during pregnancy (RR: 0.93, 95% CI: 0.74-1.17). For LBW, they 
observed a significantly increased risk in women who had (RR: 2.54, 95% CI:1.52-4.25), 
but no increased risk in women who did not have an asthma exacerbation during  
pregnancy (RR: 1.12, 95% CI: 0.89-1.40) (113). The differences between these results 
and those found in our study could be partly explained by important differences in the 
study sample sizes. In their meta-analysis, Murphy et al compared 855 asthmatic women 
with 31,662 non-asthmatic women coming from three studies as to their risk of having a 
LBW infant. To investigate the impact of asthma on prematurity, Murphy et al. compared 
1,312 pregnancies from asthmatic women to 31,899 pregnancies from non-asthmatic 
women. The corresponding samples in our study were 13,007 asthmatic women and 
27,781 non-asthmatic women at the first stage of sampling. 
 
The major strength of our study is that it was based on a large cohort of 13,007 
pregnancies of asthmatic women and 27,781 pregnancies of non-asthmatic women 
selected over a 12-year period. All asthma diagnoses were made by a physician and 
asthma diagnoses recorded in the RAMQ database were formally evaluated and found to 
be valid (230). We also avoided recall bias in measuring outcomes and the main exposure 
since these variables were collected using administrative databases in which data are 
prospectively collected. Moreover, the validity of the outcomes; birth weight and length 
of gestation have been evaluated by comparing the database values to the woman’s 
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medical chart values for 728 pregnant women and found to be highly valid (195). 
Another strength of the study is the two-stage sample design in which database data were 
coupled with questionnaire data in order to obtain information on confounding variables 
that are not recorded in the databases. We were thus able to construct models that 
considered a large number of variables that may intervene in the development of the 
fetus.  
 
This study has also some limitations that should be kept in mind while interpreting the 
results. Asking questions related to a pregnancy that occurred many years ago could 
result in recall bias. However, Yawn et al have shown that “maternal reports of perinatal 
events in which they directly participated can be accurately and reliably reported 10 to 15 
years after birth” (231). The response rate to the questionnaire was 40.2% for asthmatic 
women and 36.4% for non-asthmatic women, but it is reassuring to see that the 
distribution of the databases driven variables were quite similar between responders and 
non responders. Finally, our cohort is not representative enough of women in the higher 
socio-economic level because it included women receiving social assistance and middle 
class working women. However, the non representativeness of our cohort would be a 
threat to external validity only if socio-economic status is an effect modifier for the 
associations under study. But there is no evidence in the literature suggesting that the 
impact of maternal asthma or its severity or control on newborns differs in different 
levels of socio-economic status. In fact, there is literature on the association between 
asthma severity or control and socio-economic status (232, 233), but it is not reported that 
the relationship between asthma and perinatal outcomes varies between high and low 
levels of socio-economic status.  
 
The scientific evidence provided by this study showed that asthmatic women are more at 
risk of having SGA, LBW and preterm infants than non-asthmatic women. Considering 
the high prevalence of asthma among pregnant women and the fact that uncontrolled 
asthma has been associated with adverse perinatal outcomes (91, 99, 102), it is essential 
to develop preventive, therapeutic and health care strategies to insure an optimal 
treatment of asthma during pregnancy to minimize the adverse perinatal outcomes of 
asthma. 
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Table 1. Characteristics of all pregnancies of asthmatic and non-asthmatic women 
include in the cohort: database driven variables at the first stage of sampling 
 
 
 Pregnancies of 
asthmatic women 
(n=13007) 
Pregnancies of 
non-asthmatic 
women (n=27781) 
 
Number (%) 
Maternal socio-demographic variables  
Age at beginning of pregnancy (years)  
< 18  875 (6.7) 987 (3.5) 
            18 - 34  11,333 (87.1) 24,136 (86.9) 
     > 34  799 (6.1) 2658 (9.6) 
    *Recipient of social assistance 10,346 (79.5) 15,970 (57.5) 
Urban residency at delivery  10,528 (80.9) 21,407 (77.1) 
Pregnancy related variables  
Primiparous 4,191 (32.3) 9,611 (34.8) 
High risk pregnancy 4,700 (36.1) 8,131 (29.3) 
Gestational diabetes 1,000 (7.7) 1,886 (6.8) 
Pregnancy induced hypertension 846 (6.5) 1,437 (5.2) 
Gynecologist or obstetrician visit 
during pregnancy 10,713 (82.4) 22,453 (80.8) 
Number of prenatal visits 
 
               ≤ 5 2,048 (15.8) 4,831 (17.4) 
               6-14  9,477 (72.9) 20,577 (74.1) 
               > 14 1,482 (11.4) 2,373 (8.5) 
Maternal co-morbidities  
Chronic diabetes 314 (2.4) 381 (1.4) 
Chronic hypertension 304 (2.3) 368 (1.3) 
*Social assistance status in the year before pregnancy    
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Table 2. Characteristics of the pregnancies of asthmatic and non-asthmatic women 
selected at the second stage of sampling (n=2080): questionnaire driven variables 
 
 Pregnancies of 
asthmatic women 
(n=1274) 
Pregnancies of non-
asthmatic women 
(n=806) 
 Number (%) 
Maternal characteristics  
Highest level of education attained 
during pregnancy  
   Elementary school 105 (8.2) 35 (4.3) 
   High school   948 (74.4) 527 (65.4) 
   College & University    194 (15.2) 226 (28.0) 
   Unknown  27 (2.1) 18 (2.2) 
Annual family income during 
pregnancy   
        < $18,000 762 (59.8) 377 (46.8) 
        $18,001 - $46,000 407 (31.9) 323 (40.1) 
        > $46,001  76 (6.0) 90 (11.2) 
        Unknown    29 (2.3) 16 (2.0) 
Weight at birth 
 
         < 2.5 kg 248 (19.5) 124 (15.4) 
         2.5 – 5.0 kg         879 (69.0) 548 (68.0) 
         > 5.0 kg 16 (1.3) 11 (1.4) 
         Unknown    131 (10.3) 123 (15.3) 
Pregnancy related variables  
Weight gain during pregnancy 
 
        < 8 kg 179 (14.1) 115 (14.3) 
        8 - 16 kg        531 (41.7) 423 (52.5) 
        > 16 kg 517 (40.6) 245 (30.4) 
        Unknown  47 (3.7) 23 (2.8) 
BMI pre-pregnancy 
 
         < 18.5 178 (14.0) 124 (15.4) 
          18.5 – 24.9 667 (52.4) 468 (58.1) 
          24.9 – 29.9 231 (18.1) 132 (16.4) 
          > 29.9  155 (12.2) 61 (7.6) 
          Unknown  42 (3.4) 21 (2.6) 
Preterm birth prior to the current 
delivery  
        Yes 210 (16.5) 111 (13.8) 
         No 1,055 (82.8) 692 (85.9) 
         Unknown  9 (0.7) 3 (0.4) 
LBW infant prior to the current 
delivery  
        Yes 192 (15.1) 119 (14.8) 
         No 1,073 (84.2) 684 (84.9) 
         Unknown  9 (0.7) 3 (0.4) 
Life style habits during pregnancy 
 
Maternal cigarette smoking 
 
        Yes 805 (63.2) 395 (49.0) 
         No 462 (36.3) 402 (49.9) 
         Unknown  7 (0.5) 9 (1.1) 
Paternal cigarette smoking 
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           Yes 648 (50.9) 346 (42.9) 
           No 601 (47.2) 451 (56.0) 
         Unknown 25 (2.0) 9 (1.1) 
Maternal alcohol consumption 
 
           Yes 221 (17.4) 148 (18.4) 
           No 1,008 (79.1) 619 (76.8) 
         Unknown 45 (3.5) 39 (4.8) 
 
 
 
 
Table 3. Asthma related characteristics of the pregnancies of asthmatic women 
(n=13007)  
 
During pregnancy Number (%) 
Asthma severity level 
Mild 10,737 (82.6) 
Moderate 1,618 (12.4) 
Severe 652 (5.0) 
Asthma control level Controlled  8,331 (64.1) Uncontrolled 4,676 (35.9) 
* Average daily dose of 
ICS (µg) 
0 7,729 (59.4) 
0-500 4,812 (37.0) 
500-1000 334 (2.6) 
>1000 132 (1.0) 
**Average number of 
doses of SABA per week 
0 4,973 (38.2) 
> 0-3 4,199 (32.3) 
> 3 3,835 (29.5) 
Leukoteriene-receptor antagonists use 34 (0.3) 
Long-acting beta2-agonists use 229 (1.8) 
Theophyline use 311 (2.4) 
Oral corticosteroids use 980 (7.5) 
At least one asthma medication  8,580 (66.0) 
≥ 1 respiratory physician visit 750 (5.8) 
≥ 1 ED visit for asthma  1,611 (12.4) 
≥ 1 hospitalization for asthma 196 (1.5) 
  * ICS daily dose in beclomethasone-CFC equivalent  
  **SABA: short-acting inhaled beta2-agonist 
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Table 4. Crude and adjusted odds ratio of adverse perinatal outcomes comparing pregnancies of asthmatic and non-asthmatic 
women  
 
  Pregnancies 
of asthmatic 
women  
N=13,007 
Pregnancies of 
non-asthmatic 
women 
N=27,781 
OR (95% CI)  
Asthmatic versus non-asthmatic women 
(first stage estimates) 
OR (95% CI)  
Asthmatic versus non-asthmatic women 
(final estimates) 
Number (%) Crude Adjusted Corrected  Crude Corrected Adjusted 
SGA  1,886 (14.5) 2,948 (10.6) 1.43 (1.34-1.52) 1.29 (1.21-1.37)† 1.43 (1.34-1.52) 1.27 (1.14-1.41)* 
LBW 1,197 (9.2) 1,575 (5.7) 1.69 (1.56-1.82) 1.52 (1.40-1.65)††  1.69 (1.56-1.82) 1.41 (1.22-1.63)** 
Preterm 1,340 (10.3) 1,848 (6.7) 1.61 (1.50-1.73) 1.51 (1.40-1.64) ††† 1.61 (1.50-1.73) 1.64 (1.46-1.83)*** 
 
†Adjusted for socio-economic status, urban residency at delivery, parity, high risk pregnancy, gestational diabetes, chronic diabetes, pregnancy induced 
hypertension, gynecologist or obstetrician visit during pregnancy, and prenatal visits.  
††Adjusted for socio-economic status, urban residency at delivery, parity, high risk pregnancy, gestational diabetes, pregnancy induced hypertension, 
chronic hypertension, gynecologist or obstetrician visit during pregnancy, and prenatal visits.  
†††Adjusted for socio-economic status, parity, high risk pregnancy, chronic diabetes, pregnancy induced hypertension, chronic hypertension, 
gynecologist or obstetrician visit during pregnancy, and prenatal visits 
* Adjusted for socio-economic status, parity, pregnancy induced hypertension, prenatal visits, maternal weight at birth, maternal weight gain during 
pregnancy, maternal BMI pre-pregnancy, preterm birth prior to the current delivery, LBW infant prior to the current delivery and maternal cigarette 
smoking. 
** Adjusted for socio-economic status, parity, high risk pregnancy, pregnancy induced hypertension, gynecologist or obstetrician visit during pregnancy, 
prenatal visits, chronic hypertension, maternal weight at birth, maternal weight gain during pregnancy, maternal BMI pre-pregnancy, LBW infant prior to 
the current delivery and maternal cigarette smoking. 
*** Adjusted for socio-economic status, high risk pregnancy, gynecologist or obstetrician visit during pregnancy, prenatal visits, maternal weight gain 
during pregnancy, preterm birth prior to the current delivery. 
 
 
 
 Electronic attachment  
 
Characteristics of asthmatic and non-asthmatic women who responded to the 
questionnaire (N=2080) and those who did not respond (N=3304) 
 
 
Asthmatic women 
N=3168 
Non-Asthmatic women 
N=2216 
Responding  Non-
responding  
Responding  Non-
responding  
Numbers (%) 
1,274 (40.2) 1,894 (59.8) 806 (36.4) 1,410 (63.6) 
Maternal socio-
demographic variables  
Age at beginning of 
pregnancy (years)  
           < 18  117 (9.2) 167 (8.8) 23 (2.8) 74 (5.3) 
           18 - 34  1,096 (86.0) 1,627 (85.9) 703 (87.2) 1,196 (84.8) 
           > 34  61 (4.8) 100 (5.3) 80 (9.9) 140 (9.9) 
   Recipient of social   
   Assistance 983 (77.2 ) 1592 (84.0) 440 (54.6) 914 (64.8) 
   Urban residency at  
   Delivery 984 (77.2) 1586 (83.7) 577 (71.6) 1130 (80.1) 
Pregnancy related variables  
Primiparous 517 (40.8) 625 (33.1) 355 (44.2) 518 (36.9) 
High risk pregnancy 493 (38.7) 755 (39.9) 302 (37.5)  579 (41.1) 
Gestational diabetes 107 (8.4) 128 (6.8) 51 (6.3) 110 (7.8) 
Pregnancy induced 
hypertension 98 (7.7) 105 (5.5) 77 (9.6) 133 (9.4) 
Gynecologist or 
obstetrician visit during 
pregnancy 
1,037 (81.4) 1,614 (85.2) 671 (83.3) 1,208 (85.7) 
Number of prenatal visits  
               ≤ 5 182 (14.3) 390 (20.6) 164 (20.4) 326 (23.1) 
               6-14  950 (74.6) 1,331 (70.3) 599 (74.3) 991 (70.3) 
               > 14 142 (11.2) 173 (9.1) 43 (5.3) 93 (6.6) 
Maternal co-morbidities  
Chronic diabetes 27 (2.1) 49 (2.6) 10 (1.2) 25 (1.8) 
Chronic hypertension 31 (2.4) 46 (2.4) 27 (3.3) 30 (2.1) 
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Electronic attachment  
 
Final odds ratio of perinatal outcomes comparing asthmatic (n=1,274) and non-
asthmatic women (n=806) adjusted for variables derived from the databases and the 
mailed questionnaire 
 
 
SGA LBW Preterm 
Final adjusted OR (95% CI) 
Asthmatic versus non-asthmatic 
women 
1.27 (1.14-1.41) 1.41 (1.22-1.63) 1.64 (1.46-1.83) 
Recipient of social  assistance 1.22 (0.98-1.52) 1.27 (0.99-1.65) 0.82 (0.65-1.02) 
Primiparous 0.78 (0.63-0.95) 0.63 (0.50-0.80) --------------- 
High risk pregnancy --------------- 1.74 (1.38-2.19) 1.84 (1.48-2.28) 
Pregnancy induced hypertension 1.59 (1.04-2.43) 1.95 (1.22-3.13) --------------- 
Gynecologist or obstetrician visit 
during pregnancy --------------- 1.51 (1.10-2.07) 1.62 (1.19-2.19) 
Number of prenatal visits (>14) 1.75 (1.19-2.59) 0.26 (0.16-0.44) 0.25 (0.16-0.41) 
Number of prenatal visits (5-14) 1.35 (1.04-1.74) 0.58 (0.44-0.77) 0.53 (0.41-0.69) 
Chronic hypertension  2.10 (1.15-3.83) --------------- 
Maternal Weight at birth (<2.5 kg) 1.41 (1.11-1.79) 2.13 (1.64-2.78) --------------- 
Maternal Weight at birth (=>5.0 
kg) 1.16 (0.51-2.61) 0.81 (0.31-2.12) --------------- 
Maternal Weight gain during 
pregnancy (>16.0 kg) 0.71 (0.58-0.87) 0.63 (0.49-0.80) 0.92 (0.74-1.15) 
Maternal Weight gain during 
pregnancy (<8.0 kg) 1.00 (0.76-1.32) 1.92 (1.42-2.61) 1.76 (1.32-2.34) 
Maternal BMI pre-pregnancy 
(>24.9) 0.85 (0.68-1.06) 0.66 (0.51-0.86) --------------- 
Maternal BMI pre-pregnancy 
(<18.5) 1.58 (1.21-2.06) 1.42 (1.05-1.92) --------------- 
Preterm birth prior to the current 
delivery 0.36 (0.25-0.52) --------------- 2.75 (2.12-3.58) 
LBW infant prior to the current 
delivery 2.90 (2.03-4.14) 3.55 (2.63-4.81) --------------- 
Maternal cigarette smoking 1.92 (1.57-2.35) 1.31 (1.04-1.65) --------------- 
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5.4. Fourth article 
 
Titre: Effect of maternal moderate to severe asthma on perinatal outcomes 
 
Submitted to the Respiratory Medicine 
Included in the present thesis by the permission of the co-authors. 
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Abstract 
Background / Objectives 
It has been reported that adverse fetal outcomes are more prevalent in pregnant women 
with asthma than they are in women without asthma. In our study, we investigated the 
effect that the severity of asthma during pregnancy has on the risk of a small for 
gestational age (SGA) infant, low birth weight (LBW), and preterm birth. 
 
Methods 
A population-based cohort of 13,007 pregnancies from asthmatic women was 
reconstructed through the linking of three of Quebec’s (Canada) administrative databases 
covering the period between 1990 and 2002. A two-stage sampling cohort design was 
used to collect additional information on the selected women’s life-style habits via a 
mailed questionnaire. Asthma severity during pregnancy was measured with a validated 
database index. A logistic regression model was used to obtain the adjusted odds ratios of 
SGA, LBW and preterm birth as a function of the level of asthma severity. 
 
Results 
The proportions of women with mild, moderate and severe asthma were 82.5%, 12.5% 
and 5.0%, respectively. We sent 3,168 questionnaires to selected women, with a 40.2% 
(n=1274) response rate. Final estimates showed that the risk of SGA was significantly 
higher among severe (OR:1.48, 95%CI: 1.15-1.91) and moderate asthmatic women (OR: 
1.30,  95%CI:1.10-1.55) than mild asthmatic women. No significant associations were 
found between asthma severity, preterm birth and LBW. 
 
Conclusions 
Mothers with severe and moderate asthma during pregnancy have a higher risk of SGA 
babies than those with mild asthma. 
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Introduction  
The prevalence of asthma among pregnant women is estimated to be between 4 and 7% 
(3-5, 7, 47). Lack of oxygen to the fetus can lead to intrauterine growth retardation 
(IUGR), preterm birth or neonatal hypoxia (55, 56, 234). Maternal severe or uncontrolled 
asthma is potentially dangerous to the fetus since it can induce hypoxia combined with 
potentially an acute respiratory alkalosis that decrease the placental blood flow (54, 235). 
Moreover, asthmatic women may have minimal symptoms but still have abnormal 
pulmonary function tests and potentially impaired fetal oxygenation (57). Indeed, adverse 
fetal outcomes such as preterm birth and low birth weight have been reported as being 
more prevalent in pregnant asthmatic women than non-asthmatic ones (14, 16, 17, 19, 
103). However, scientific evidence is scarce regarding the impact of asthma severity 
during pregnancy on these perinatal outcomes.  
 
Although studies have reported associations between severe exacerbations requiring 
hospitalization during pregnancy and adverse perinatal outcomes (18-20), only a few 
small studies investigated the association between the level of asthma severity during 
pregnancy and perinatal outcomes and these studies yielded inconsistent results. Bracken 
et al found that IUGR was more common among infants of mothers with mild to 
moderate persistent asthma as compared to those with no symptoms or medication use 
(99). However, Dombrowski et al. found that the rate of preterm birth (≤ 37 weeks) and 
SGA did not vary according to asthma severity (100). Moreover, Stenius-Aarniala et al 
found no significant difference in birth weight between mothers with moderate-to-severe 
asthma and mothers with very mild to mild asthma (22). 
 
Methodological differences between studies, such as the definition of asthma severity, the 
choice of the outcome, and lack of adjustment for potential confounding variables, as 
well as the small sample size make it difficult to come to a reasonable conclusion. We 
undertook a population-based cohort study of 13,007 pregnancies of asthmatic women to 
further investigate the effect of the severity of asthma during pregnancy on the risk of 
SGA, LBW, and preterm birth.  
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Materials and Methods 
Source of data 
Our data came from three administrative databases of the province of Quebec, Canada; 
the Régie de l’Assurance Maladie du Quebec (RAMQ), MED-ECHO, and the Fichier 
des événements démographiques (birth and death registries) managed by the Institut de la 
statistique du Québec (ISQ)). These data were supplemented by mailed questionnaires 
filled by selected mothers. The RAMQ databases provide information on the medical 
services and on prescribed medications dispensed to residents covered by the RAMQ’s 
Public Drug Insurance Plan (186). Data recorded in the Prescription database and asthma 
diagnoses recorded in the Medical Services database have been validated (187, 188). The 
MED-ECHO database records data on acute care hospitalizations of all Quebec residents 
(187). The Fichier des événements démographiques provides information on all births 
and stillbirths. Additional information regarding siblings and maternal lifestyles during 
pregnancy which are not included in the databases were retrieved from a mailed 
questionnaire completed by a number of selected women.  
 
Study Design and Population 
A two-stage sampling cohort design (balanced selection) was used for this study (184, 
185, 190, 225). The first stage of sampling corresponds to the cohort formed of singleton 
pregnancies of asthmatic women ending in a delivery between January 1, 1990 and 
December 31, 2002. Pregnant women and newborns were identified in the RAMQ 
database using diagnostic and act codes related to prenatal care, pregnancy complications, 
and deliveries (189). Moreover, to be included, women must have been between 13-50 
years of age at the beginning of their pregnancy, have had an asthma diagnosis (ICD-9 
code 493, except 493.2), one or more prescriptions for an asthma medication dispensed in 
the two years prior or during pregnancy, and being covered by the RAMQ Drug 
Insurance Plan for at least one year prior to, and throughout the duration of pregnancy. 
We allowed a maximum of four pregnancies per woman to enter in the cohort and only 
the more recent ones were kept. For each pregnancy, the data from RAMQ and MED-
ECHO databases were obtained one year before and during pregnancy. This mother-child 
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cohort was then linked with the Fichier des événements démographiques database to 
obtain information on socio-demographic variables for the mothers and the newborns.  
 
At the second stage of sampling, we selected a sample of women to whom a 
questionnaire was sent, using a balance sampling strategy (184, 190). This strategy 
oversamples women with moderate to severe asthma who had a SGA, a LBW, or a 
preterm baby in order to increase the statistical power (184). A maximum of two 
pregnancies per woman were selected at this stage of sampling. For all pregnancies 
selected at this stage, the RAMQ provided us with the current postal addresses and 
spoken language of the mother.  
 
The questionnaire was used to obtain information on lifestyles, maternal characteristics, 
and pregnancy-related variables that are not recorded in the administrative databases. The 
questionnaire was pre-tested by 40 women for clarity and assessed the ability of the 
women to remember the answers to the questions that related to a pregnancy that 
occurred several years ago. First, we sent 3,168 questionnaires to selected women. A 
second questionnaire was sent a month and half later as a reminder to women who did not 
respond to the first mailing. A 10$ compensation was given to women who completed the 
questionnaire. The questionnaires’ data were recorded in a computerized database, using 
a double entry method to improve data quality.  
 
Linkage between data obtained from the RAMQ and MED-ECHO databases, ISQ, and 
the filled questionnaires as well as the request of the names and the mailing address of 
selected women at the second stage of sampling was approved by the Commission 
d’accès à l’information du Quebec (CAI). This research project was also approved by the 
ethic committee of the Hôpital du Sacré-Cœur de Montréal. 
 
Exposure 
The main exposure variable is the severity level of maternal asthma during pregnancy 
measured with an index that we had previously developed and validated (196, 196). This 
index is based on dispensed prescriptions of asthma medications as well as acute care for 
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asthma recorded in the RAMQ and MED-ECHO databases. This severity index is based 
upon the definitions provided in the Canadian Asthma Consensus Guidelines (26) and 
was validated with lung function measures such as the FEV1 and the FEV1/FVC ratio. It 
was found that the index correlates well with these clinical measures. Moreover, the 
frequency distribution of the levels of asthma severity found in the general cohort of 
asthmatic patients was compared with the distributions obtained using other severity 
indexes (based on GINA) applied to different populations. Details of the severity index 
are provided in the electronic attachment.  
 
Outcomes 
The outcomes of interest included SGA newborns, preterm birth and LBW. SGA was 
defined as a birth weight < 10th percentile for gestational age and gender, using new 
Canadian standards (226, 236). Preterm birth was defined as a birth before 37 weeks of 
gestation while LBW was defined as birth weight < 2,500g. Validated algorithms based 
on data recorded in the RAMQ, MED-ECHO or ISQ databases were used to measure 
these variables (192).  
 
Confounding variables  
Maternal characteristics i.e. age at beginning of pregnancy (228), receiving social 
assistance in the year before or during pregnancy, urban residency at delivery, being 
primiparous, maternal education, annual family income during pregnancy (228) and birth 
weight. Pregnancy-related variables i.e. high risk pregnancies, gestational diabetes, 
pregnancy-induced hypertension, gynecologist or obstetrician visit during pregnancy, 
number of prenatal visits, maternal weight gain during pregnancy, maternal body mass 
index (BMI) at beginning of pregnancy and another preterm or LBW infant prior to the 
current delivery (237). Maternal co-morbidities i.e. diabetes mellitus, and chronic 
hypertension. Lifestyles i.e. maternal & paternal cigarette smoking during pregnancy and 
maternal alcohol consumption during pregnancy. All potential confounding variables 
were included in the models however, only some of them remained in the final reduced 
model. 
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Data Analysis 
Descriptive statistics were used to report the characteristics of the pregnancies included in 
the first and second stage of sampling as a function of asthma severity levels during 
pregnancy. We also calculated the prevalence of perinatal outcomes by maternal asthma 
severity level among all pregnancies included in the cohort.  
 
Crude and adjusted odds ratios (OR) for SGA, LBW and preterm birth comparing 
pregnancies of mild asthmatic women with those with moderate and severe asthma were 
first estimated for the first stage of sampling using separate Generalized Estimation 
Equation (GEE) models. The GEE models take into account the fact that a woman could 
contribute more than one pregnancy to the analysis by estimating the correlation between 
consecutive pregnancies.  
 
We also obtained adjusted OR estimates based on pregnancies selected at the second 
stage of sampling and GEE models that adjusted for confounding variables collected at 
the first and second stages of sampling. The best reduced models were found using a 
backward selection strategy, keeping in the model only confounders or covariates that 
were significantly associated with the outcome (p<0.05).  
 
The final adjusted OR estimates were then obtained by correcting the second stage 
adjusted OR with the second stage sampling fractions and the OR found at the first stage 
of sampling using the methodology proposed by Collet et al (184). This methodology 
provides unbiased estimates of the association under study. 
 
Results 
At the first stage of sampling, the cohort included 13,007 singleton pregnancies from 
9925 asthmatic women. From this cohort, a total of 3,347 pregnancies were selected for 
the second stage of sampling. The RAMQ provided us with the addresses of 3,152 
women which corresponded to 3,168 pregnancies. We received 1,274 completed 
questionnaires which represents a response rate of 40.2%.  
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Table 1 shows the distribution of the variables retrieved from the administrative 
databases by asthma severity level for women included in the first stage of sampling. In 
our cohort, 82.6%, 12.4% and 5.0% of pregnancies were from women with mild, 
moderate and severe asthma, respectively. A high risk pregnancy was more frequent 
among pregnancies of severe asthmatic than moderate and mild ones (40.5% vs. 36.2% 
and 35.9%, respectively).  
 
In Table 2, we present the distribution of variables retrieved from the questionnaire by 
asthma severity level among pregnancies selected at the second stage of sampling. The 
prevalence of maternal cigarette smoking during pregnancy was higher among women 
with severe asthma (67.1%) compared to women with moderate and mild asthma (57.7% 
and 63.9%, respectively). The high prevalence of cigarette smoking among these women 
could be explained by their low socio-economic status and also the fact that we 
oversampled the women with moderate-to-severe asthma who had a SGA baby, a LBW 
baby, or a preterm delivery. Also, on average women with severe asthma had a lower 
annual family income and were less likely to have post high school education. Maternal 
weight gain during pregnancy was more important among women with severe asthma 
(58.5% >16 kg) than in women with moderate or mild asthma (40.7% and 39.1%, 
respectively). Also, these women had a higher pre-pregnancy BMI as compared to 
women in the two other groups.  
 
We compared the characteristics of 1,274 pregnancies of women who answered to the 
questionnaires with the characteristics of the 1,894 pregnancies of women who did not 
answer. Overall, there was not notable difference between the responders and non 
responders (c.f. electronic attachment for details).  
 
We identified 1886 SGA babies (14.5%) from the first stage of sampling (Table 3). The 
prevalence of SGA babies was higher among pregnancies of severe than moderate or 
mild asthmatic women: 19.5%, 17.4% and 13.8%, respectively. However, the same trend 
was not observed for the two other outcomes. The prevalence of adverse perinatal 
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outcomes is much higher at the second stage of sampling since SGA, LBW and 
premature infants were oversampled.  
 
In Table 4, we present the first stage and final estimates of the ORs for the three perinatal 
outcomes. Final estimates showed that the risk of SGA was significantly higher among 
severe (OR:1.48, 95%CI: 1.15-1.91) and moderate asthmatic women (OR: 1.30, 
95%CI:1.10-1.55) than mild asthmatic women. On the other hand, the final estimates 
showed a 25% non significant increased risk of LBW and no significant increased risk of 
preterm birth among severe as compared to mild asthmatic mothers (OR=1.25; 95% CI: 
0.87-1.80). 
 
Discussion 
Our results show that severe and moderate asthma during pregnancy were significantly 
associated with an increased risk of SGA babies as compared to mild asthma. We also 
found a non significant increase in the risk of LBW babies and no increased risk of 
preterm delivery among severe and moderate asthmatic women.  
 
Some physiologic hypotheses can explain our results. The effects of chronic oxygen 
deprivation on the fetus are described by several clinicians and were also confirmed by 
observation of pregnancies at high altitude and in females with congenital heart diseases 
(50). Maternal asthma can induce hypoxia combined with respiratory alkalosis that 
decreases the placental blood flow (54, 238). Lack of oxygen to the fetus and the long-
term effect of hypoxemia could affect fetal growth (50, 52, 120). Our results support the 
findings of Schatz et al who reported a significant association between lower maternal 
mean FEV1 during pregnancy and the risk of a birth weight in the lower quartile of the 
infant population (p=0.002) and ponderal indices < 2.2 (suggestive of asymmetric IUGR) 
(p<0.05), but no increased risk of preterm birth and LBW infants (56). These results and 
our results suggest that severe maternal asthma is more likely to affect the growth of the 
baby than the timing of the delivery which is more precisely captured by the SGA 
measure than the weight at birth alone. 
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The literature reports conflicting results on the association between the severity of 
maternal asthma and perinatal outcomes. The results found in this study are consistent 
with those of Fitzsimmons et al and Mabie et al (61, 98) who reported a significant 
increased risk of SGA babies associated with severe asthma (p=0.02 and p<0.05, 
respectively). However, their definition of severe asthma was quite restrictive including 
only patients who were hospitalized for status asthmaticus, had mechanical ventilation or 
required chronic maintenance therapy with oral prednisone. Another factor that 
differentiates these studies from our study is the lack of any adjustment for confounding 
variables (61, 98). On the other hand, our results differ from those of Perlow et al, 
Greenberg et al and Dombrowski et al. who found no significant increased risk of SGA 
associated with severe asthma (91, 100, 106).  
 
Bracken et al used a definition of asthma severity that is closer to ours (based on asthma 
symptoms and medication use), but reported inconsistent results. Indeed, they reported 
adjusted significant increased risks of IUGR (< 10th percentile of birth weight for 
gestational age) that ranged from 1.74 to 1.98 among women with moderate-to-mild 
persistent asthma and no significant increased risk among women with severe persistent 
asthma (OR=1.39; 95% CI: 0.69-2.77) as compared to asthmatic women with no 
symptoms or medication use (99).  
 
Several studies have evaluated the association between markers of severe asthma and the 
risk of preterm delivery (20, 22, 56, 61, 91, 98, 99, 106). Only Perlow et al. found a 
significant increased risk of preterm delivery associated with severe asthma that was 
defined as the mother being corticosteroid dependent during pregnancy (91). This 
definition is quite restrictive, identifies the most severe asthmatic and corresponds to only 
a small proportion of women with severe asthma. The other studies have found no 
significant association between asthma severity and preterm birth but some of them had a 
small sample size (20, 99) or suffered from the lack of adjustment from confounding 
variables, including cigarette smoking during pregnancy (20). 
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A significant increase in LBW (OR:5.1, 95%CI: 1.6-17.0) was found by Perlow et al 
among infants of corticosteroid dependent mothers as compared to non-corticosteroids 
dependent mothers (91). Also, Jana et al found a significantly higher incidence of LBW 
among infants of 15 mothers requiring as compared to 167 mothers not requiring 
emergency admission during pregnancy (53.3% vs. 20.5%; p<0.01) (20). Moreover, 
Greenberg et al and Fitzsimmons et al have found a significant decrease in mean birth 
weight (ranging from 300 to 500 g) among women who were hospitalized for asthma 
during pregnancy (61, 106). However, the lack of adjustment for any confounding 
variables including maternal smoking and also the use of a much stricter definition of 
severe asthma could explain the discrepancies between these studies and our study. In 
concordance with our results, Stenius-Aarniala et al found no difference between the birth 
weight of infants of mothers with moderate-to-severe and very mild-to-mild asthma 
(3418 vs. 3479 g) (22).   
 
Our study has some limitations. Firstly, recall bias, however, a recent study has 
demonstrated that “maternal reports of perinatal events in which they directly participated 
can be accurately and reliably reported 10 to 15 years after birth (231). Moreover, this 
bias, if present, could not have affected the outcomes and the main exposure since they 
were measured from databases data that are routinely and prospectively collected.  
Secondly, the response rate of the mailed questionnaire was about 40%, a participation 
bias could be present if women who answered the questionnaire are different from 
women who did not answer the questionnaire on characteristics that are associated with 
the outcomes under study. However, it is reassuring to observe that it was not the case. 
Finally, our cohort is less representative of women in the higher socio-economic level. 
However, the non representativeness of our cohort in this study would be a threat to 
external validity only if socio-economic status is an effect modifier for the associations 
under study. 
 
Our study has also several strengths. Firstly, we had a very large sample size, which 
provided adequate power to detect small but clinically important differences. Secondly, 
the measurement of the severity of asthma during pregnancy was based on a validated 
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database index, which assesses asthma severity among patients already under treatment 
(26). Thirdly, the gestational age at birth and birth weight were validated by comparing 
the database values to medical chart values and were found to be highly valid (195). 
Fourthly, we used an SGA definition which is based on new Canadian standards and 
considers the Canadian growth pattern in its definition (226, 239). Finally, the two-stage 
sampling design allowed us to obtain information on some variables that are not recorded 
in the administrative databases.  
 
In conclusion, our study showed an association between asthma severity during 
pregnancy and the risk of SGA babies, but no significant association with LBW and 
preterm birth. These results confirm the need to closely follow pregnant women with 
markers of severe asthma, being those hospitalized for an exacerbation or needing high 
doses of inhaled corticosteroids to treat their asthma. Our results need to be confirmed in 
other settings and populations to reinforce the message to be transmitted to pregnant 
asthmatic women and healthcare professionals. 
 
ACKNOWLEDGEMENTS 
We thank Mrs Marie-Claude Giguère from RAMQ, Mrs Chantal Girard from ISQ and 
Mrs Louise Légaré and collaborators from the Ministère de la Santé et des Services 
sociaux du Québec for assistance with the data. We are grateful to the CAI for 
authorizing the study. We thank Mrs Karine Chouinard for helping with the logistics of 
the study. Finally, many thanks to all the women who kindly participated in this study by 
filling out the questionnaire. This study was funded by the Canadian Institutes for Health 
Research (CIHR) and the authors declare no conflict of interest for the submitted 
manuscript. 
 155 
Table 1. Characteristics of all study women included in the cohort by asthma severity 
level during pregnancy (database driven variables, n=13 007) 
 Pregnancies of 
Severe asthmatic 
women 
N=652 (5.0%) 
Pregnancies of 
moderate asthmatic 
women 
N=1618 (12.4) 
Pregnancies of 
mild asthmatic 
women 
N=10737 (82.6) 
 Numbers (%) 
Maternal characteristics  
Age at beginning of pregnancy: 
              < 18 years old 39 (6.0) 89 (5.5) 747 (7.0) 
              18 - 34 years old 552 (84.7) 1401 (86.6) 9380 (87.4) 
              > 34 years old 61 (9.4) 128 (7.9) 610 (5.7) 
*Recipient of social assistance 541 (83.0) 1312 (81.1) 8493 (79.1) 
Urban residency at delivery  532 (81.6) 1287 (79.5) 8709 (81.1) 
Primiparous 261 (40.0) 551 (34.1) 3418 (31.8) 
Pregnancy related variables  
High risk pregnancy 264 (40.5) 585 (36.2) 3851 (35.9) 
Gestational diabetes 64 (9.8) 132 (8.2) 804 (7.5) 
Pregnancy induced hypertension 55 (8.4) 115 (7.1) 676 (6.3) 
Gynecologist or obstetrician visit 
during pregnancy 554 (85.0) 1349 (83.4) 8810 (82.1) 
Number of prenatal visits  
               ≤ 5 95 (14.6) 253 (15.6) 1700 (15.8) 
               6-14  481 (73.8) 1173 (72.5) 7823 (72.9) 
               > 14 76 (11.7) 192 (11.9) 1214 (11.3) 
Asthma related variables measured 
during pregnancy  
**ICS use (µg per day)   
                    0 57 (8.7) 404 (25.0) 7268 (67.7) 
                 0-500 364 (55.8) 979 (60.5) 3469 (32.3) 
                500-1000 106 (16.3) 228 (14.1) 0 (0.0) 
                > 1000 125 (19.2) 7 (0.4) 0 (0.0) 
***SABA use (number of doses 
per week)  
                   0 0 (0.0) 12 (0.7) 4961 (46.2) 
               > 0-3 0 (0.0) 22 (1.4) 4177 (38.9) 
                > 3 652 (100.0) 1584 (97.9) 1599 (14.9) 
Leukoteriene-receptor          
antagonists use 14 (2.2) 14 (0.9) 6 (0.1) 
Oral corticosteroids use 384 (58.9) 260 (16.1) 336 (3.1) 
 ≥ 1 respiratory physician visit 170 (26.1) 179 (11.1) 401 (3.7) 
 ≥ 1 ED visit for asthma 457 (70.1) 444 (27.4) 710 (6.6) 
 ≥ 1 hospitalization for asthma 90 (13.8) 49 (3.0) 57 (0.5) 
Maternal co-morbidities  
Chronic diabetes 14 (2.2) 56 (3.5) 244 (2.3) 
Chronic hypertension 23 (3.5) 43 (2.7) 238 (2.2) 
*Social assistance status in the year before pregnancy    
**ICS daily dose in beclomethasone-CFC equivalent over a 12-month period 
***SABA: short-acting inhaled beta2-agonist 
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Table 2. Characteristics of women selected at the second stage of sampling by asthma 
severity level during pregnancy (questionnaire driven variables, n=1274) 
 Pregnancies of 
Severe asthmatic 
women 
N=82 (6.4%) 
Pregnancies of 
moderate 
asthmatic women 
N=189 (14.8%) 
Pregnancies of 
mild asthmatic 
women 
N=1003 (78.7%) 
 Numbers (%) 
Maternal characteristics  
Maternal education (highest    
level attained)  
               Elementary school 12 (14.6) 7 (3.7) 86 (8.6) 
               High school   59 (72.0) 143 (75.7) 746 (74.4) 
               College & University    10 (12.2) 35 (18.5) 149 (14.9) 
               Unknown  1 (1.2) 4 (2.1) 22 (2.2) 
Annual family income during 
pregnancy  
                   < $ 18 000 56 (68.3) 115 (60.9) 591 (58.9) 
                  $18 001 - $46 000 22 (26.8) 52 (27.5) 333 (33.2) 
                   > $46 001  2 (2.4) 35 (9.5) 56 (5.6) 
                   Unknown    2 (2.4) 4 (2.1) 23 (2.3) 
Maternal weight at birth 
 
                   < 2.5 kg 16 (19.5) 27 (14.3) 205 (20.4) 
                   2.5 – 5.0 kg         58 (70.7) 141 (74.6) 680 (67.8) 
                    > 5.0 kg 1 (1.2) 4 (2.1) 11 (1.1) 
Unknown    7 (8.5) 17 (9.0) 107 (10.7) 
Pregnancy related variables  
Maternal weight gain during 
pregnancy  
                  < 8 kg 9 (11.0) 24 (12.7) 146 (14.6) 
                  8 - 16 kg        19 (23.2) 77 (40.7) 435 (43.4) 
                  > 16 kg 48 (58.5) 77 (40.7) 392 (39.1) 
                   Unknown  6 (7.3) 11 (5.8) 30 (3.0) 
Maternal BMI pre-pregnancy 
 
                   < 18.5 12 (14.6) 17 (9.0) 149 (14.9) 
                   18.5 – 24.9 41 (50.0) 99 (52.4) 527 (52.5) 
                   24.9 – 29.9 14 (17.1) 40 (21.2) 177 (17.7) 
                  > 29.9  14 (17.1) 26 (13.8) 115 (11.5) 
                  Unknown  1 (1.2) 7 (3.7) 35 (3.5) 
Preterm birth prior to the 
current delivery 11 (13.4) 22 (11.6) 177 (17.7) 
                   Unknown   0 (0.0) 2 (1.1) 7 (0.7) 
LBW infant prior to the current 
delivery 6 (7.3) 23 (12.2) 163 (16.3) 
                   Unknown    0 (0.0) 0 (0.0) 9 (0.9) 
Life style habits 
 
Maternal cigarette smoking 
during pregnancy 
 
 
                Yes 55 (67.1) 109 (57.7) 641 (63.9) 
                No 27 (32.9) 79 (41.8) 356 (35.5) 
                Unknown  0 (0.0) 1 (0.5) 6 (0.6) 
Paternal cigarette smoking 
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during pregnancy 
 
                   Yes 40 (48.8) 95 (50.3) 513 (51.2) 
                    No 39 (47.6) 93 (49.2) 469 (46.7) 
                   Unknown 3 (3.7) 1 (0.5) 21 (2.1) 
Maternal alcohol consumption 
during pregnancy 
 
 
Yes 17 (20.7) 34 (18.0) 170 (17.0) 
                   No 64 (78.1) 149 (78.8) 795 (79.2) 
                   Unknown  1 (1.2) 6 (3.2) 38 (3.8) 
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Table 3. Prevalence of adverse perinatal outcomes by asthma severity level: first and 
second stages of sampling 
 
 
 
Pregnancies of 
Severe asthmatic 
women 
Pregnancies of 
moderate 
asthmatic women 
Pregnancies of 
mild asthmatic 
women 
 Number (%) 
1st stage 
(N=13007)  
 
Number of patients 652  1618  10737  
SGA               127 (19.5) 281 (17.4) 1478 (13.8) 
LBW             65 (10.0) 160 (9.9) 972 (9.1) 
Preterm         65 (10.0) 146 (9.0) 1129 (10.5) 
*2nd stage 
(N=1274)  
Number of patients  82  189  1003  
SGA               26 (31.7) 48 (25.4) 416 (41.5) 
LBW              13 (15.9) 18 (9.5) 231 (23.0) 
Preterm         12 (14.6) 15 (7.9) 268 (26.7) 
*The prevalence of outcomes obtained at the second stage of sampling is not representative of the real 
prevalence because of the sampling method which oversamples pregnancies with an adverse perinatal 
outcome that we used to select women at this stage of sampling 
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Table 4. Crude and adjusted odds ratios for perinatal outcomes comparing severe and 
moderate asthmatic to mild asthmatic women 
 
OR (95% CI) Severe vs. Mild Moderate vs. Mild 
SGA   
1st stage 
Crude  1.52 (1.24-1.85) 1.32 (1.14-1.51) 
Adjusted  1.44 (1.18-1.76)† 1.30 (1.13-1.49)† 
Final 
estimates*** Adjusted 1.48 (1.15-1.91)†† 1.30 (1.10-1.55)†† 
LBW  
1st stage Crude  1.11 (0.85-1.45) 1.10 (0.92-1.31) Adjusted  1.04 (0.80-1.37)‡ 1.08 (0.90-1.29)‡ 
Final 
estimates*** Adjusted  1.25 (0.87-1.80)‡‡ 1.04 (0.81-1.34)‡‡ 
Preterm birth  
1st stage Crude  0.94 (0.72-1.23) 0.84 (0.70-1.01) Adjusted  0.90 (0.69-1.18)* 0.82 (0.68-0.99)* 
Final 
estimates*** Adjusted  0.93 (0.67-1.29) ** 0.83 (0.65-1.05) ** 
*** Final estimates obtained by adjusting the second stage estimates with the second stage 
sampling fractions  
†Adjusted for recipient of social assistance in the year before pregnancy, primiparous and high 
risk pregnancy  
††Adjusted for primiparous, chronic diabetes, maternal cigarette smoking during pregnancy, 
maternal weight at birth, maternal weight gain during pregnancy, preterm birth prior to the 
current delivery, and LBW infant prior to the current delivery 
‡ Adjusted for recipient of social assistance in the year before pregnancy, urban residency at 
delivery, primiparous, high risk pregnancy, gynaecologist or obstetrician visit during pregnancy, 
number of prenatal visits and chronic hypertension, 
‡‡ Adjusted for recipient of social assistance in the year before pregnancy, primiparous, high risk 
pregnancy, number of prenatal visits, chronic hypertension, maternal weight at birth, maternal 
weight gain during pregnancy, and LBW infant prior to the current delivery 
* Adjusted for recipient of social assistance in the year before pregnancy, high risk pregnancy, 
gynaecologist or obstetrician visit during pregnancy, number of prenatal visits, and chronic 
diabetes and hypertension 
** Adjusted for high risk pregnancy, gynaecologist or obstetrician visit during pregnancy, 
number of prenatal visits, maternal weight gain during pregnancy and preterm birth prior to the 
current delivery 
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Electronic attachment  
 
Comparison of the characteristics of the women who responded and those who did 
not respond to the mailed questionnaires  
 
 
Pregnancies of 
responding women 
Pregnancies of non-
responding women 
 Numbers (%) 
Numbers 1274 (40.2) 1894 (59.8) 
Age  
 
< 18 years old 117 (9.2) 167 (8.8) 
18 - 34 years old 1096 (86.0) 1627 (85.9) 
> 34 years old 61 (4.8) 100 (5.3) 
Recipient of social assistance 983 (77.2) 1592 (84.1) 
Urban residency at delivery  984 (77.2) 1586 (83.7) 
Primiparous 750 (59.2) 1265 (66.9) 
High risk pregnancy 493 (38.7) 755 (39.9) 
Gestational diabetes 107 (8.4) 128 (6.8) 
Chronic diabetes 27 (2.1) 54 (2.9) 
Pregnancy induced hypertension 98 (7.7) 105 (5.5) 
Chronic hypertension 31 (2.4) 46 (2.4) 
Gynecologist or obstetrician visit 
during pregnancy 1037 (81.4) 1614 (85.2) 
Number of prenatal visits 
 
               ≤ 5 182 (14.3) 390 (20.6) 
               6-14  950 (74.6) 1331 (70.3) 
               > 14 142 (11.2) 173 (9.1) 
SGA delivery 490 (38.5) 714 (37.7) 
LBW delivery 262 (20.6) 432 (22.8) 
Premature delivery 295 (23.2) 516 (27.2) 
Control of asthma 
 
                         Controlled   740 (58.1) 1110 (58.6) 
                         Uncontrolled  534 (41.9) 784 (41.4) 
Severity of asthma 
 
                         Mild 1003 (78.7) 1509 (79.7) 
                         Moderate  189 (14.8) 280 (14.8) 
                         Severe 82 (6.4) 105 (5.5) 
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Electronic attachment  
 
Definition of the Database Indexes of Asthma Severity Developed According to the 
Canadian Asthma Consensus Guidelines 
 
Asthma severity 
and control 
*ICS daily dose 
(µg) 
**Other 
controller 
therapy 
+SABA doses 
per week 
++ Marker of 
moderate to severe 
exacerbations 
Mild      
         
0-500 No 0-3 No 
 
0-250 Yes 0-3 No 
 
0-250 Yes 0-3 Yes 
 
0-500 No 0-3 Yes 
 
0-250 Yes 4-10 No 
 
0-500 No 4-10 No 
Moderate     
          
251-500 Yes 0-10 No 
 
501-1000 Yes/No 0-10 No 
 
>1000 Yes/No 0-3 No 
         
0-250 Yes 4-10 Yes 
 
0-500 No 4-10 Yes 
 
0-250 Yes >10 No 
 
0-500 No >10 No 
 
251-500 Yes >10 No 
 
251-500 Yes 0-10 Yes 
 
501-1000 Yes/No >10 No 
 
501-1000 Yes/No 0-10 Yes 
Severe     
 
>1000 Yes/No 4-10 No 
 
0-1000 Yes/No >10 Yes 
 
>1000 Yes/No 0-10 Yes 
 
>1000 Yes/No >10 Yes/No 
 
*ICS daily dose in beclomethasone-CFC equivalent over a 12-month period 
** Other controller therapy: at least 6 prescriptions of long-acting beta2-agonist (LABA), 
theophylline or leukotriene-receptor antagonists dispensed over a 12-month period 
+SABA: Average number of inhaled short-acting beta2-agonist doses per week calculated 
over a 12-month period 
++ An emergency department visit for asthma, a hospitalization for asthma or a filled 
prescription of an oral corticosteroid over a 12-month period. 
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Electronic attachment  
 
Final odds ratio of perinatal outcomes comparing Severe (n=82) and moderate 
(n=189) asthmatic to mild asthmatic women (n=1003) adjusted for variables derived 
from the databases and the mailed questionnaire 
 
 
SGA LBW Preterm 
Final adjusted OR (95% CI) 
Severe asthmatic versus mild 
asthmatic women 1.48 (1.15-1.91) 1.25 (0.87-1.79) 0.93 (0.67-1.29) 
Moderate asthmatic versus mild  
asthmatic women 1.30 (1.10-1.55) 1.04 (0.81-1.34) 0.83 (0.65-1.05) 
Recipient of social  assistance --------------- 1.71 (1.14-2.55) --------------- 
Primiparous 0.66 (0.51-0.86) 0.65 (0.47-0.90) --------------- 
High risk pregnancy --------------- 1.94 (1.44-2.63) 1.86 (1.38-2.51) 
Gestational Diabetes --------------- --------------- --------------- 
Pregnancy induced hypertension --------------- --------------- --------------- 
Gynecologist or obstetrician visit 
during pregnancy --------------- --------------- 1.56 (1.02-2.39) 
Number of prenatal visits (>14) --------------- 0.19 (0.10-0.38) 0.30 (0.17-0.54) 
Number of prenatal visits (5-14) --------------- 0.57 (0.39-0.85) 0.53 (0.37-0.77) 
Chronic diabetes 2.27 (1.10-5.11)   
Chronic hypertension --------------- 2.72 (1.23-6.03) --------------- 
Maternal Weight at birth (<2.5 kg) 1.60 (1.19-2.15) 2.13 (1.52-2.99) --------------- 
Maternal Weight at birth (=>5.0 kg) 1.72 (0.58-5.11) 0.83 (0.21-3.24) --------------- 
Maternal Weight gain during 
pregnancy (>16.0 kg) 0.67 (0.52-0.87) 0.60 (0.43-0.84) 0.99 (0.72-1.35) 
Maternal Weight gain during 
pregnancy (<8.0 kg) 1.02 (0.71-1.46) 1.77 (1.18-2.63) 1.89 (1.28-2.81) 
Preterm birth prior to the current 
delivery 0.35 (0.22-0.54) --------------- 3.36 (2.42-4.65) 
LBW infant prior to the current 
delivery 2.62 (1.69-4.08) 3.24 (2.20-4.77) --------------- 
Maternal cigarette smoking 2.36 (1.82-3.06) --------------- --------------- 
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 Abstract 
 
Background/Objectives 
Adverse perinatal outcomes are more prevalent in pregnant women with asthma as 
compared to women without asthma. We investigated whether women with adequately 
controlled asthma during pregnancy are at increased risk of adverse perinatal outcomes 
than non-asthmatic women.  
 
Methods 
A population-based cohort of 36,115 pregnancies from controlled asthmatic and non-
asthmatic women was reconstructed through the linking of three of Quebec’s (Canada) 
administrative databases between 1990 and 2002. A two-stage sampling cohort design 
was used to collect additional information on the selected women’s life-style habits by 
way of a mailed questionnaire. The degree of asthma control during pregnancy was 
assessed with a validated database index. A generalized estimation equation model was 
used to obtain the adjusted odds ratios of small-for-gestational-age (SGA) infants, low-
birth-weight (LBW) infants and preterm births comparing women with adequately 
controlled asthma to non-asthmatic women. 
 
Results 
The cohort included 8,334 pregnancies of women with adequately controlled asthma and 
27,781 pregnancies of non-asthmatic women. At the second stage of sampling, we sent 
4,066 questionnaires to selected women, with a 38.0% (n=1546) response rate. Final 
estimates showed that the risk of SGA (OR:1.28, 95%CI: 1.15-1.43), LBW (OR: 1.42,  
95%CI:1.22-1.66), and preterm deliveries (OR: 1.63,  95%CI:1.46-1.83) was 
significantly higher among mother with adequately controlled asthma than non-asthmatic 
women.  
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Conclusions 
Mothers with adequately controlled asthma during pregnancy are at higher risk of adverse 
perinatal outcomes than non-asthmatic women.  
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Introduction 
Asthma is known as one of the most frequent chronic diseases encountered during pregnancy 
with prevalence estimated between 4 and 8% (3-5, 7, 47, 71). The risk of adverse perinatal 
outcomes, such as preterm birth, low-birth-weight (LBW) infant and small-for-gestational-age 
(SGA) infant has been reported to be higher among asthmatic than non-asthmatic women (14, 
16, 17, 19, 93, 102, 103). It has also been reported that the risk of adverse perinatal outcomes is 
higher among  asthmatic women with uncontrolled asthma than asthmatic women with 
adequately controlled asthma (20, 93, 106). It has been hypothesized that adverse fetal 
outcomes could be related to decreased fetal blood oxygen, due to poorly controlled asthma 
(50, 52, 54, 56, 104, 120).  
 
Knowing that, it would be clinically relevant to evaluate whether the risk of perinatal outcomes 
of women with adequately controlled asthma is still higher or is similar to the risk observed 
among non-asthmatic women. To our knowledge, three studies evaluated whether or not women 
with adequately controlled asthma are at higher risk of perinatal outcomes than non-asthmatic 
women. In a prospective controlled study comparing women with actively managed asthma 
during pregnancy and non-asthmatic women, Schatz et al observed relative risks as large as 1.65 
for perinatal outcomes, but concluded that there was no difference between the groups since the 
relative risks were not statistically significant (21). In two other studies, Stenius-Aarniala et al 
and Jana et al. came to the same conclusion (20, 22). These three studies should however be 
interpreted with caution since their statistical power was limited. 
 
To further investigate whether or not women with adequately controlled asthma during 
pregnancy are at increased risk of adverse perinatal outcomes including SGA infant, 
LBW infant, and preterm birth, we conducted a population-based two-stage sampling 
cohort study.  
 
 
 
 169 
Materials and Methods 
Source of data  
The data for our study came from three administrative databases of the province of 
Quebec; the Régie de l’Assurance Maladie du Quebec (RAMQ), MED-ECHO, and the 
Fichier des événements démographiques du Québec (birth and death registries) managed 
by the Institut de la statistique du Québec (ISQ)). These data were supplemented by a 
mailed questionnaire filled by selected mothers.  
 
The RAMQ databases provide information on medical services dispensed to all residents 
of Quebec and on prescribed medications filled in community pharmacies by residents 
covered by the RAMQ’s Public Prescription Drug Insurance Plan. Approximately 43% 
of the population of Quebec is covered by the RAMQ Public Prescription Drug 
Insurance Plan, most notably the elderly and social assistance beneficiaries since 1980. 
Furthermore, since the enactment of mandatory drug coverage in 1997, the RAMQ’s 
Public Prescription Drug Insurance Plan now provides coverage for an additional 1.7 
million adherents, mainly workers and their families who have no access to a group drug 
insurance plan at work (186). The RAMQ Prescribed Medication database provides 
information on dispensed medications – i.e. date of filling, name, dose, quantity, dosage 
form and duration of the prescription – while the RAMQ Medical Services database 
provides information on medical services dispensed in a clinic, an emergency department 
(ED) or a hospital and include information pertaining to date, diagnosis coded with 9th 
international classification of diseases (ICD-9), where the service was dispensed, and so 
on. Data recorded in the RAMQ Prescribed Medication database and asthma diagnoses 
recorded in the RAMQ Medical Services database have been formally evaluated and 
found to be valid (187, 188). The MED-ECHO database is a provincial database which 
records data on acute care hospitalizations and covers all residents of Quebec (187). The 
Fichier des événements démographiques provides information on all births and stillbirths 
in the province of Quebec. Some additional information regarding siblings and maternal 
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life styles during pregnancy which are not included in the administrative databases were 
retrieved from a mailed questionnaire completed by selected women.  
 
Study Design and Population 
We performed a two-stage sampling cohort design (balanced selection) (184, 185, 190, 
225). The first stage of sampling corresponds to the cohort formed of singleton 
pregnancies of adequately controlled asthmatic and non-asthmatic women ending in a 
delivery (live birth or stillbirth) between January 1st, 1990 and December 31st, 2002 in the 
province of Quebec (Canada). Pregnant women and newborns were identified in the 
RAMQ database using diagnostic and act codes related to prenatal care, pregnancy 
complications, and deliveries (189). Moreover, to be included in our cohort, a woman 
must have been between 13-50 years of age at the beginning of her pregnancy as well as 
being covered by the RAMQ Public Prescription Drug Insurance Plan for at least one 
year prior to and throughout the duration of pregnancy. Women were considered as 
having asthma if they had a diagnosis of asthma (ICD-9 code 493, except 493.2), and one 
or more prescriptions for an asthma medication dispensed in the two years prior or during 
pregnancy. Then, the women with adequately controlled asthma during their pregnancy 
were identified using an index that we had previously developed and validated, please 
refer to the section on compared subgroups for more details on the measure of asthma 
control (196). We allowed a maximum of four pregnancies per woman to enter in the 
cohort and only the more recent ones were retained. For each pregnancy, the data from 
RAMQ and MED-ECHO databases were obtained one year before and during pregnancy. 
This mother-child cohort was then linked with the Fichier des événements 
démographiques database to obtain information on socio-demographic variables for the 
mothers and the newborns.  
 
At the second stage of sampling, we selected a sample of women to whom a 
questionnaire was sent by mail, using a balance sampling strategy (184, 190). This 
strategy oversamples women who had a SGA infant, a LBW infant, or a preterm delivery 
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in order to increase the statistical power (184). A maximum of two pregnancies per 
woman were selected at this stage of sampling not to overload a mother with more than 
two questionnaires to fill. Selected women had to be at least 18 years old at the beginning 
of the pregnancy to be eligible for the second stage of sampling due to ethical 
considerations. For all pregnancies selected at this stage, the RAMQ provided us with the 
current postal address of the mother as well as her spoken language.  
 
The questionnaire was used to obtain information on life style variables during pregnancy 
(including maternal cigarette smoking, maternal alcohol consumption, and paternal 
cigarette smoking), maternal characteristics, and pregnancy related variables that are not 
recorded in the administrative databases. The questionnaire underwent prior testing by 
about 40 women for its clarity and also its facility to be understood and answered. By 
pretesting, we also assessed the capacity of women to remember the events which 
happened up to 25 years ago. First, we sent 4,066 questionnaires to selected women. A 
second questionnaire was sent a month and half later as a reminder. A 10$ compensation 
was given to women who completed the questionnaire. The questionnaires’ data were 
recorded in a computerized database, using a double entry method to improve data 
quality.  
 
The linkage between data obtained from the RAMQ, MED-ECHO and ISQ databases, 
and the filled questionnaires as well as the request of the name and the mailing address of 
selected women at the second stage of sampling was approved by the Commission 
d’accès à l’information du Quebec (CAI). This research project was also approved by the 
ethics committee of the Hôpital du Sacré-Cœur de Montréal (Montreal, Quebec, 
Canada). 
 
Compared groups 
In this study, women with adequately controlled asthma during pregnancy were 
compared to non-asthmatic women. Asthma control during pregnancy was measured with 
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an index that we had previously developed and validated (196). This control index is 
based upon the definition provided in the Canadian Asthma Consensus Guidelines (26). 
Two levels of asthma control during pregnancy were defined based on the average 
number of doses of short-acting beta2 agonists (SABA) per week and the presence of 
markers of moderate-to-severe asthma exacerbations – a filled prescription of oral 
corticosteroids (less than 14 days), an ED visit for asthma, or a hospitalization for asthma 
(197). Patients were considered adequately controlled if they had no marker of moderate-
to-severe asthma exacerbation and no more than three doses of SABA per week for mild 
asthma and ten doses of SABA per week for moderate and severe asthma (196). Details 
of the index of control are provided in the electronic attachment.  
 
Outcomes 
The outcomes of interest included SGA infants, preterm births and LBW infants. SGA 
was defined as a birth weight below the 10th percentile for gestational age and gender, 
using new Canadian standards (226, 240). Preterm birth was defined as a birth before 37 
weeks of gestation while LBW was defined as birth weight lower than 2,500g. Validated 
algorithms based on data recorded in the RAMQ, MED-ECHO or ISQ databases were 
used to measure these outcomes (195).  
 
Confounding Variables  
Four categories of variables were considered as potential confounding variables. 
Maternal characteristics derived from administrative databases include age at the 
beginning of the pregnancy (< 18, 18-34, > 34 years) (228), receiving social assistance 
benefits in the year before or during pregnancy (yes/no), urban residency at delivery 
(yes/no), and being primiparous (yes/no). Maternal characteristics derived from the 
questionnaire include maternal education (highest level reached: elementary school, 
high school, college & University), annual family income during pregnancy (<$18,000, 
$18,000-$46,000, >$46,000) (228) and birth weight (<2.5, 2.5-5, >5 kg). Pregnancy-
related variables derived from administrative databases include high risk pregnancies 
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(ICD-9 codes V23 except V238,  6932, 6938, 6939, 6941, 9157 and 9167 recorded in the 
RAMQ or MED-ECHO databases) (yes/no), gestational diabetes (yes/no), pregnancy-
induced hypertension (yes/no), a gynecologist or obstetrician visit during pregnancy 
(yes/no), and number of prenatal visits (≤5, 6-14, >14). Pregnancy-related variables 
derived from the questionnaire include maternal weight gain during pregnancy (<8, 8-
16, >16 kg), maternal body mass index (BMI) (<18.5, 18.5-24.9, 25-29.9, >29.9) at 
beginning of pregnancy and another preterm or LBW infant prior to the current delivery 
(yes/no) (241). Maternal co-morbidities derived from administrative databases 
include diabetes mellitus (yes/no) and chronic hypertension (yes/no). Life style habits 
derived from the questionnaire include maternal and paternal cigarette smoking during 
pregnancy (yes/no) and maternal alcohol consumption during pregnancy (yes/no).  
  
Data Analysis 
Descriptive statistics were used to report the characteristics of adequately controlled 
asthmatic and non-asthmatic women included in the first stage of sampling (cohort) and 
those selected at the second stage of sampling. Also, the characteristics related to asthma 
were reported for asthmatic women. The unit of analysis was the pregnancy, since a 
woman could contribute more than one pregnancy during the study period. 
 
We then calculated the first-stage prevalence of study outcomes for adequately controlled 
asthmatic and non asthmatic women separately. Crude and adjusted odds ratios (OR) for 
SGA infants, LBW infants and preterm births comparing pregnancies of adequately 
controlled asthmatic with non-asthmatic women were then estimated for the first stage of 
sampling using Generalized Estimation Equation (GEE) models (198). The GEE models 
can estimate the effect of independent variables, including the main exposure and 
confounding variables, on several types of outcomes, namely dichotomous outcomes 
such as the presence or the absence of SGA infant, LBW infant or preterm delivery with a 
logit function as well as take into account the fact that a woman could contribute more 
than one pregnancy to the analysis by estimating the correlation between consecutive 
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pregnancies. The best reduced models were found using a backward selection strategy, 
keeping in the model only covariates that were found to act as a confounder or those that 
were significantly associated with the outcome (p-value < 0.05).  
 
We also obtained adjusted OR estimates based on pregnancies selected at the second 
stage of sampling with GEE models that adjusted for confounding variables collected at 
the first (administrative databases) and second (questionnaire) stages of sampling. 
Missing values for variables retrieved from the questionnaire were included in the 
reference category for modeling purposes since the proportion of missing values was low. 
The final adjusted OR estimates were then obtained by correcting the second stage 
adjusted estimates with the second stage sampling fractions and adjusted estimates found 
at the first stage of sampling using the methodology developed by Collet et al (184).  
 
Results 
At the first stage of sampling, the cohort included 8,334 singleton pregnancies of 
adequately controlled asthmatic women and 27,781 singleton pregnancies of non-
asthmatic women. At the second stage of sampling, we sent a total of 4,066 
questionnaires to selected adequately controlled asthmatic and non-asthmatic women. We 
received 1,546 completed questionnaires (response rate; 38.0%): 740 questionnaires from 
adequately controlled asthmatic women (response rate: 40.0%) and 806 questionnaires 
from non-asthmatic women (response rate; 36.4%).  
 
In Table 1 we present the distribution of the variables retrieved from the administrative 
databases for pregnancies included in the first stage of sampling. When comparing 
adequately controlled asthmatic to non-asthmatic women, we found a higher prevalence 
of recipients of social assistance, high risk pregnancy, maternal chronic diabetes and 
maternal chronic hypertension among pregnancies of adequately controlled asthmatic 
than those of non-asthmatic women.  
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Table 2 shows the distribution of variables retrieved from the questionnaires among 
pregnancies selected at the second stage of sampling. Overall, adequately controlled 
asthmatic women had a lower education and a lower annual family income than non-
asthmatic women. However, the prevalence of several other characteristics was higher 
among pregnancies of controlled asthmatic than non-asthmatic women: maternal birth 
weight <2.5 kg, maternal weight gain >16 kg, maternal BMI pre-pregnancy >29.9, 
preterm birth and LBW infant prior to the current delivery, maternal cigarette smoking, 
and paternal cigarette smoking. This table also shows that the percentage of missing 
values was lower than 3.2% for variables retrieved from the questionnaires, except for the 
maternal weight at birth. 
 
In Table 3, we present the distribution of asthma related variables among pregnancies of 
adequately controlled asthmatic women included in the first stage of sampling. The use of 
inhaled corticosteroids (ICS) and SABA during pregnancy among these women was 
25.1% and 42.9%, respectively and 51.5% of these women had no asthma medications 
during pregnancy.  
 
In Table 4, we observe that the first-stage prevalence of SGA babies was higher among 
pregnancies of adequately controlled asthmatic than those of non-asthmatic women 
(13.7% vs. 10.6%). The same trend was observed for LBW (9.1% vs. 5.7%) and preterm 
births (10.5% vs. 6.7%). Adjusted final ORs estimates showed that the risk of the three 
adverse perinatal outcomes was significantly higher among adequately controlled 
asthmatic than non-asthmatic women. The highest risk was found for preterm births with 
an OR of 1.63 (95% CI: 1.46-1.83).  
 
Discussion 
In this study, women with adequately controlled asthma during pregnancy were found to 
be at significantly higher risk of delivering SGA, LBW and preterm babies than women 
without asthma.  
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We found three studies in the literature that evaluated the impact of appropriate asthma 
care or asthma control during pregnancy on perinatal outcomes (21). Schatz et al assessed 
perinatal outcomes in actively managed pregnant asthmatic women as compared with 
matched non-asthmatic pregnant women. They found a RR of 1.33 for SGA, a RR of 1.64 
for LBW, and a RR of 1.65 for preterm births, point estimates that are similar to those 
found in our study. However, the authors concluded that there was no difference between 
the groups since these RRs were not found to be statistically sig nificant.  It is however, 
worth noting that this study had only 18% power to detect a RR of 1.33 for SGA (21).  
 
In two other studies, Jana et al. and Stenius-Aarniala et al came to the same conclusion as 
Schatz (20, 22). Jana et al. compared the risk of adverse perinatal outcomes in 167 
women with mild well controlled asthma and 364 non-asthmatic controls (20). They 
found that incidence of prematurity and LBW were not affected by asthma (p>0.05). 
Since asthma control was not defined in the article and that the study power was limited, 
it is difficult to interpret the results. Similarly, Stenius-Aarniala et al. found no significant 
differences in the risk of perinatal outcomes between 109 asthmatic women that were 
classified in very mild to mild groups (used asthma medication but had no ER or hospital 
admission for asthma during pregnancy) and 199 non-asthmatic women and concluded 
that asthmatic women with well controlled asthma have the same risk as non-asthmatic 
women (22). Again these results should be interpreted with caution due to lack of 
statistical power. 
 
One of the hypotheses that could explain the results observed in our study is that fetuses 
of  asthmatic women might suffer from abnormal growth and development due to 
decreased fetal blood oxygen, despite the apparent control of the mother’s asthma (120).  
Indeed, women with asthma may have minimal symptoms, but still have potentially 
impaired fetal oxygenation (57). Another hypothesis is that asthma per say, whether 
adequately or poorly controlled, is associated with an unknown pathophysiology of the 
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placenta that can cause impair fetal development. At last, the observed association might 
be due, at least in part, to the limits of our measure of asthma control. The index that we 
used is in part based on filled prescriptions of rescue medications and this might not 
always reflect exactly the use of medications. Moreover, with this index, we cannot 
capture women with uncontrolled asthma who might have deprived themselves from 
rescue medications despite asthma symptoms because of the fear of the potential adverse 
effects of these medications. However, this should be tempered by the fact that the index 
of control was also based on other markers of exacerbations such as ED visits and 
hospitalizations for asthma.  
 
Our study also has other limitations. Firstly, asking questions related to a pregnancy that 
occurred many years ago could result in recall bias. However, a recent study has 
demonstrated that “maternal reports of perinatal events in which they directly participated 
can be accurately and reliably reported 10 to 15 years after birth.” (231). Secondly, the 
response rate was low among asthmatic and non-asthmatic women (40% and 36%, 
respectively). However, it was reassuring to see that the distribution of the database 
driven variables was similar between responders and non-responders among asthmatic 
and non-asthmatic women, the data is available in the electronic attachment. Finally, our 
cohort is less representative of women with a higher socio-economic level, which could 
be a threat to external validity. 
 
Our study has also several strengths. Firstly, we had a very large sample size, which 
provided adequate power to detect clinically important differences. Secondly, the 
measurement of the control of asthma during pregnancy was based on a validated index 
(26). Thirdly, the gestational age at birth and birth weight were validated by comparing 
the database values to medical chart values and were found to be highly valid (195). 
Fourthly, we used an SGA definition which is based on new Canadian standards and 
considers the Canadian growth pattern in its definition (226, 242). Finally, the two-stage 
sampling design allowed us to obtain confounding variables, such as cigarette smoking, 
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which are not recorded in the administrative databases. Having the possibility to adjust 
the association under study for a large number of potential confounding variables led to a 
better model, more representative of “real life,” one that takes into consideration the wide 
variety of variables that may intervene in the development of the fetus.  
 
In conclusion, we observed that pregnant women with adequately controlled asthma still 
had an increased risk of having SGA, LBW or preterm infants when compared to non-
asthmatic women. Further research are needed to confirm these results and to investigate 
whether the pathophysiology of asthma, being adequately controlled or not, can induce 
abnormal fetal growth. 
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Table 1. Characteristics of study women from the first stage of sampling (database driven 
variables, n=36115) 
 
 Pregnancies of 
adequately 
controlled asthmatic 
women (n=8334) 
Pregnancies of non-
asthmatic women 
(n=27781) 
 
Number (%) 
Maternal socio-demographic variables  
Age at beginning of pregnancy:         
< 18 years old 576 (6.9) 987 (3.5) 
            18 - 34 years old 7,286 (87.5) 24,136 (86.9) 
     > 34 years old 469 (5.6) 2,658 (9.6) 
    Recipient of social assistance in the 
year before pregnancy 6,536 (78.4) 15,970 (57.5) 
Urban residency at delivery  6,787 (81.5) 21,407 (77.1) 
Pregnancy related variables  
Primiparous 2,612 (31.4) 9,611 (34.8) 
High risk pregnancy 2,955 (35.5) 8,131 (29.3) 
Gestational diabetes 591 (7.1) 1,886 (6.8) 
Pregnancy induced hypertension 507 (6.1) 1,437 (5.2) 
Gynecologist or obstetrician visit 
during pregnancy 6,848 (82.2) 2,2453 (80.0) 
Number of prenatal visits  
               ≤ 5 1,299 (15.6) 4,831 (17.4) 
               6-14  6,106 (73.3) 20,577 (74.1) 
               > 14 926 (11.1) 2,373 (8.5) 
Maternal co-morbidity  
Chronic diabetes 191 (2.3) 381 (1.4) 
Chronic hypertension 190 (2.3) 368 (1.3) 
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Table 2. Characteristics of women selected at the second stage of sampling 
(questionnaire driven variables, n=1546) 
 
 Pregnancies of adequately 
controlled asthmatic women 
(n=740) 
Pregnancies of non-
asthmatic women 
(n=806) 
 Number (%) 
Maternal characteristics  
Education (highest level attained) 
 
   Elementary school 66 (8.9) 35 (4.3) 
   High school   554 (74.9) 527 (65.4) 
   College & University    101 (13.6) 226 (28.0) 
   Unknown  19 (2.6) 18 (2.2) 
Annual family income during pregnancy 
 
        < $18,000 436 (58.9) 377 (46.8) 
        $18,001 - $46,000 249 (33.6) 323 (40.1) 
        > $46,001  38 (5.1) 90 (11.2) 
        Unknown    17 (2.3) 16 (2.0) 
Weight at birth 
 
         < 2.5 kg 163 (22.0) 124 (15.4) 
         2.5 – 5.0 kg         494 (66.8) 548 (68.0) 
         > 5.0 kg 8 (1.1) 11 (1.4) 
         Unknown    75 (10.1) 123 (15.3) 
Pregnancy related variables  
Maternal weight gain during pregnancy 
 
        < 8 kg 112 (15.1) 115 (14.3) 
        8 - 16 kg        313 (42.3) 423 (52.5) 
        > 16 kg 291 (39.3) 245 (30.4) 
        Unknown  24 (3.2)  23 (2.8) 
Maternal BMI pre-pregnancy 
 
         < 18.5 114 (15.4) 124 (15.4) 
          18.5 – 24.9 391 (52.8) 468 (58.1) 
          25 – 29.9 129 (17.4) 132 (16.4) 
          > 29.9  83 (11.2) 61 (7.6) 
          Unknown  23 (3.1) 21 (2.6) 
Preterm birth prior to the current 
delivery  
        Yes 143 (19.3) 111 (13.8) 
         No 593 (80.1) 692 (85.9) 
         Unknown  4 (0.5) 3 (0.4) 
LBW infant prior to the current delivery 
 
        Yes 135 (18.2) 119 (14.8) 
         No 597 (80.7) 684 (84.9) 
         Unknown  8 (1.1) 3 (0.4) 
Life style habits (during pregnancy) 
 
Maternal cigarette smoking 
 
        Yes 474 (64.1) 395 (49.0) 
         No 262 (35.4) 402 (49.9) 
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         Unknown  4 (0.5) 9 (1.1) 
Paternal cigarette smoking 
 
           Yes 369 (49.9) 346 (42.9) 
           No 353 (47.7) 451 (56.0) 
         Unknown 18 (2.4) 9 (1.1) 
Maternal alcohol consumption 
 
           Yes 125 (16.9) 148 (18.4) 
           No 588 (79.5) 619 (76.8) 
         Unknown 27 (3.7) 39 (4.8) 
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Table 3. Asthma related characteristics of adequately controlled asthmatic women 
during pregnancy (n=8334) 
 
During pregnancy Number of pregnancies (%) 
* ICS use (µg per day) 
0 6,244 (74.9) 
0-500 2,013 (24.2) 
500-1,000 68 (0.8) 
>1,000 9 (0.1) 
**SABA use (number of 
doses per week) 
0 4,763 (57.1) 
> 0-3 3,521 (42.3) 
> 3 50 (0.6) 
Leukoteriene-receptor antagonists use 5 (0.1) 
Long-acting beta2-agonists use 69 (0.8) 
Theophyline use 80 (1.0) 
At least one asthma medication 4,054 (48.6) 
≥ 1 respiratory physician visit 201 (2.4) 
Oral corticosteroids use 0 (0.0) 
≥ 1 ED visit for asthma  0 (0.0) 
≥ 1 hospitalization for asthma 0 (0.0) 
* Inhaled corticosteroids 
** Short-acting beta2-agonists 
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Table 4. The first stage prevalence and crude and adjusted odds ratios of adverse 
perinatal outcomes comparing pregnancies of adequately controlled asthmatic to non-
asthmatic women 
 
 
SGA LBW Preterm birth 
Number (%) 
 
1st stage 
Pregnancies of 
women with 
adequately 
controlled asthma 
(N=8,334) 
1,139 (13.7) 755 (9.1) 871 (10.5) 
Pregnancies of 
non-asthmatic 
women 
(N=27,781) 
2,948 (10.6) 1,575 (5.7) 1,848 (6.7) 
 OR (95% CI) 
1st stage 
Crude 1.33 (1.24-1.43) 1.66 (1.51-1.81) 1.64 (1.50-1.78) 
Adjusted *1.22 (1.13-1.31) **1.52 (1.38-1.67) ***1.56 (1.43-1.70) 
Final 
estimates‡ Adjusted †1.28  (1.15-1.43) ††1.42 (1.22-1.66) †††1.63 (1.46-1.83) 
‡ Final estimates obtained by correcting the second stage adjusted estimates with the second stage sampling 
fractions  
*Adjusted for maternal age at beginning of pregnancy, socio-economic status, primiparous, high risk 
pregnancy, gestational diabetes, pregnancy induced hypertension, prenatal visits, and chronic diabetes.  
** Adjusted for socio-economic status, urban residency at delivery, primiparous, high risk pregnancy, 
gestational diabetes, pregnancy induced hypertension, gynecologist or obstetrician visit during pregnancy, 
prenatal visits, and chronic hypertension.  
***Adjusted for socioeconomic status, primiparous, high risk pregnancy, pregnancy induced hypertension, 
gynecologist or obstetrician visit during pregnancy, prenatal visits, chronic diabetes, and chronic 
hypertension.  
†Adjusted for primiparous, pregnancy induced hypertension, prenatal visits, maternal weight at birth, 
maternal weight gain during pregnancy, maternal BMI pre-pregnancy, preterm birth prior to the current 
delivery, LBW infant prior to the current delivery, and maternal cigarette smoking during pregnancy. 
†† Adjusted for socio-economic status, primiparous, high risk pregnancy, pregnancy induced hypertension, 
gynecologist or obstetrician visit during pregnancy, prenatal visits, maternal weight at birth, maternal 
weight gain during pregnancy, maternal BMI pre-pregnancy, and LBW infants prior to the current delivery. 
††† Adjusted for primiparous, high risk pregnancy, gestational diabetes, pregnancy induced hypertension, 
gynecologist or obstetrician visit during pregnancy, prenatal visits, maternal weight gain during pregnancy, 
maternal BMI pre-pregnancy, preterm births prior to the current delivery, and LBW infants prior to the 
current delivery. 
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Electronic attachment  
 
Definition of the Database Indexes of Asthma Control Developed According to the 
Canadian Asthma Consensus Guidelines 
 
Asthma Control *ICS daily dose (µg) 
**Other 
controller 
therapy 
+SABA doses 
per week 
++ Marker of 
moderate to severe 
exacerbations 
Mild      
        Controlled 0-500 No 0-3 No 
 
0-250 Yes 0-3 No 
       Uncontrolled 0-250 Yes 0-3 Yes 
 
0-500 No 0-3 Yes 
 
0-250 Yes 4-10 No 
 
0-500 No 4-10 No 
Moderate     
         Controlled 251-500 Yes 0-10 No 
 
501-1,000 Yes/No 0-10 No 
 
>1000 Yes/No 0-3 No 
       Uncontrolled 0-250 Yes 4-10 Yes 
 
0-500 No 4-10 Yes 
 
0-250 Yes >10 No 
 
0-500 No >10 No 
 
251-500 Yes >10 No 
 
251-500 Yes 0-10 Yes 
 
501-1,000 Yes/No >10 No 
 
501-1,000 Yes/No 0-10 Yes 
Severe     
        Controlled >1,000 Yes/No 4-10 No 
       Uncontrolled 0-1,000 Yes/No >10 Yes 
 
>1,000 Yes/No 0-10 Yes 
 
>1,000 Yes/No >10 Yes/No 
 
*ICS daily dose in beclomethasone-CFC equivalent over a 12-month period 
** Other controller therapy: at least 6 prescriptions of long-acting beta2-agonist (LABA), 
theophylline or leukotriene-receptor antagonists dispensed over a 12-month period. 
+SABA: Average number of inhaled short-acting beta2-agonist doses per week calculated 
over a 12-month period. 
++ An emergency department visit for asthma, a hospitalization for asthma or a filled 
prescription of an oral corticosteroid over a 12-month period. 
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Electronic attachment  
 
Characteristics of adequately controlled asthmatic and non-asthmatic women who 
answered the questionnaire (N=1546) and those who did not answer (N=2598) 
 
 
Controlled Asthmatic 
women 
Non Asthmatic women 
Responding Non-
responding  Responding 
Non-responding  
Numbers (%) 
740 (40.0) 1,110 (60.0) 806 (36.4) 1,410 (63.6) 
Age at beginning of 
pregnancy  
    < 18 years old,  54 (7.3) 82 (7.4) 23 (2.8) 74 (5.3) 
    18 - 34 years old,  650 (87.8) 966 (87.0) 703 (87.2) 1,196 (84.8) 
    > 34 years old,  36 (4.9) 62 (5.6) 80 (9.9) 140 (9.9) 
Recipient of social 
assistance,  570 (77.0 ) 914 (82.3) 440 (54.6) 914 (64.8) 
Urban residency at 
delivery,   579 (78.2) 928 (83.6) 577 (71.6) 1,130 (80.1) 
Primiparous,  273 (37.1) 339 (30.6) 355 (44.2) 518 (36.9) 
High risk pregnancy,  294 (39.7) 452 (40.7) 302 (37.5)  579 (41.1) 
Gestational diabetes,  51 (6.9) 78 (7.0) 51 (6.3) 110 (7.8) 
Chronic diabetes,  22 (3.0) 22 (2.0) 10 (1.2) 25 (1.8) 
Pregnancy induced 
hypertension,  61 (8.2) 65 (5.9) 77 (9.6) 133 (9.4) 
Chronic hypertension,  21 (2.8) 28 (2.5) 27 (3.4) 30 (2.1) 
Gynecologist or 
obstetrician visit 
during pregnancy,  
605 (81.8) 949 (85.5) 671 (83.3) 1208 (85.7) 
Number of prenatal 
visits,   
               ≤ 5 108 (14.6) 247 (22.3) 164 (20.4) 326 (23.1) 
               6-14  545 (73.7) 777 (70.0) 599 (74.3) 991 (70.3) 
               > 14 87 (11.8) 86 (7.8) 43 (5.3) 93 6.6) 
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Electronic attachment  
 
Final odds ratio of perinatal outcomes comparing adequately controlled asthmatic 
(n=740) and non-asthmatic women (n=806) adjusted for variables derived from the 
databases and the mailed questionnaire 
 
 
SGA LBW Preterm 
Final adjusted OR (95% CI) 
Adequately controlled asthmatic 
versus non-asthmatic women 1.28 (1.15-1.43) 1.42 (1.22-1.66) 1.63 (1.46-1.83) 
Recipient of social  assistance --------------- 1.36 (1.05-1.78) --------------- 
Primiparous 0.77 (0.61-0.97) 0.59 (0.46-0.77) 0.81 (0.64-1.04) 
High risk pregnancy --------------- 1.73 (1.35-2.21) 1.68 (1.33-2.13) 
Gestational Diabetes --------------- --------------- 1.26 (0.82-1.94) 
Pregnancy induced hypertension 1.70 (1.05-2.76) 1.83 (1.09-3.09) 1.29 (0.79-2.10) 
Gynecologist or obstetrician visit 
during pregnancy --------------- 1.52 (1.09-2.12) 1.62 (1.17-2.23) 
Number of prenatal visits (>14) 1.59 (1.02-2.49) 0.31 (0.18-0.53) 0.28 (0.17-0.46) 
Number of prenatal visits (5-14) 1.24 (0.93-1.64) 0.63 (0.46-0.85) 0.57 (0.43-0.75) 
Maternal Weight at birth (<2.5 kg) 1.38 (1.05-1.81) 2.03 (1.52-2.71) --------------- 
Maternal Weight at birth (=>5.0 kg) 1.38 (0.54-3.54) 0.93 (0.34-2.56) --------------- 
Maternal Weight gain during 
pregnancy (>16.0 kg) 0.73 (0.58-0.92) 0.61 (0.47-80) 0.88 (0.69-1.12) 
Maternal Weight gain during 
pregnancy (<8.0 kg) 1.02 (0.75-1.40) 1.83 (1.31-2.56) 1.55 (1.13-2.13) 
Maternal BMI pre-pregnancy (>24.9) 0.82 (0.64-1.06) 0.59 (0.45-0.79) 0.84 (0.65-1.10) 
Maternal BMI pre-pregnancy (<18.5) 1.56 (1.15-2.11) 1.31 (0.94-1.81) 0.81 (0.59-1.11) 
Preterm birth prior to the current 
delivery 0.29 (0.19-0.44) --------------- 3.05 (2.08-4.47) 
LBW infant prior to the current 
delivery 3.53 (2.32-5.37) 3.77 (2.71-5.24) 0.76 (0.51-1.12) 
Maternal cigarette smoking 1.72 (1.38-2.15) --------------- --------------- 
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General discussion 
Considering the high prevalence of asthma among pregnant women and the fact 
that expectant mother and health professionals might underestimate the impact of a sub-
optimal treatment of asthma during pregnancy, we considered that evaluation of the 
consequences of maternal asthma on the health of the newborn would be necessary. We 
conducted a large population-based cohort study to further investigate the reciprocal 
effect of asthma and pregnancy.  
 
In the first methodological study related to the development and validation of 
database indexes of asthma severity and control, we have demonstrated that our database 
indexes correlate well with lung function measures, such as the FEV1 and the FEV1/FVC 
ratio, which are reliable indices reflecting asthma severity and control (39, 118). 
Moreover, the application of our database severity index to a population-based cohort of 
asthmatic patients led to a distribution of asthma severity similar to that found with other 
severity indexes. These database indexes were used to measure exposure in the study 4 
and 5. Moreover, we used the indexes to describe the study population (exposed and non-
exposed) in the study 2 and the asthma-related characteristics of the exposed women 
during pregnancy in the study 3. 
 
In the second study, we evaluated the impact of pregnancy on maternal asthma. 
No significant differences were found between mothers of a female and male fetus as to 
the occurrence of asthma exacerbations (adjusted rate ratio=1.02; 95% CI: 0.92 to 1.14), 
the daily dose of ICS (adjusted mean difference (AMD): 2.46 µg; 95% CI: -4.01 to 8.93), 
and the weekly dose of SABA (AMD: 0.004 dose; 95% CI: -0.23 to 0.24). Based on these 
results, we concluded that fetal gender is unlikely to affect maternal asthma during 
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pregnancy to the point where acute care and medications are more often required among 
women pregnant with a female fetus. Thus, although pregnancy could influence the 
course of asthma but at least fetal gender could not have a serious impact on maternal 
asthma during pregnancy.  
 
To understand better the impact of asthma in pregnancy, we conducted three last 
studies. In the third study, the cohort (first stage of sampling) included 13,007 
pregnancies from asthmatic women and 27,781 pregnancies from non-asthmatic women. 
In this study, we have found that asthma during pregnancy was significantly associated 
with an increased risk of SGA (OR: 1.27, 95% CI: 1.14-1.41), LBW (OR: 1.41, 95% 
CI:1.22-1.63) and preterm births (OR: 1.64, 95%CI:1.46-1.83). Knowing that, we 
considered that it would be clinically relevant to evaluate whether the risk of perinatal 
outcomes of women with moderate and severe asthma is still higher or is similar to the 
risk observed among mild asthmatic women. 
 
In the fourth study, our results show that the proportions of women with mild, 
moderate and severe asthma were 82.5%, 12.5% and 5.0%, respectively. Final estimates 
showed that the risk of SGA was significantly higher among severe (OR:1.48, 95%CI: 
1.15-1.91) and moderate asthmatic women (OR: 1.30,  95%CI:1.10-1.55) than mild 
asthmatic women. No significant associations were found between asthma severity, 
preterm birth and LBW. These results suggest that severe maternal asthma is more likely 
to affect the growth of the baby than the timing of the delivery which is more precisely 
captured by the SGA measure than the weight at birth alone. Some physiologic 
hypotheses can explain at least in part these findings. Maternal asthma can induce 
hypoxia combined with respiratory alkalosis that decreases the placental blood flow (54, 
243) and as a result chronic oxygen deprivation of the fetus could affect fetal growth (50, 
52, 120). 
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The remaining question was whether the risk of perinatal outcomes of women 
with adequately controlled asthma is similar to the risk observed among non-asthmatic 
women, so we conducted the fifth study. In this study, the cohort included 8,334 
pregnancies of women with adequately controlled asthma and 27,781 pregnancies of non-
asthmatic women. Final estimates showed that the risk of SGA (OR:1.28, 95%CI: 1.15-
1.43), LBW (OR: 1.42,  95%CI:1.22-1.66), and preterm deliveries (OR: 1.63,  
95%CI:1.46-1.83) was significantly higher among mother with adequately controlled 
asthma than non-asthmatic women.  
 
5.5. Contribution of our results to the literature in the field 
of asthma in pregnancy 
 
5.5.1. Impact of feminine sex hormones on asthma 
Some data suggest that feminine sex hormones could play a role in the modulation 
of immunological inflammation in asthma (244). Serum levels of feminine sex hormones 
have been directly correlated with the clinical and functional features of asthma (244). In 
peri- menopausal and post-menopausal period, asthma may worsen in women with prior 
disease (245). Knowing this characteristic of asthma, the question has raised whether 
feminine sex of the fetus might influence the maternal asthma. We investigated this 
question in our second study among 11,257 pregnancies of asthmatic women. Although, 
three other smaller studies have found increased markers of poorly controlled asthma 
among pregnancies of female fetuses (8-10), we detected no significant increase in the 
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rate of maternal asthma exacerbations, the use of ICS and SABA during pregnancy 
among mothers of female fetus, whether examined between or within mothers. 
 
5.5.2. Impact of asthma on adverse perinatal outcomes 
In our last three studies, we evaluated the impact of maternal asthma, and its 
severity and control during pregnancy on three adverse perinatal outcomes. Comparing to 
the findings reported in the literature on the impact of asthma on adverse perinatal 
outcomes (113), our results are much more precise (narrow confidence interval) because 
of our large study population. The same precision was also observed in the study 4 and 5 
comparing to the results found in the literature. Moreover, most of the studies in the field 
of asthma in pregnancy, evaluated the impact of maternal asthma on other adverse 
perinatal outcomes rather than SGA infant. However, our results suggest that the effect of 
maternal asthma and more precisely severe maternal asthma is more likely to be captured 
by the SGA measure than the weight at birth alone or the timing of the delivery. These 
results are in concordance with the results found by Schatz et al. (56).  
 
5.5.3. Smoking during pregnancy 
While the percentage of women who smoked was higher in our cohort than 
general population, smoking was not found to be a confounder for the associations under 
study in the three last studies. As found in other studies (125, 142, 155, 159-161), we 
observed that smoking during pregnancy was significantly associated with increased risk 
of adverse perinatal outcomes but this co-variable did not act as a confounder for the 
association between asthma, its severity and control during pregnancy and adverse 
perinatal outcomes. One of the possible explanations of this phenomenon is the presence 
of several other confounding variables along with smoking in multivariate regression 
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models. Although smoking is a risk factor for adverse perinatal outcomes and it is 
associated with maternal asthma but it is possible that smoking is simultaneously 
associated with other confounding variables, included in the model, such as “receiving 
social assistance benefits”. In this case, removing the associated confounding variable in 
backward selection eliminates the effect of smoking. Moreover, as it was shown in study 
4, the percentage of women who smoked during pregnancy does not vary a lot according 
to the level of asthma severity. 
 
5.6. Strengths of the study 
5.6.1. Databases 
One of the strengths of our studies is using the databases.  Using three Quebec’s 
administrative databases to measure exposures and outcomes presents many advantages 
over other means of data collection, such as personal interview or self-administered 
questionnaires. First, we avoid recall bias and we capture real patient’s filling of 
medications and use of clinical practice. Second, it is usually difficult for patients to 
report the medications they are taking when details, such as the exact name, dose and 
quantity, are required (220-222, 246, 247) and they tend to overestimate their adherence 
(219). Third, the use of computerized databases allows us to capture drug history over a 
long period of time (one year before and during pregnancy) and for a very large number 
of subjects in a standardized format. Fourth, one of the most important advantages of 
using data recorded prospectively in administrative databases is that we could study a 
large number of pregnant women (generally understudied population) in a reasonable 
time frame and budget. Fifth, the high quality of personal identifier in Quebec’s 
administrative databases helps correct linkage between databases. Sixth, it has been 
shown that data recorded in Quebec’s administrative databases has good internal quality 
(good validity, and reliability of data) (188, 192, 230, 248). 
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5.6.2. Questionnaire  
Another strength of our studies is that database data was coupled with 
questionnaire data in order to obtain confounding variables such as parental smoking and 
lifestyle of the mother during pregnancy not recorded in the databases. The short and 
simple questions of our questionnaire made it possible to use self-administered 
questionnaire method to collect data in the second stage of sampling of the last three 
studies. This method of data collection has some advantages over interview-administered 
questionnaire. First, self-administered questionnaire generally cost less than interview-
administered questionnaire (249). Second, this method of data collection may yield more 
accurate data on embarrassing topics such as illicit drug use or smoking during 
pregnancy. Third, self-administered questionnaire provide greater confidentiality than 
interview-administered questionnaire and may increase the subject’s willingness to 
answer the questions (249). Fourth, the less educated subjects are more willing to answer 
a self-administered questionnaire rather than an interview-administered questionnaire 
(249). Fifth, with this method of data collection, there is always a possibility to ask the 
responders for more clarification by telephone if it is needed (249). 
 
5.7. Limits of the study 
5.7.1. Biases in the study design 
Two types of error threat epidemiologic studies; random error and systematic 
error (250). Random error is the variability in the data and represents the precision of the 
study (250). It could be reduced by increasing the sample size (increasing the power of 
the study). A small p-value and a narrow confidence interval imply a great precision and 
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small random error. Systematic error or bias is a result of an error in the way that the 
study has been carried out and can influence the internal validity of the study i.e. the 
result is a difference between the estimated association and the real association value in 
the population. The bias could occur in the design, in the conduct or in the analysis of a 
study.  
 
Selection Bias 
Participation Bias 
Participation bias or self-selection bias is a systematic error in a study which 
stems from the procedures used to select subjects and factors that influence study 
participation (250). This bias occurs when the participants are not representative of the 
general population and they are different from the persons who did not accept to 
participate (250). The self-selection bias could be a threat to the validity of the study if 
the reasons for self-selection are associated with the outcome under study (249). In 
summary, the association between exposure and outcome differs for those who 
participated and those who did not participate in the study. If bias occurs, the 
interpretation of the study findings is getting complicated.  
 
In the second stage of sampling of the last three studies, the risk of participation 
bias could have been present, if women who answered the questionnaire were different 
from women who did not answer. However, the bias is present only if the differences in 
the characteristics between two groups of responders and non-responders are associated 
with the outcomes under study. To verify the possibility of participation bias in our 
studies, we compared the characteristics (driven from databases, i.e. the first stage of 
sampling) of the pregnancies of women who answered the questionnaire with the 
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characteristics of the pregnancies of women who did not answer in each of the three 
studies separately. Overall, responders and non-responders were quite similar for the 
variables retrieved from the administrative databases (maternal socio-demographic 
variables, pregnancy-related variables and maternal co-morbidities). The tables 
presenting the details of the comparisons are available in the three last articles included in 
the present thesis. Considering the similarity of two groups of responders and non-
responders for the characteristics retrieved from the administrative databases, there is less 
chance that they differ in other characteristics to the point that the selection bias affects 
our studies, however, if it happened, we do not know in which direction the selection bias 
might operate and how it might affect the study results. 
 
Confounding Bias 
Confounding is a distortion of the association between the exposure and the 
outcome of interest because the effect of some extraneous risk factors  is mixed with the 
effect of the exposure of interest (250). Confounding could occur if the extraneous risk 
factors of the outcome are unevenly distributed between the compared populations. In 
this case, extraneous risk factor would be an alternative explanation for the relationship 
observed between exposure and outcome (183). To handle the problem of confounding in 
our studies, we used multivariate regression models to adjust the ORs by controlling 
simultaneously for several confounding variables (see section of Confounding variables). 
However, knowing the difficulty to measure some of the confounding variables such as 
maternal socio-economic status, cigarette smoking and alcohol consumption during 
pregnancy, we cannot be sure entirely of the efficacy of the adjustment. Moreover, 
although we tried to include all the known risk factors of the adverse perinatal outcomes 
in the regression models, we cannot be assured that we considered all the risk factors. We 
suppose that we took into account all confounding variables that could affect the 
interpretation of our results; however, considering that observational studies do not have 
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the same efficacy as clinical trials to control for all confounding variables, we cannot 
eliminate the possibility of confounding bias. If we failed to control some unknown 
confounding variables, the conclusion of the studies could be biased.  
  
Information Bias 
This systematic error occurs in assessing the association between exposure and 
outcome as a result of error in measurement of exposure or outcome status (250). The 
information bias occurs, when the misclassification happens which can be differential or 
non-differential (250). 
 
Recall Bias 
A common type of information bias is recall bias which occurs in retrospective 
studies due to differentials in memory capabilities of sample subjects to recall the past 
events or experiences (250). The recall of exposures or events may differ in two 
compared groups. Subjects with the outcome are more likely to carefully consider 
whether or not an exposure occurred. 
 
The most important bias that could occur with data collection via a mailed 
questionnaire is recall bias. However, in our studies, the results of the pre-testing of the 
questionnaire was reassuring and a study published in the literature showed that women 
had no problem to recall pregnancy related variables for pregnancies that happened as far 
as 15 years ago (231).  
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Moreover, the questionnaire data were not used to measure the outcome and the 
main exposure variables. Via the mailed questionnaire we only collected some potential 
confounders that were not recorded in the administrative databases. The outcomes and 
main exposure variables were measured with data recorded in the administrative 
databases. In these databases there is no potential for recall bias since the data are 
routinely and prospectively collected, independently of the outcome under study. The 
recall bias, if present, could have affected only the confounding variables, not the 
outcomes and the main exposure variables. If misclassification of confounding variables 
occurred, it could be differential for some of confounding variables because it is possible 
that women with asthma were more concerned about their health and reporting the details 
about smoking or other variables than non-asthmatic women or they prefer to under-
report some of their characteristics intentionally. Then, the recall bias could be present 
more in the exposed group than in non-exposed group but we are unable to predict that. 
However, remembering the pregnancy-related characteristics could be as difficult (if so) 
for asthmatic women as non-asthmatic ones. As a result, recall bias could be present in 
both exposed and unexposed group and its direction is not predictable (183). 
 
Other information bias  
In historical cohort studies, in which information is obtained from past records, 
information bias can be introduced if the quality and extent of information obtained is 
different for exposed persons than for non-exposed persons (183). In our studies, the 
outcome assessment for exposed and non-exposed persons was made through data 
obtained from administrative databases. As a result, if there is any inaccuracy in outcome 
measurement, it will not be related to exposure status and only a non-differential 
misclassification can be introduced. The usual effect of non-differential misclassification 
is that the effect tends to be diluted, and it will produce an underestimation of the OR 
(towards 1.0) (183). 
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The indexes that we used in our studies to measure asthma severity and control 
are in part based on filled prescriptions of asthma medications. However, data regarding 
asthma medications recorded in RAMQ databases represents the filled prescriptions and 
might not always reflect exactly the use of medications. Then, a misclassification of 
exposure can be introduced in studies 4 and 5. However, the asthma severity and control 
measurement is not only based on the medication use but also on the medical care 
services use. Moreover, a recent article showed that  only 6% of drugs dispensed to 
pregnant women were not used (231). Then, although the adherence to asthma treatment 
could be different between severe asthmatic and mild asthmatic patients, there is little 
chance that exposure misclassification occurred.  But, in the case of misclassification, 
there is a higher risk that a severe asthmatic patient misclassified as mild asthmatic one 
than the contrary case. The result of a differential misclassification bias is either an 
association even if one does not really exist or an association when one does in fact exist 
and we cannot predict the direction of bias (183). In the case of our study, the 
misclassification bias, if occurred, would probably result in an underestimation of the 
association; because as it was explained, most likely, the severe asthmatic patients would 
be misclassified as mild asthmatics.  
 
Also, there is a potential of non-differential misclassification of asthmatic women 
due to possible inaccurate diagnosis of asthma entered into the databases. Aaron et al. 
have shown that about one-third of individuals with physician-diagnosed asthma did not 
have asthma when objectively assessed (251). However, in our studies, asthma during 
pregnancy is defined as having at least one diagnosis of asthma and at least one dispensed 
prescription for an asthma medication. Having the second source of data (filled asthma 
prescriptions) may improve the validity of our operational definition of asthma and 
reduce the risk of misclassification. Moreover, the asthma diagnostic codes recorded in 
the RAMQ database were validated by comparing the database values to medical chart 
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values and were found to be valid (230). Although Aaron et al. have shown that there is a 
risk of over-diagnosis of asthma, it has been reported that there is a risk of under-
diagnosis of asthma too (252). Then, if the misclassification occurred, it would probably 
be non-differential which result in an under detection of an association even if one really 
exists (183). However, if we consider that the misclassification was mostly among 
asthmatic than non-asthmatics, then the misclassification will be differential.  
 
5.7.2. External Validity 
The external validity of a study refers to the appropriateness by which its results 
can be applied to non-study patients or populations (its generalizability) (183). Our cohort 
is not representative enough of women in the higher socio-economic level because it 
included women receiving social assistance and middle class working women. However, 
the non representativeness of our cohort would be a threat to external validity only if 
socio-economic status is an effect modifier for the associations under study. But there is 
no evidence in the literature suggesting that the impact of maternal asthma or its severity 
or control on newborns differs in different levels of socio-economic status. In fact, there 
is literature on the association between asthma severity or control and socio-economic 
status (232, 233), but it is not reported that the relationship between asthma and perinatal 
outcomes varies between high and low levels of socio-economic status. 
 
5.8. Clinical implication of our results 
The knowledge provided by our studies is transferable immediately to health 
professionals and asthmatic women. First, the results of the second study suggest that 
fetal gender should not be considered to plan the management of asthma during 
pregnancy, and that the management should aim at asthma control regardless of the 
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gender of the fetus. Second, our results in the three last studies will help health 
professionals and asthmatic women to realise that all asthmatic women even those with 
adequately controlled asthma should be closely monitored during pregnancy, because 
they are at increased risk of adverse perinatal outcomes. Third, the scientific evidence 
provided by our studies will help health professionals and decision makers to develop 
preventive, therapeutic and health care strategies to ensure an optimal treatment of 
asthma during pregnancy that will improve maternal care by reducing the frequency of 
asthma exacerbations and as a result improving asthma control during pregnancy and 
improve perinatal outcomes by preventing SGA, LBW and premature birth. 
 
5.9. Further research 
Further research is needed to answer some other questions in the field of asthma 
during pregnancy. There is a real need to know better the factors that can yield to poorly 
controlled asthma during pregnancy. Although, it is reported that adherence to prescribed 
medications for chronic diseases reduces during pregnancy (253-256), there are certainly 
other factors that can induce poorly controlled asthma. Moreover, further research is 
needed to clarify the pathophysiology of asthma in inducing abnormal fetal growth even 
in women with adequately controlled asthma. Another interesting question that comes up 
from the results of our fourth study is why severe maternal asthma during pregnancy does 
affect SGA but not LBW and preterm birth. Also, there is a lack of knowledge regarding 
how to treat better asthma during pregnancy and it will be helpful to develop and evaluate 
different interventions during pregnancy on this regard. 
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6. Conclusion 
The five studies of this thesis were conducted to achieve an ultimate objective; 
knowing better the reciprocal effect of asthma and pregnancy. The database indexes 
developed and validated in the first study were used in the other studies included in the 
present thesis to measure the control and the severity of asthma. These database indexes 
can be used in epidemiologic studies using administrative databases that record data on 
dispensed prescriptions and medical services for asthma to correctly assess the severity 
and control of asthma in currently treated asthmatic patients. The results of the second 
study helped us to conclude that fetal gender is unlikely to affect maternal asthma during 
pregnancy to the point where acute care and medications are more often required among 
women pregnant with a female fetus. The results of the three last studies provided us with 
a better understanding of the impact of maternal asthma on adverse perinatal outcomes. 
The third study showed that the risk of SGA, LBW and preterm delivery was 
significantly higher among asthmatic than non-asthmatic women. The results of the 
fourth study showed that severe and moderate asthma during pregnancy were 
significantly associated with an increased risk of SGA babies as compared to mild 
asthma. And results of the fifth study helped us to conclude that women with adequately 
controlled asthma during pregnancy are significantly at higher risk of delivering SGA, 
LBW and preterm babies than women without asthma. The scientific evidence provided 
by these studies can help health professionals and women to develop preventive, 
therapeutic and health care strategies to ensure an optimal treatment of asthma during 
pregnancy. All asthmatic women even those with adequately controlled asthma should be 
closely monitored during pregnancy, because they are at increased risk of adverse 
perinatal outcomes. 
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Appendix B 
List of asthma medications  
  1. Bronchodilatateurs beta-agoniste inhalés à courte durée d'action 
 3380 épinéphrine (bitartrate d') 
 2639 Suspension Aérosol avec applicateur 
 3406 épinéphrine (chlorhydrate d') 
 1856 Solution Aérosol 
 3419 épinéphrine racémique (chlorhydrate d') 
 1972 Solution pour Inhalation 
 6721 orciprénaline (sulfate d') 
 1972 Solution pour Inhalation 
 2610 Suspension Aérosol 
 10530 salbutamol 
 1856 Solution Aérosol 
 5584 Aérosol oral 
 33634 salbutamol (sulfate de) 
 1305 Poudre Aérosol 
 1334 Poudre Aérosol avec applicateur 
 1972 Solution pour Inhalation 
 5563 Poudre pour inhalation avec applicateur 
 5564 Poudre pour inhalation 
 5619 Poudre pour inhalation applicateur 
 34180 terbutaline (sulfate de) 
 1334 Poudre Aérosol avec applicateur 
 5563 Poudre pour inhalation avec applicateur 
 III 
III 
 5564 Poudre pour inhalation 
 5619 Poudre pour inhalation applicateur 
 38548 fénotérol (bromhydrate de) 
 1305 Poudre Aérosol 
 1972 Solution pour Inhalation 
 46299 pirbutérol (acétate de) 46299 * 
 5584 Aérosol oral 
 46737 salbutamol (sulfate de) 46737 * 
 1305 Poudre Aérosol 
 1334 Poudre Aérosol avec applicateur 
 1972 Solution pour Inhalation 
 5563 Poudre pour inhalation avec applicateur 
 5564 Poudre pour inhalation 
 5619 Poudre pour inhalation applicateur 
 47153 pirbutérol (acétate de) 
 5584 Aérosol oral 
2. Bronchodilatateurs beta-agoniste inhalés à longue durée d'action 
 46247 salmétérol (xinafoate de) 46247 * 
 5563 Poudre pour inhalation avec applicateur 
 5564 Poudre pour inhalation 
 5584 Aérosol oral 
 5619 Poudre pour inhalation applicateur 
 46430 formoterol (fumarate dihydraté de) 46430 * 
 5564 Poudre pour inhalation 
 47112 salmétérol (xinafoate de) 
 5563 Poudre pour inhalation avec applicateur 
 IV 
IV
 5564 Poudre pour inhalation 
 5584 Aérosol oral 
 5619 Poudre pour inhalation applicateur 
 47231 formoterol (fumarate de) 
 5564 Poudre pour inhalation 
 47271 formoterol (fumarate dihydrate de) 
 5564 Poudre pour inhalation 
3. Bronchodilatateurs anticholinergique à courte durée d'action 
 43124 ipratropium (bromure d') 
 1885 Solution Aérosol avec applicateur 
 1972 Solution pour Inhalation 
 5584 Aérosol oral 
 46640 ipratropium (bromure d') 46640 * 
 1885 Solution Aérosol avec applicateur 
 1972 Solution pour Inhalation 
 5584 Aérosol oral 
4. Bronchodilatateurs théophylline 
 364 aminophylline 
 203 Comprimé 
 435 Comprimé Longue Action 
 2117 Solution Injectable I.V. 
 2262 Solution Orale 
 9464 théophylline 
 116 Capsule 
 145 Capsule Longue Action 
 203 Comprimé 
 V 
V 
 435 Comprimé Longue Action 
 754 Elixir 
 1827 Sirop 
 2262 Solution Orale 
 5075 Solution sans Alcool 
 5555 Solution sans sucre 
 5606 Solution orale sans sucre 
 5607 Elixir sans sucre 
 5611 Capsule longue action 
 9490 théophylline (aminoacétate calcique de) 
 203 Comprimé 
 9503 théophylline (aminoacétate sodique de) 
 203 Comprimé 
  43475 oxtriphylline 
 203 Comprimé 
 435 Comprimé Longue Action 
 754 Elixir 
 1827 Sirop 
 46428 aminophylline 46428 * 
 203 Comprimé 
 435 Comprimé Longue Action 
 2117 Solution Injectable I.V. 
 2262 Solution Orale 
 46847 théophylline 
 116 Capsule 
 145 Capsule Longue Action 
 203 Comprimé 
 VI 
VI
 435 Comprimé Longue Action 
 754 Elixir 
 1827 Sirop 
 2262 Solution Orale 
 5075 Solution sans Alcool 
 5555 Solution sans sucre 
 5606 Solution orale sans sucre 
 5607 Elixir sans sucre 
 5611 Capsule longue action 
5. Bronchodilatateurs beta-agonistes oral à courte durée d'action 
 6721 orciprénaline (sulfate d') 
 203 Comprimé 
 1827 Sirop 
 33634 salbutamol (sulfate de) 
 203 Comprimé 
 2262 Solution Orale 
 34180 terbutaline (sulfate de) 
 203 Comprimé 
 38548 fénotérol (bromhydrate de) 
 203 Comprimé 
 46737 salbutamol (sulfate de) 46737 * 
 203 Comprimé 
 2262 Solution Orale 
6. Corticostéroïdes inhalé 
 780 béclométhasone (dipropionate de) 
 1305 Poudre Aérosol 
 VII 
VII 
 1334 Poudre Aérosol avec applicateur 
 1856 Solution Aérosol 
 5563 Poudre pour inhalation avec applicateur 
 5564 Poudre pour inhalation 
 5584 Aérosol oral 
 5619 Poudre pour inhalation applicateur 
  
Catégorie dencom forme  
 9737 triamcinolone (acétonide de) 
 1856 Solution Aérosol 
 5584 Aérosol oral 
 38730 flunisolide 
 1856 Solution Aérosol 
 5584 Aérosol oral 
 45499 budésonide 
 1856 Solution Aérosol 
 1972 Solution pour Inhalation 
 5563 Poudre pour inhalation avec applicateur 
 5564 Poudre pour inhalation 
 5619 Poudre pour inhalation applicateur 
 46345 fluticasone (propionate de) 46345 * 
 5564 Poudre pour inhalation 
 5584 Aérosol oral 
 47050 fluticasone (propionate de) 
 5564 Poudre pour inhalation 
 5584 Aérosol oral 
 47213 flunisolide * 
 VIII 
VIII 
 1856 Solution Aérosol 
 5584 Aérosol oral 
7. Anti-allergiques cromoglycate 
 2223 cromoglycate disodique 
 1305 Poudre Aérosol 
 1334 Poudre Aérosol avec applicateur 
 1972 Solution pour Inhalation 
 5563 Poudre pour inhalation avec applicateur 
 5564 Poudre pour inhalation 
 5584 Aérosol oral 
 5619 Poudre pour inhalation applicateur 
 39419 cromoglicate sodique 
 1305 Poudre Aérosol 
 1334 Poudre Aérosol avec applicateur 
 1972 Solution pour Inhalation 
 5563 Poudre pour inhalation avec applicateur 
 5564 Poudre pour inhalation 
 5584 Aérosol oral 
 5619 Poudre pour inhalation applicateur 
 47315 cromolyn * 
 1305 Poudre Aérosol 
 1334 Poudre Aérosol avec applicateur 
 1972 Solution pour Inhalation 
 5563 Poudre pour inhalation avec applicateur 
 5564 Poudre pour inhalation 
 5584 Aérosol oral 
 IX 
IX
 5619 Poudre pour inhalation applicateur  
8. Anti-allergiques nédocromil 
 45563 nédocromil sodique * 
 2610 Suspension Aérosol 
 5584 Aérosol oral 
 46463 nédocromil sodique 46463 * 
 2610 Suspension Aérosol 
 5584 Aérosol oral 
 47033 nédocromil sodique 
 2610 Suspension Aérosol 
 5584 Aérosol oral 
9. Antileucotriènes zafirlukast 
 46401 zafirlukast 46401 * 
 203 Comprimé 
 47266 zafirlukast 
 203 Comprimé 
10. Antileucotriènes montelukast 
 46467 montélukast sodique 46467 * 
 203 Comprimé 
 464 Comprimé Masticable 
 47302 montélukast sodique * 
 203 Comprimé 
 464 Comprimé Masticable 
 47303 montélukast sodique 
 203 Comprimé 
 464 Comprimé Masticable 
 X 
X 
11. Autres agents inhalés 
 5070 isoprotérénol (sulfate d') 
 2639 Suspension Aérosol avec applicateur 
 5083 isoprotérénol (chlorhydrate d') 
 1856 Solution Aérosol 
 1972 Solution pour Inhalation 
 5584 Aérosol oral 
 5096 isoprotérénol (chlorhydrate d')/ phényléphrine (bitartrate de) 
 2639 Suspension Aérosol avec applicateur 
 5109 isoprotérénol (chlorhydrate d')/ phényléphrine (chlorhydrate de) 
 1856 Solution Aérosol 
 45547 procatérol hémihydraté (chlorhydrate de) 
 1856 Solution Aérosol 
 5584 Aérosol oral 
12. Autres agents par voie orale 
 5083 isoprotérénol (chlorhydrate d') 
 493 Comprimé Sub-lingual 
 45555 kétotifène (fumarate de) 
 203 Comprimé 
 1827 Sirop 
 46752 kétotifène (fumarate de) 46752 * 
 203 Comprimé 
 1827 Sirop  
   13. Produit de combinaison  Bronchodilatateurs (beta-agoniste CA et antichol.)  
 46302 ipratropium (bromure d')/ salbutamol (sulfate de) 46302 * 
 1972 Solution pour Inhalation 
 5584 Aérosol oral 
 XI 
XI
 47186 ipratropium (bromure d')/ salbutamol (sulfate de) 
 1972 Solution pour Inhalation 
 5584 Aérosol oral 
 14.  Produit de combinaison Bronchodilatateurs (beta-agoniste LA  et CSI) 
                    46597    salmétérol (xinafoate de)/ fluticasone(propionate de) 46597 * 
 5564 Poudre pour inhalation 
 5584 Aérosol oral 
 46800 budésonide/formoterol(fumara- te dihydrate de) 46800 * 
 5564 Poudre pour inhalation 
 47335 salmétérol (xinafoate de)/ fluticasone (propionate de) 
 5564 Poudre pour inhalation 
 5584 Aérosol oral 
 47428 formotérol (fumarate dihydraté de)/budésonide 
 5564 Poudre pour inhalation 
15. Bronchodilatateurs beta-agoniste oral à longue durée d'action 
 33634 salbutamol (sulfate de) 
 435 Comprimé Longue Action 
 46737 salbutamol (sulfate de) 46737 * 
 435 Comprimé Longue Action 
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Appendix C 
VCF07_Diabète 
VCF= Variable confondante fixe dans le temps. 
BUT 
Création d'une variable indiquant pour chaque grossesse si la femme souffrait de 
diabète mellitus ou de diabète de grossesse. 
 
Algorithme 
 
 
Périodes : 
Avant = [ début avant1, début de la grossesse [ 
P1 = [ début de la grossesse, fin de la 12ième semaine de grossesse2 ] 
P2 = [ début de la 13ième semaine de grossesse, fin de la 23ième semaine de grossesse ] 
P3 = [ début de la 24ième semaine de grossesse, fin de grossesse] 
P43 = ] fin de la grossesse, Fin 3mois1 ] 
Après = ] Fin 3mois1, Fin Après1] 
 
Diabète mellitus : 
 
Si 
1. Au moins un Rx7 ou Dx8 (DM/DG)4 durant «avant» ou durant   P1  
            ou 
2. Au moins un Rx ou Dx (DM/DG) durant P2 ou  P3  et au moins un Dx (DM/DG) 
durant «après»6 
ou 
3. Au moins un Dx (DM/DG) durant P45-6  et au moins un  Dx (DM/DG) durant 
«après» 
alors DM=1. 
Avant P1 P2 P3 Après 
Début Avant 1                       Début gros              12ieme           23ième         fin gros          Fin 3mois1              Fin Après1 
                                                                                Semaine2         semaine                       
P43 
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Diabète gestationnel: 
 
Si DM=0 et 
1. Au moins un  Rx ou Dx (DM/DG) durant P3 ou durant P2 
   ou 
2. Au moins un Dx (DM/DG) durant P4    
alors DG=1. 
 
****************************ATTENTION******************************** 
Si au moins un code de syndrome des ovaires poly kystiques (code ICD-9 256.4) avant ou 
pendant  la grossesse nous effectuerons ce même algorithme sans tenir compte des Rx 
****************************ATTENTION********************************
 
 
NOTES 
1
 S’il existe une grossesse précédente (GP), nous établirons une borne supérieure à cette 
grossesse.   
 
                                       fin de la GP + 1 + 3 mois    si durée GP ≥ 12 semaines complètes 
         Borne GP =    
                                       fin de la GP + 1                  si durée GP < 12 semaines complètes 
 
Si borne GP est supérieure au début de la grossesse actuelle nous remplacerons Borne GP 
par le début de la grossesse actuelle. 
 
Une fois cette borne trouvée nous choisirons la date maximale entre la borne de la 
grossesse précédente et un an avant la grossesse. 
 
                  Début Avant = MAX (début de la grossesse-365 jours, borne GP) 
 
 XIV 
XIV
ET 
                  Fin 3mois     = MIN (fin de la grossesse + 91 jours,  début gros suivante - 1 ) 
 
                  Fin Après     =  MIN (fin gros +365 jours,  début gros suivante - 1 ) 
 
 
2
 Habituellement le test de diabète gestationnel s’effectue entre  la 24ième et la 28ième 
semaine de grossesse. Mais il peut aussi avoir lieu à  la12 ième  ou encore à la  20 ième  
semaine s’il y a des facteurs de risque important ( ex une femme qui pèserait 130 kg) 
 
3 Le diabète gestationnel prend généralement 6 semaines pour se résorber. Une minorité 
cependant peut prendre jusqu’à 3 mois avant que la glycémie ne redevienne normale. C’est 
pourquoi nous devons attendre 3 mois avant de vérifier si la maladie persiste. 
 
4
 Tous les codes sont considérés comme un code de diabète peu importe s’il s’agit d’un 
code de diabète mellitus ou de diabète gestationnel. C’est plutôt le moment où ce code à été 
émis qui décidera s’il s’agit de diabète mellitus ou de diabète gestationnel. 
 
5
 S’il n’y a eu aucun code et aucun rx durant la grossesse mais qu’il y a néanmoins un code 
durant la période 1-3 mois inclusivement après la grossesse, cela signifie qu’il y a eu 
quelques chose puisque qu’on lui fait passer le test pour voir si tout redevient normal après 
la grossesse. En effet, le test de diabète gestationnel n’est pas fait systématiquement après 
la grossesse. Il est effectué seulement chez celles qui ont eu du diabète gestionnel ou du 
diabète mellitus qui se serait développé après les 12 premières semaines de grossesse.  
 
6
 Pour les périodes P4 et «Après» nous ne considérons pas les Rx puisque nous n’avons pas 
exigé que ces périodes soient couvertes par la RAMQ pour le remboursement des 
médicaments. 
 
7-8
 Voir l’annexe pour les listes de médicaments et de codes pertinents.
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Annexes  
DX : Codes diagnostiques pour le diabète (Codes ICD-9) 
 
 DX(DM) 
250.0 à 250.9   -  Diabète mellitus 
648.0               -  Diabète mellitus  (code spécifique à la grossesse)  
 
 DX(DG) 
          648.8  -  Diabète de gestationnel 
 
 
Rx : Prescription d’un médicaments pour le diabète 
 classe dencom forme  
 Analogues méglitinide 
 46810 nateglinide 203 Comprimé 
 47357 répaglinide 203 Comprimé 
 46568 repaglinide 46568 * 203 Comprimé 
 Biguanides 
 47208 metformine 203 Comprimé 
 46862 metformine ( chlorhydrate de)/ rosiglitazone  0 
 (maléate de) 
 5824 metformine (chlorhydrate de) 203 Comprimé 
 Inh. alpha-glucosidose 
 47151 acarbose 203 Comprimé 
 46300 acarbose 46300 * 203 Comprimé 
 Insulines 
 47424 insuline aspart 2146 Solution Injectable S.C. 
 46798 insuline aspart 46798 * 2146 Solution Injectable S.C. 
 4823 insuline globine zinc 0 
 46603 insuline injectable(humaine) 0 
 39133 insuline isophane (boeuf et porc) 2755 Suspension Injectable S.C. 
 46537 insuline isophane (boeuf et porc) 46537 * 2755 Suspension Injectable S.C. 
 XVI 
XVI
 18348 insuline isophane (boeuf) 0 
 39458 insuline isophane (boeuf) * 0 
 18335 insuline isophane (porc) 2755 Suspension Injectable S.C. 
 44164 insuline isophane bio-synthétique de séquence  2755 Suspension Injectable S.C. 
 humaine 
 44151 insuline isophane semi-synthétique de séquence  2755 Suspension Injectable S.C. 
 humaine 
 46602 insuline isophane(humaine) 0 
 46592 insuline isophane(humaine)/ insuline  0 
 injectable(humaine) 
 39120 insuline lente (boeuf et porc) 2755 Suspension Injectable S.C. 
 46538 insuline lente (boeuf et porc) 46538 * 2755 Suspension Injectable S.C. 
 41655 insuline lente (porc) 2755 Suspension Injectable S.C. 
 45415 insuline lente bio-synthétique de séquence  2755 Suspension Injectable S.C. 
 humaine 
 44476 insuline lente semi-synthétique de séquence  2755 Suspension Injectable S.C. 
 humaine 
 47206 insuline lispro 2146 Solution Injectable S.C. 
 47426 insuline lispro / insuline lispro protamine 2755 Suspension Injectable S.C. 
 46322 insuline lispro 46322 * 2755 Suspension Injectable S.C. 
 46607 insuline lispro/insuline isophane (humaine) 46607  0 
 39146 insuline protamine zinc (boeuf et porc) 2755 Suspension Injectable S.C. 
 18309 insuline protamine zinc (boeuf) 0 
 39484 insuline protamine zinc (boeuf) * 0 
 18322 insuline protamine zinc (porc) 0 
 39497 insuline protamine zinc (porc) * 0 
 39159 insuline semilente (boeuf et porc) 2755 Suspension Injectable S.C. 
 4888 insuline sulfatée 2755 Suspension Injectable S.C. 
 
 classe dencom forme  
 39172 insuline ultralente (boeuf et porc) 2755 Suspension Injectable S.C. 
 45483 insuline ultralente bio-synthétique de séquence  2755 Suspension Injectable S.C. 
 humaine 
 44996 insuline ultralente semi-synthétique de séquence 2755 Suspension Injectable S.C. 
  humaine 
 39185 insuline zinc cristalline (boeuf et porc) 2146 Solution Injectable S.C. 
 XVII 
XVII 
 46536 insuline zinc cristalline (boeuf et porc) 46536 * 2755 Suspension Injectable S.C. 
 43735 insuline zinc cristalline (boeuf) 0 
 39523 insuline zinc cristalline (boeuf) * 0 
 18296 insuline zinc cristalline (porc) 2146 Solution Injectable S.C. 
 18296 insuline zinc cristalline (porc) 2755 Suspension Injectable S.C. 
 47004 insuline zinc cristalline (porc) * 2146 Solution Injectable S.C. 
 47004 insuline zinc cristalline (porc) * 2755 Suspension Injectable S.C. 
 43033 insuline zinc cristalline (porc)/insuline isophane  2755 Suspension Injectable S.C. 
 (porc) 
 44489 insuline zinc cristalline bio-synthétique de  2146 Solution Injectable S.C. 
 séquence humaine 
 44502 insuline zinc cristalline semi-synthétique de  2146 Solution Injectable S.C. 
 séquence humaine 
 45511 insulines isophane et zinc cristalline  2755 Suspension Injectable S.C. 
 bio-synthétique de séquence humaine 
 45405 insulines isophane et zinc cristalline  2755 Suspension Injectable S.C. 
 semi-synthétiques de séquence humaine 
 45531 insulines zinc cristalline et isophane  2755 Suspension Injectable S.C. 
 bio-synthétiques de séquence humaine 
 45535 insulines zinc cristalline et isophane de séquence 0 
  humaine 
 45534 insulines zinc cristalline et isophane  0 
 semi-synthétiques de séquence humaine 
 Matériel médical 
 43995 réactif quantitatif du glucose dans le sang 3828 Bandelette 
 43995 réactif quantitatif du glucose dans le sang 87 Bâtonnet 
 47350 réactif quantitatif du glucose dans le sang ( one  3828 Bandelette 
 touch) 
 47350 réactif quantitatif du glucose dans le sang ( one  87 Bâtonnet 
 touch) 
 Sulfonylurée 
 91 acétohexamide 203 Comprimé 
 1937 chlorpropamide 203 Comprimé 
 47329 gliclazide 203 Comprimé 
 47329 gliclazide 435 Comprimé Longue Action 
 46056 gliclazide 46056 * 203 Comprimé 
 46056 gliclazide 46056 * 435 Comprimé Longue Action 
 47427 glimépiride 203 Comprimé 
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 46799 glimepiride 46799 * 203 Comprimé 
 4264 glyburide 203 Comprimé 
 9672 tolbutamide 203 Comprimé 
 15184 tolbutamide sodique 203 Comprimé 
 Thiazolidinédiones 
 47392 pioglitazone (chlorhydrate de) 203 Comprimé 
 46678 pioglitazone (chlorhydrate de) 46678 * 203 Comprimé 
 47371 rosiglitazone (maléate de) 203 Comprimé 
 46642 rosiglitazone (maléate de) 46642 * 203 Comprimé 
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Appendix D 
VCF09_Hypertension 
VCF= Variable confondante fixe dans le temps. 
BUT 
Création d'une variable indiquant pour chaque grossesse si la femme souffrait 
d’hypertension chronique, d’hypertension de grossesse, de prééclampsie ou 
d’éclampsie. 
 
Algorithme 
 
Périodes : 
 
Avant = [ début avant1,  début de la grossesse [ 
P1 = [ début de la grossesse,  BorneP21] 
P2 = ] BorneP21, fin de la grossesse [ 
PT2-3 = ] fin de la grossesse,  Fin 3mois1 ] 
Après = ] Fin 3mois1,  Fin Après1] 
 
Hypertension chronique 
Si 
1. Au moins  Rx7 ou Dx8 (HC/HG)4 durant « Avant » 
ou 
2. Au moins  Rx ou Dx (HC/HG) durant P1 
 ou 
3.  Au moins  Rx ou Dx (HC/HG) durant P2  et au moins Dx (HC/HG) durant « Apres »  5-6 
Alors HC=1 
 
Avant P1 P2 PT2-3 Après 
Début avant1                 Début gros                  BorneP21                fin gros      Fin 3mois1                               Fin Apres1 
                                                                                                           
 XX 
XX 
Hypertension de grossesse 
 
Si au moins Rx ou Dx (HC/HG) durant « Avant » ou durant P1: 
 Au moins Dx (HG) durant P2  (Hypertension Sur ajoutée) 
Sinon, 
 Au moins  Rx ou Dx (HG/HC) durant P2   
Alors HG=1 
 
*********************************ATTENTION********************************* 
S’il y a au moins un code ou une prescription d’exclusion9  avant ou pendant la grossesse nous 
effectuerons ce même algorithme sans tenir compte des Rx. 
****************************************************************************** 
Pré-éclampsie
 
    
Si au moins un DX (PE) durant P2 alors PE=1; 
Éclampsie 
   
Si au moins un DX (ECL) durant P2 alors ECL=1; 
 XXI 
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NOTES : 
 
1
 S’il existe une grossesse précédente (GP), nous établirons une borne supérieure à cette grossesse.   
 
                                                    fin de la GP + 1 + 3 mois    si durée GP ≥ 12 semaines complètes 
                  Borne GP    =    
                                                     fin de la GP + 1                  si durée GP < 12 semaines complètes 
 
Si borne GP est supérieure au début de la grossesse actuelle nous remplacerons Borne GP par le 
début de la grossesse actuelle. 
 
Une fois cette borne trouvée nous choisirons la date maximale entre la borne de la grossesse 
précédente et un an avant la grossesse. 
 
                  Début Avant  =  MAX (début de la grossesse-365 jours   ,  borne GP ) 
 
De façon générale, l’hypertension de grossesse se déclare après la fin de la 20ième semaine. S’il 
s’agit d’une grossesse multiple, l’hypertension peut déclarer dès la fin de la 15ième semaine. Nous 
considèrerons donc se fait dans le choix de la BorneP2. 
 
                                                      fin de la 20ième semaine de grossesse   si  grossesse « simple » 
                  Borne P2     =    
                                  fin de la 15ième semaine de grossesse   si  grossesse multiple 
 
ET 
                  Fin 3mois     =  MIN ( fin de la grossesse + 91 jours  ,  début gros suivante - 1 ) 
 
                  Fin Après     =   MIN ( fin gros +365 jours  ,  début gros suivante - 1 ) 
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2
 L’hypertension de grossesse prend généralement 6 semaines pour se résorber. Une minorité 
cependant peut prendre jusqu’à 3 mois avant que la tension ne redevienne normale. C’est pourquoi 
nous devons attendre 3 mois avant de vérifier si la maladie persiste. 
 
3
 Ici on ne peut analyser la période PT (période tampon) comme on l’a fait pour le diabète 
gestationnel puisqu’il n’y a pas de test particulier pour identifier l’hypertension de grossesse, il 
s’agit seulement d’une prise de tension généralement effectuer à chaque visite. Donc si une femme 
n’a aucun rx ou dx avant et pendant sa grossesse mais qu’il y a néanmoins un code durant la période 
1-3 mois inclusivement après la grossesse, on ne peut l’interpréter comme de l’hypertension 
(chronique ou de grossesse) car il peut seulement s’agir d’une mauvaise lecture de la tension. 
 
4
 Tous les codes sont considérés comme un code d’hypertension peu importe s’il s’agit d’un code 
d’hypertension chronique ou d’hypertension de grossesse. C’est plutôt le moment où ce code à été 
émis qui décidera s’il s’agit d’hypertension chronique ou d’hypertension de grossesse 
 
5Attention, si HG après 21 semaines et HC entre 4-12 mois il peut y  avoir HC+HG et non 
seulement HC. Toutefois, nous ne sommes pas en mesure de décider s’il s’agit d’hypertension 
surajoutée ou seulement d’hypertension chronique avec les informations que nous possédons.  Nous 
conclurons donc pour ces grossesses qu’il s’agit d’hypertension chronique. 
 
6
 Pour la période «Après» nous ne considérons pas les Rx puisque nous n’avons pas exigé que cette 
période soient couvertes par la RAMQ pour le remboursement des médicaments.
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7RX : prescription d’un médicaments pour l’hypertension : 
 
 
Classe pharmacologique Noms génériques Dénomination commune 
 
  
Antagonistes α-adrénergiques* Doxazosine 45625 
 Prazocin 37742, 46831 
 Térazosine 45520 
 
  
Agonistes α-adrénergiques Clonidine 10751 
 Méthyldopa 06136, 46389 
 
  
*α-blockers 
 
8 DX : Codes Diagnostiques pour l’hypertension ( codes ICD-9)  
 
 
 
 DX(HC)  
 pour l’hypertension chronique: 
401   Essential Hypertension 
402   Hypertensive Heart Disease 
403   Hypertensive Renal Disease 
404   Hypertensive Heart and Renal Disease 
405   Secondary Hypertension 
 
 pour l’hypertension chronique spécifique à la grossesse : 
642.0   Hypertension essentielle ou chronique 
642.1 Maladie hypertensive associée à des problèmes rénaux 
642.2 Autre hypertension préexistante compliquant la grossesse 
642.7   Hypertension super-imposée -autres hypertensions chroniques 
 
 
 DX(HG) 
 pour l’hypertension de grossesse: 
 
642.3   Hypertension de grossesse   (gestationnelle) 
642.9   Hypertension de novo – nouvellement hypertendue et  
            sans protéinurie 
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 DX(PE) 
  pour la pré-éclampsie: 
 
642.4 Pré-éclampsie 
642.5 Pré-éclampsie grave 
 
 DX(ECL) 
  pour l’éclampsie: 
 
642.6 Éclampsie 
 
 
 
 
 
